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ABSTRACT. 
Using monoclonal antibodies (mAbs) characterised at the Fourth International 
Leucocyte Typing Workshop, the expression and distribution of the cell- surface 
antigen CDw75 on normal peripheral blood lymphocytes and on cells from patients 
with B -cell chronic lymphocytic leukaemia (B -CLL) was studied and further defined. 
In addition, expression of the antigen on solid lymphoid and non -lymphoid tissues 
was studied, and a comparison was made between expression on normal tissues and 
on tumour tissues. 
The structure of the epitopes recognised by the different CDw75 mAbs was also 
analysed, and several attempts were made to isolate and characterise the antigen 
biochemically. The CDw75 antigen had been reported to be a cell- surface 13- 
galactoside-a-2,6-sialyltransferase enzyme, the amino acid sequence of which had 
already been determined. From this amino acid sequence, synthetic peptides were 
constructed and mAbs were raised against sialyltransferase. These mAbs were used to 
isolate the enzyme and characterise it biochemically. 
The results of this study show that CDw75 is expressed primarily on the surface of 
mature B -cells and on leukaemias and lymphomas. It is also expressed on T -cell 
subsets, and different epitopes are expressed on T -cells at different activation states. 
CDw75 is also expressed in B -cell areas of lymphoid tissues as well as on non - 
lymphoid tissues such as liver, breast, pancreas and intestine. Expression levels are 
altered in tumour tissues. 
The CDw75 mAbs do not recognise a single epitope. Some recognise a sialylated 
epitope, whereas one epitope is masked by sialic acid. The a- 2,6- sialyltransferase 
enzyme is expressed in a perinuclear area of the cell, likely to be the Golgi Apparatus, 
and is not expressed on the surface of B- cells. The CDw75 antigen is not a cell - 
surface sialyltransferase enzyme, but is a cell- surface carbohydrate epitope whose 
expression is regulated by the activity of the (3- galactoside- a -2,6- sialyltransferase 
enzyme. 
ABBREVIATIONS. 
B -CLL B -cell chronic lymphocytic leukaemia 
BSA Bovine serum albumin 
CAMs Cell adhesion molecules 
CMPNeuAc Cytidine monophosphate Neuraminic Acid 
ELISA Enzyme linked inmmunosorbent assay 
FACScan Fluorescence activated cell scanner 
FCS Foetal calf serum 
FITC Fluorescein Isothiocyanate 
Gal 1,4G1cNAc ß 1,4- Galactose -N- Acetyl Glucosamine 
G1cNAc N- Acetyl glucosamine 
HRP Horse radish peroxidase 
Ig immunoglobulin 
kDa kilo Daltons 
MAA MaackiaAmurensis Agglutinin 
mAb monoclonal antibody 
MPC Magnetic particle collector 
mr molecular weight 
N -CAMs Neural cell adhesion molecules 
NHSS- biotin sulpho- N- hydroxysuccinimidobiotin 
NK cells Natural killer cells 
NRS Normal rabbit serum 
PBL peripheral blood lymphocytes 
PBS Phosphate buffered saline 
PE Phycoerythrin 
PEG Polyethylene glycol 
PHA Phytohaemagglutinin 
SDS PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
sIg+ surface immunoglobulin positive 
SNA Sambucus NigraAgglutinin 
TBS Tris buffered saline 
v/v volume /volume 
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1.1 The Human Leucocyte Differentiation Antigen: CDw75. 
CDw75 is a cell -surface antigen found predominantly on cells of B -cell origin, but is 
also expressed on some T -cell subsets(Dorken, B., Moller, P., Pezzutto, A., 
Schwartz -Albiez, R. and Moldenhauer, G., 1989). It was originally clustered in 1989 
at the Fourth International Leucocyte Typing Workshop where four monoclonal 
antibodies (mAbs) were designated to be part of this cluster. These are HH2(Smeland, 
E., Funderud, S., Ruud, E., Blomhoff, H.K. and T, G., 1985), OKB4(Mittler, 
R.S., Talle, M.A., Carpenter, K., Rao, P.E. and Goldstein, G., 1983), LN- 
1(Epstein, A.L., Marder, R.J., Winter, J.N. and Fox, R.I., 1984), and EBU - 
141(Gramatzki, M., Lauer, U., Burger, R., Huber, C., Rohwer, P., Kalden, J.R. 
and Henschke, F., 1989), with a fifth mAb, EBU -65 also found to exhibit "CDw75 - 
like" staining patterns(Gramatzki, M., Burger, R., Kraus, J., Lauer, U., Rohwer, P., 
Eger, G., Kalden, J.R. and Henschke, F., 1991). It has since been shown that it is 
statistically likely that this mAb also recognises CDw75(Guy, K. and Andrew, J.M., 
1991). Interestingly, all five mAbs are of IgM isotype, and although OKB4 was first 
cloned in 1983, LN -1 in 1984, HH2 in 1985 and EBU -141 and EBU -65 in 1989, at 
the start of this project in 1990, very little was known about the structure of the 
antigen CDw75 which is identified by all of these mAbs. 
Surprisingly, the five mAbs were produced in response to a variety of different 
immunogens. HH2 was raised in mice in response to immunisations with lymphoma 
cells from a patient with a follicular lymphoma. OKB4 was produced by immunisation 
with Raji cells and cells from a patient with Burkitt's Lymphoma. EBU -141 and EBU - 
65 were both raised in response to immunisations with the plasma cell line U266, and 
LN -1 was produced by immunising mice with isolated nuclei from pokeweed 
mitogen- stimulated peripheral blood lymphocytes (PBL). 
Previous reports indicated that CDw75 was only expressed on mature surface 
immunoglobulin positive (sIg +) B- cells, and corresponding mature B- cell -like 
leukaemias and lymphomas, but not on Ig- secreting plasma cells, or plasma cell 
tumours(Dorken, B., Moller, P., Pezzutto, A., Schwartz -Albiez, R. and 
Moldenhauer, G., 1989). This distribution seems strange if we consider that mAbs 
EBU -141 and EBU -65 were raised in response to a plasma cell line. The mAbs have 
also been reported to stain some normal peripheral blood T -cells with low intensity, 
and in solid lymphoid tissue, all mAbs strongly stain B -cells of germinal centres. They 
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also weakly stain some cells of the mantle zone(Dorken, B., Moller, P., Pezzutto, A., 
Schwartz -Albiez, R. and Moldenhauer, G., 1989). 
LN -1 was found to stain erythrocyte precursors of the bone marrow, ciliated epithelial 
cells of the bronchus, distal tubular cells of the kidney, ductal cells from several 
organs, and most epithelium- derived cell lines(Okon, E., Felder, B., Epstein, A., 
Lukes, R.J. and Taylor, C.R., 1985; Erikstein, B.K., Beiske, K., Smeland, E.B., 
Davies, C.D.L., Blomhoff, H.K. and S, F., 1989). The LN -1 epitope is also 
neuraminidase sensitive, which means that it must contain sialic acid. I-1112 is reported 
to stain the same types of lymphoid cells as LN-1 (Smeland, E., Funderud, S., Ruud, 
E., Blomhoff, H.K. and T, G., 1985; Erikstein, B.K., Beiske, K., Smeland, E.B., 
Davies, C.D.L., Blomhoff, H.K. and S, F., 1989). OKB4 reacts with Burkitt's 
Lymphoma cells and 90% of sIg+ cells, but does not stain activated B- cells(Mittler, 
R.S., Talle, M.A., Carpenter, K., Rao, P.E. and Goldstein, G., 1983). EBU -141 
and EBU -65 are also reported to bind to mature sIg+ B- cell -type leukaemias and 
lymphomas(Gramatzki, M., Lauer, U., Burger, R., Huber, C., Rohwer, P., Kalden, 
J.R. and Henschke, F., 1989), but also to hepatocytes and glandular structures such 
as salivary gland ducts, salivary acini, sweat glands, endometrial glands and prostatic 
gland cells(Gramatzki, M., Burger, R., Kraus, J., Lauer, U., Rohwer, P., Eger, G., 
Kalden, J.R. and Henschke, F., 1991). 
Therefore, the cluster CDw75 defines a cell -surface antigen, predominantly of B- cells, 
which appears at a stage of differentiation around the same time as sIg, and which is 
lost from the cell -surface when these cells are further activated to become plasma cells 
which secrete Ig. Limited information is available as to the tissue distribution of the 
antigen outside of lymphoid tissue, and no direct comparisons of staining patterns of 
each of the five mAbs in different tissues has yet been reported. Biochemical 
information about the antigen is also very sparse. Immunoprecipitation of antigens 
with OKB4 and EBU -141 have been reported giving molecular weights (mrs) of 87 
kDa ( Mittler, R.S., Talle, M.A., Carpenter, K., Rao, P.E. and Goldstein, G., 1983) 
and 53 kDa(Dorken, B., Moller, P., Pezzutto, A., Schwartz -Albiez, R. and 
Moldenhauer, G., 1989) with OKB4 and 34 -38 kDa with EBU- 141(Okon, E., 
Felder, B., Epstein, A., Lukes, R.J. and Taylor, C.R., 1985). However, no 
satisfactory evidence for such claims has yet been published. 
In 1990, it was reported that the CDw75 gene had been cloned(Stamenkovic, I., 
Asheim, H.C., Deggerdal, A., Blomhoff, H.K., Smeland, E.B. and Funderud, S., 
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1990). A cDNA library was introduced into COS cells and was screened using HH2 
to label the cell surface. A positive cDNA clone was reintroduced into COS cells and 
was found to react with all CDw75 mAbs. The sequence of this cDNA was found to 
be almost identical to that of the human enzyme 3- galactoside- a -2,6- sialyltransferase. 
It was therefore claimed that CDw75 had been identified as a cell- surface version of 
this enzyme. It was later shown that transfection of this cDNA into COS cells also 
leads to expression of the EBU -65 epitope(Erikstein, B.K., Funderud, S., Beiske, 
K., Aas -Eng, A., De Lange Davies, C., Blomhoff, H.K. and Smeland, E.B., 1992), 
and that HH2 not only stained the surface of these transfected cells, but also stained 
the cytoplasm in the juxtanuclear region. This seemed to suggest that not only was 
EBU -65 definitely part of the CDw75 cluster, but that the sialyltransferase enzyme 
might be expressed in the Golgi Apparatus, where it is more conventionally found, as 
well as on the cell surface. 
1.2 Human 13- galactoside- a -2,6- sialyltransferase. 
13- galactoside- a -2,6- sialyltransferase was first purified from bovine colostrum in 
1977(Paulson, J.C., Beranek, W.E. and Hill, R.L., 1977). It is an enzyme normally 
found in the Golgi apparatus, which catalyses the transfer of sialic acid from its 
nucleotide sugar Cytidine Mono Phosphate Neuraminic Acid (CMPNeuAc) to 
substrates with the non -reducing terminal sequence 131,4- Galactose -N- Acetyl 
Glucosamine (Gal[31,4G1cNAc) (Paulson, J.C., Rearick, J.I. and Hill, R.L., 1977). 
Another sialyltransferase enzyme, f3- galactoside- a -2,3- sialyltransferase also utilises 
this terminal sequence for transfer of sialic acid, and competes for the same substrate 
as a- 2,6- sialyltransferase when the two enzymes are co- expressed(Lee, E.U., Roth, 
J. and Paulson, J.C., 1989). 
The activity of the a- 2,3- sialyltransferase enzyme must therefore be taken into account 
in any sialyltransferase assay, and a method of identifying a- 2,6- sialylated products 
must be incorporated into any specific assay. Figure 1.2.1 illustrates three possible 
sialylation patterns of N- linked carbohydrate when the two enzymes are active. 
The primary structure of rat a- 2,6- sialyltransferase has been predicted from its amino 
acid sequence using a Hopp -Woods hydrophilicity plot(Weinstein, J., Lee, E.U., 
McEntee, K., Lai, P.H. and Paulson, J.C., 1987). This indicates an enzyme with a 
membrane -spanning region of 17 hydrophobic amino acids located 10 residues from 
the NH2- terminus with a large catalytic C- terminal domain which is located 
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extracellularly or in the lumen of the Golgi Apparatus. This gives an idea of the 
structure of the human enzyme as the rat enzyme shares 87.6% homology with the 
human form(Grundmann, U., Nerlich, C., Rein, T. and Zettlmeissl, G., 1990). Like 
the rat form, the human enzyme contains a short cytoplasmic domain followed by a 15 
residue transmembrane domain and a hydrophilic catalytic domain with two potential 
N- linked glycosylation sites. A schematic view of this primary structure is illustrated 
in figure 1.2.2. 
















The diagram illustrates three possible pathways for sialylation when 0- galactoside -a- 
2,6-sialyltransferase, and ß- galactoside -a -2 ,3- sialyltransferase compete for the same 
substrate. Pathway A illustrates the action of p- galactoside- a -2,3- sialyltransferase 
alone with no competition for the substrate, pathway B illustrates a possible outcome 
when both enzymes are active, and pathway C shows a- 2,6- sialylation of the same 
substrate in the presence of 3- galactoside- a -2,6- sialyltransferase alone. 
Abbreviations: Gal = galactose, GlcNAc = NAcetylglucosamine, Man = mannose, 
NeuAc = neuraminic acid (sialic acid). 
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Soluble forms of a- 2,6- sialyltransferase have also been detected in humans and rats. 
Enzyme activity has been detected in plasma and colostrum(Bartholomew, B.A., 
Jourdian, G.W. and Roseman, S., 1973; Paulson, J.C., Beranek, W.E. and Hill, 
R.L., 1977; Wang, X.C., O'Hanlon, T.P. and Lau, J.T., 1989; Nemansky, M. and 
Van den Eijnden, D.H., 1992; Aasheim, H.C., Aas -Eng, D.A., Deggerdal, A., 
Blomhoff, H.K., Funderud, S. and Smeland, E.B., 1993). It has been shown that a 
Cathepsin D -like lysosomal enzyme cleaves the catalytic domain of a -2,6- 
sialyltransferase from the transmembrane domain and releases the catalytic domain as a 
soluble form of the enzyme(Jamieson, J.C., McCaffrey, G. and Harder, P.G., 1993). 
It has also been shown that levels of soluble a- 2,6- sialyltransferase are higher during 
the acute phase response, and it is thought that increased levels of the cleaving enzyme 
are induced during the acute phase response(Lammers, G. and Jamieson, J.C., 1989; 
Harder, G., Jamieson, J.C. and Woloski, B.M., 1990). 
Multiple transcripts of a- 2,6- sialyltransferase mRNA have also been identified in rat 
tissues. mRNAs of 3 different sizes - 4.3 kb, 4.7 kb and 3.6 kb have been 
detected(Paulson, J.C., Weinstein, J. and Schauer, A., 1989). All have high 
homology and have been shown to be generated by alternate splicing from a single 
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gene(O'Hanlon, T.P., Lau, K.M., Wang, X.C. and Lau, J.T., 1989). The 4.7 kb 
message has been shown to be identical to that of the 4.3 kb mRNA with the addition 
of 2 untranslated exons at the 5' end(Wen, D.X., Svensson, E.C. and Paulson, J.C., 
1992). The 4.7 kb form appears to be constitutively expressed whereas the 4.3 kb 
form is restricted to liver cells, but both mRNA forms encode the same protein. The 
3.6 kb mRNA actually represents 3 transcripts of similar size. These are only 
expressed in kidney, and are generated by alternative splicing and alternative promoter 
utilisation. There are therefore at least five transcripts of the a- 2,6- sialyltransferase 
gene(Wang, X.C., Smith, T.J. and Lau, J.T., 1990; Wen, D.X., Svensson, E.C. 
and Paulson, J.C., 1992). 
1.3 A cell- surface a-2,6-sialvitransferase? 
There is a large body of evidence proving the existence of functional cell -surface 
glycosyltransferases including sialyltransferases. Indeed, cell- surface sialyl- 
transferases have been reported to be involved in platelet aggregation, in gamete 
adhesion(Shur, B.D., 1982), in the repair of neuraminidase- treated cell -surfaces and 
in the specific clearance of desialysed plasma proteins by the liver(Shur, B.D. and 
Roth, S., 1975). Cell- surface sialyltransferase on erythrocytes is also thought to be a 
major source of serum sialyltransferase activity(Kim, Y .S., Perdomo, J., Bella, A. 
and Nordberg, J., 1971). It has been shown that sialyltransferases on the surface of 
human sperm cells mediate the adhesion of the sperm to the ovum, and that patches of 
intense sialyltransferase activity on the surface of the ovum correspond to sites of 
sperm penetration(Daunter, B. and Newlands, J., 1981; Shur, B.D., 1982). Sialyl- 
transferase activity has also been detected on the surface of embryonic chick cells, and 
it has been shown that neuraminidase treatment of these cells leads to an increased rate 
of cell re- aggregation. This is thought to be mediated by an increased exposure of non- 
sialylated sites which act as receptors for cell- surface sialyltransferases, as re- 
aggregation is inhibited by the addition of glycoproteins possessing the same terminal 
sugar residues as the neuraminidase- treated cells. There is also evidence that 
lymphocytes possess numerous cell- surface glycosyltransferases, and that transferases 
on cytotoxic T -cells may participate in T -cell cytolysis of their target cells. It has been 
shown that the increase in T -cell surface galactosyltransferase activity is directly 
proportional to the increase in the ability of these T -cells to bind target cells 
(Shur,B.D., 1982). Cell- surface galactosyltransferase activity is increased by 5- 
fold on metastatic murine melanoma cells (Passanati, A. and Hart, G.W., 1990), and 
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has been found on embryonal carcinoma cells, mesenchymal cells, mouse embryo, 
melanoma cells, neural crest cells and on mouse sperm cells. It has also been shown to 
bind to laminin and to promote cell spreading, but not cell adhesion, on laminin- coated 
surfaces. This enzyme has also been found on the surface epithelium of human 
stomach cells(Feizi, T., Thorpe, S.J. and Childs, R.A., 1987). 
However, despite all the evidence indicating the existence of cell- surface 
glycosyltransferases, in 1992 it was shown that CDw75 is unlikely to be a cell -surface 
sialyltransferase. It was discovered that transfection of 13- galactoside- a -2,6- 
sialyltransferase into COS cells not only produces expression of CDw75, but also 
CD76, and an epitope defined by the mAb HB- 6(Bast, B.J., Zhou, L.J., Freeman, 
G.J., Colley, K.J., Ernst, T.J., Munro, J.M. and Tedder, T.F., 1992; Keppler, 
O.T., Moldenhauer, G., Oppenlander, M., Schwartz -Albiez, R., Berger, E.G., 
Funderud, S. and Pawlita, M., 1992; Munro, S., Bast, B.J., Colley, K.J. and 
Tedder, T.F., 1992). Moreover, it was shown that the sialyltransferase enzyme is not 
found on the cell surface, but is localised to the perinuclear Golgi region(Bast, B.J., 
Zhou, L.J., Freeman, G.J., Colley, K.J., Ernst, T.J., Munro, J.M. and Tedder, 
T.F., 1992). In addition, all three antigens were shown to be sensitive to 
neuraminidase treatment, and CD76 has been identified as a sialylated 
glycolipid(Munro, S., Bast, B.J., Colley, K.J. and Tedder, T.F., 1992). All things 
considered, it seems more likely that CDw75 is not a cell surface sialyltransferase, but 
is in fact a carbohydrate epitope on a cell -surface glycoprotein or glycoproteins, which 
is generated by the intracellular activity of f3-galactoside-a-2,6-sialyltransferase. 
The three sets of mAbs (CDw75, CD76 and HB -6) exhibit similar but not identical 
binding patterns, indicating that although all epitopes are generated by the same 
enzyme, they must stain different sialylated glycoproteins and glycolipids on the cell 
surface whose expression is under another level of control. However, the fact that 
expression of all three antigens is greatest in mature B- cells, moderate in T -cells and 
negative in monocytes, must reflect (3- galactoside- a -2,6- sialyltransferase activity 
levels in these cell types(Bast, B.J., Zhou, L.J., Freeman, G.J., Colley, K.J., Ernst, 
T.J., Munro, J.M. and Tedder, T.F., 1992). It has also been suggested that since the 
CDw75 antigen is resistant to formalin fixation and paraffin embedding - procedures 
which very often denature cell -surface proteins - that CDw75 may also be a sialylated 
glycolipid(Bast, B.J., Zhou, L.J., Freeman, G.J., Colley, K.J., Ernst, T.J., Munro, 
J.M. and Tedder, T.F., 1992; Munro, S., Bast, B.J., Colley, K.J. and Tedder, T.F., 
1992). 
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1.4 The Importance of Carbohydrate. 
One of the major changes associated with cell differentiation and ontogenesis is the 
altered structure of the carbohydrate chains attached to glycoproteins and 
glycolipids(Feizi, T., 1985). There is strong evidence that terminal glycosylation 
sequences are involved in cell motility and in cell -cell communications(Rademacher, 
T.W., Parekh, R.B. and Dwek, R.A., 1988; Springer, T.A., 1990). In embryonic 
development, glycoproteins known as cell adhesion molecules (CAMs), influence the 
specific adhesion of neural cells and liver cells. The glycosylation patterns on these 
CAMs have been shown to play a major role in the adhesion events mediated by these 
molecules(Livingston, B.D., De Robertis, E.M. and Paulson, J.C., 1990; Feizi, T., 
1991). Sialic acid has been shown to be important in the control of the homophilic 
binding of neural cell adhesion molecules (N- CAMs), and there are differences 
between the glycosylation patterns of the embryonic and adult forms, particularly with 
respect to the extent and nature of sialylation of the N- linked oligosaccharides 
(Rademacher, T.W., Parekh, R.B. and Dwek, R.A., 1988; Kimber, S.J., 1990). 
Another CAM, endothelial leucocyte adhesion molecule (ELAM -1) mediates the 
adhesion of circulating leucocytes to the vascular endothelium. This adhesion has also 
been shown to be dependent on sialylation of the lactosaminoglycan receptor for 
ELAM- 1(Lowe, J.B., Stoolman, L.M., Nair, R.P., Larsen, R.D., Berhend, T.L. and 
Marks, R.M., 1990). Differences in carbohydrate structures have also been implicated 
in many diseases. For example, in patients with diabetes there is a lack of sialic acid in 
the glomerular basement membrane(Cohen -Forterre, L., Andre, J., Mozere, G., 
Peyroux, J. and Sternberg, M., 1990), and in patients with arthritis, Crohn's disease 
and tuberculosis, there are differences in the galactosylation patterns of 
IgG(Rademacher, T.W., Parekh, R.B. and Dwek, R.A., 1988). 
There are many reports on the involvement of carbohydrate on the tumour cell surface. 
The sugar chains of cell -surface glycoproteins and glycolipids are thought to play an 
important role in the invasiveness and metastasis of tumour cells, and it is known that 
tumour cells contain more complex and heavily sialylated carbohydrate on their 
membrane glycoproteins(Smets, L.A. and Van Beek, W.P., 1984; Yamashita, K., 
Ohkura, T., Tachibana, Y., Takasaki, S. and Kobata, A., 1984; Saitoh, O., Piller, 
F., Fox, R.I. and Fukuda, M., 1991). In fact, it has been suggested that sialic acid 
may be an important factor in the process of metastasis formation(Yogeeswaran, G. 
and Salk, P.L., 1981; Dennis, J.W., 1986). When glycopeptides from tumour cells 
are analysed by gel filtration, an overall increase in molecular weight is manifested by 
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shifts in the elution profiles compared to controls. After treatment with neuraminidase, 
the differences between tumour glycoproteins and controls disappear in most 
comparisons(Smets, L.A. and Van Beek, W.P., 1984). In addition, the observed 
alterations in cell surface carbohydrates occur independent of the histogenetic origin of 
the cells and the transforming principle involved. 
The appearance of increased levels of larger cell- surface carbohydrates is a general 
accompaniment of tumourigenic transformation, but tumour- specific differences have 
also been detected in glycolipids and glycoproteins released by the tumour into the 
circulation, and high serum levels of sialylated proteins and lipids have been detected 
in cancer patients(Smets, L.A. and Van Beek, W.P., 1984). Increased levels of 
sialyltransferase activity have also been detected in the PBL of patients with multiple 
myeloma(Cohen, A.M., Allalouf, D., Bessler, H., Djaldetti, M., Malachi, T. and 
Levinsky, H., 1989), galactosyltransferase activity levels are increased in ovarian 
cancer(Uejima, T., Uemura, M., Nozawa, S. and Narimatsu, H., 1992; Uemura, M., 
Sakaguchi, T., Uejima, T., Nozawa, S. and Narimatsu, H., 1992), and 
fucosyltransferase expression is altered in certain colon cancers(Stroup, G.B., 
Anumula, K.R., Kline, T.F. and Caltabiano, M.M., 1990). It has also been shown 
that the oncogene c- Ha -ras induces an almost two -fold increase in a -2,6- 
sialyltransferase activity in transformed NIH3T3 cells as compared to normal NIH3T3 
cells(Vandamme, V., Cazlaris, H., Le Marer, N., Laudet, V., Lagrou, C., Verbert, 
A. and Delannoy, P., 1992). When injected into mice, these transformed cells 
produced large tumours at the site of injection and micro metastases in the lungs of the 
mice. 
There is much controversy about the structure of carbohydrate on tumour cells. The 
causes of the changes are poorly understood, and there are no clear -cut differences that 
separate a normal cell phenotype from a tumour cell phenotype, and it not known what 
effect such changes may have on the metastatic potential and aggressiveness of the 
tumour cell. However, it is possible that the changes in structure observed may be due 
to the fact that metastatic cells can be of transient phenotypes with properties which are 
not necessarily the same as those of the cells of the primary tumour, nor by those of 
the metastatic nodule. In addition, cell -surface carbohydrates are capable of mediating 
the adhesion of tumour cells to the endothelium of the target organ, and increased 
sialylation may help in this process. In some animal tumours, cell- surface 
glycoconjugates have been detected that effectively mask histocompatibility antigens. 
This may reduce the ability of NK cells to recognise these cancer cells, as increased 
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sialylation of cell -surface glycoconjugates may confer resistance to NK -cell- mediated 
lysis of tumour cells(Smets, L.A. and Van Beek, W.P., 1984). 
In general, the importance of the role of carbohydrate is often not appreciated. The fact 
that the addition of sugar chains to glycoproteins and glycolipids can completely alter 
the size, shape, charge and ability to recognise receptors cannot be ignored. The 
glycosyltransferases provide an additional level of control over the expression of cell - 
surface components as a change in the glycosylation pattern of one or more cell - 
surface proteins or lipids can completely change cell -cell communication networks, 
growth regulation, host -pathogen interactions, adhesion and motility. It is a 
challenging area to work in, and hopefully as the importance of carbohydrate becomes 
more accepted, the complexities of glycosylation patterns and their functions will 
become better understood. 
1.5 Aims of the project. 
The initial aim of the project was to determine the identity, function, tissue distribution 
and regulators of expression of CDw75. As the antigen was originally thought to be a 
cell - surface ß- galactoside- a- 2,6- sialyltransferase, and as so little is known about this 
enzyme in humans, my approach was to attempt to isolate the antigen in order to find 
its molecular weight and to assay it for sialyltransferase activity. I then expected to be 
able to look for different isoforms of the enzyme in different human tissues and to 
determine if different forms had different enzyme activities and different regulators of 
expression. Isolation of the antigen proved impossible, and I decided to attempt to 
raise IgG mAbs against human ß- galactoside- a -2,6- sialyltransferase in order to 
immunoprecipitate the antigen. 
However, as it became apparent during the course of the project that CDw75 was not a 
cell -surface sialyltransferase, the aims of the project changed entirely. Effectively, the 
project became not only a study of CDw75, but also of 13- galactoside- a -2,6- 
sialyltransferase. As such, the aims were to further define the distribution and 
carbohydrate structure of CDw75, and to compare expression of CDw75 on resting 
and activated cells and on normal and tumour cells and tissues. At the same time it was 
aimed to compare CDw75 distribution with that of 13- galactoside- a -2,6- 
sialyltransferase. More specific aims are listed below. 
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1.5.1 Tissue distribution of CDw75. 
Further characterisation of CDw75 expression pattern on lymphocytes using all 
available CDw75 mAbs. This includes normal lymphocytes, lymphocytes from 
patients with B -cell lymphocytic leukaemia (B -CLL) and Burkitt lymphoma cell lines 
representing B -cells at different stages of maturation. It was also aimed to define 
CDw75 expression on subsets of normal PBL in both resting and activated states. 
On solid tissues it was aimed to determine CDw75 expression in both lymphoid and 
non -lymphoid organs, and to compare expression patterns in normal tissues with that 
of tumour tissues. 
1.5.2 Epitope structures of CDw75 antigen. 
Further characterisation of carbohydrate structures of individual epitopes recognised 
by each mAb using glycosidic enzymes and inhibitors of glycosylation to determine if 
all epitopes are sialylated, and if carbohydrate is N- linked. 
1.5.3 Biochemical analysis of CDw75. 
CDw75 has not previously been isolated biochemically. It was aimed to use a variety 
of detergents to gently solubilise the antigen from CDw75+ cell membranes and to use 
the available mAbs to immunoprecipitate the antigen from these preparations, and 
finally determine its molecular weight by electrophoresis. 
1.5.4 Manufacture of mAbs specific for human 
(3- galactoside- a -2,6- sialyltransferase. 
Using synthetic peptides constructed from the amino acid sequence of human (3- 
galactoside-a-2,6- sialyltransferase, it was aimed to raise mAbs specific for this 
enzyme in order to isolate and characterise it and to compare its tissue distribution, and 
cellular distribution with that of CDw75. Specifically it was aimed to raise mAbs of 
IgG isotype as these are more useful for immunoprecipitation. 
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1.5.5 Development of an assay for 
a- 2,6- sialyltransferase activity. 
Development of a simple assay for ( 3- galactoside- a- 2,6- sialyltransferase activity to be 
used to measure enzyme activity in plasma samples and in immunoprecipitates from 
the specific mAbs. Several assays exist in which final products of enzyme activity 
need to be separated using complex chemical methods. It was aimed to use an a -2,6- 
sialic acid specific lectin to identify specific assay products in a quantitative manner. 
1.5.6 Participation in the Fifth International 
Leucocyte Typing Conference. 
It was aimed to use the CDw75 and CD76 panels from the Leucocyte Typing 
Workshop to compare the tissue distribution and epitope structure of CDw75 and 
CD76 antigens. It was also aimed to analyse the new mAbs of the B -cell panel in an 
attempt to identify any new putative CDw75 mAbs. In addition if the mAbs against a- 




Materials and Methods. 
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2.1 Monoclonal Antibodies. 
The mAbs listed were used in for immunofluorescent labelling of cells for flow 
cytometry (Chapters 3 and 7), for immunolabelling of Western blots and 
immunoprecipitation of labelled antigens (Chapter 5), and for immunohistochemical 
staining of tissue sections (Chapters 4, 6 and 7). 
The CDw75 mAb - HH2, OKB4, EBU -141, and EBU -65 were kindly provided by 
the originators of the clones(Dorken, B., Moller, P., Pezzutto, A., Schwartz -Albiez, 
R. and Moldenhauer, G., 1989). The CD45RA mAb (F8- 11 -13) and the CD14 mAb 
(VIM13) were obtained from the Third and Fourth Leucocyte Typing Workshops 
respectively. The CD45RO (UCHL -1), CD3 (UCHT -1) and CD8 (UCHT -4) mAb 
were generous gifts from Dr.P.Beverley. The mAbs against CD4, CD19, CD29, 
CD54 and CD58 were purchased from Serotec. L26 (CD20), MT 1 (CD43), KP -1 
(CD68), EMA (Epithelial Membrane Antigen), CK (cytokerratin) and QBEND (HEV) 
were purchased from DAKO. 
2.2 Expression and Structure of CDw75 on Lymphocytes. 
Single- colour and two -colour immunofluorescence staining were used for flow 
cytometric analysis of cell suspensions in the tissue distribution studies described in 
chapters 3 and 7. In some experiments, cells were treated with neuraminidase,or 
cultured in the presence of tunicamycin or P.H.A. prior to staining. 
2.2.1 Single -Colour Immunofluorescence Staining. 
Cells were harvested from culture and washed twice in PBS 1% BSA. Viability was 
assessed, and cells were used only if viability was >85 %. Cells were dispensed into 
capped Falcon tubes in aliquots of 2.5 x 105 cells before addition of 50 ul aliquots of 
primary mAb. Tubes were agitated and incubated at room temperature for 45 mins. 
Cells were then washed twice in PBS 1% BSA before addition of 100 ul of 1/100 
F(ab)2 FITC- sheep- anti -mouse IgG (Sigma F2883). Tubes were incubated at room 
temperature fora further 30 mins and then washed twice more in PBS 1% BSA. The 
pellets were carefully resuspended before fixing each aliquot in 0.5 ml of PBS + 1% 
formaldehyde to give a final concentration of 5 x 105 cells /ml. Flow cytometric 
analysis was carried out on a benchtop flow cytometer (FACScan, Becton Dickinson) 
equipped with an argon -ion laser emitting light at a fixed wavelength of 488nm. Light 
scatter signals were collected in linear mode, and fluorescence output in logarithmic 
mode. 
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2.2.2 Two -Colour Immunofluorescence Staining. 
Where two colour immunofluorescence staining was employed, only highly viable cell 
populations were used (viability >95 %). CDw75 mAbs (which are all of IgM isotype) 
were detected using FITC- anti -mouse IgM (Sigma) previously absorbed with IgM 
positive human Burkitt lymphoma cells to remove anti -human Ig reactivity, and 
minimal residual binding of the antibody to human cells was blocked in each test by 
the addition of 0.5% of normal human serum. IgG mAb were detected using 
biotinylated anti -mouse IgG (Sigma) and streptavidin -phycoerythrin (Amersham 
International). 2A4.5 (an IgG anti -phycoerythrin mAb) and VIM13 (an IgM CD14 
mAb) were included in all tests as isotype matched negative controls. All 
fluorochrome- conjugated reagents were titrated and used at optimal concentrations. In 
tests with OKB4, cells were pretreated with neuraminidase as described above to 
remove sialic acid and expose this epitope. Flow cytometric analysis was carried out 
on a benchtop flow cytometer (FACScan, Becton Dickinson) equipped with an argon - 
ion laser emitting light at a fixed wavelength of 488nm. Light scatter signals were 
collected in linear mode, and fluorescence output in logarithmic mode. Automatic 
compensation was set to eliminate leakage between fluorescence channels 1 and 2. Dot 
plots and data were produced using the 'Lysis' software package. 
2.2.3 Neuraminidase Digestion Of Whole Cells. 
Cells were routinely harvested, washed and resuspended to 107 cells /ml in normal 
saline (154 mM NaCl). 25 ul of 2U /m1 neuraminidase (Type X Clostridium 
perfringens Sigma) was added per 1 ml of cells to give a final concentration of 
0.05U/ml. Cells were incubated with neuraminidase for 30 mins at 37 °C with 
occasional shaking. After this time the cells were washed in PBS containing 1% BSA 
(Sigma) to remove the neuraminidase prior to immunofluorescence staining. The 
amount of neuraminidase used was initially determined by a titration as described in 
Chapter 3. 
2.2.4 Tunicamycin Inhibition Of N- Linked Glycosylation. 
Cells were harvested and washed in fresh medium and resuspended to -106cells /ml in 
RPMI 10% FCS + 0.05 U /ml neuraminidase Type X (Clostridium perfringens). Cells 
were incubated for 1 hr at 37 °C (or overnight) in an atmosphere of 5% CO2. After 
incubation, cells were harvested and washed in normal unsupplemented RPMI FCS 
before resuspending in medium containing varying concentrations of tunicamycin (0 - 
10 pg /m1)(Sigma). Cells were cultured in tunicamycin supplemented medium for 18 
hrs before harvesting, washing and immunofluorescence labelling with CDw75 
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antibodies and sialic acid specific lectins Sambucus Nigra Agglutinin (SNA) and 
Maackia Amurensis Agglutinin (MAA). Stained cells were analysed by flow 
cytometry. 
2.2.5 PHA Stimulation Of Lymphocytes. 
Normal peripheral blood lymphocytes (PBL) were obtained from blood donations 
from laboratory staff and leucocyte concentrates prepared from normal blood donors. 
PBL were prepared as follows: blood clotting was induced by the addition of a few 
drops of 1000 units /ml thrombin (ICN ImmunoBiologicals) in 1M CaCl2, and fibrin 
strands were removed as the blood clotted using applicator sticks. Bloods were then 
centrifuged at 1000g for 12 minutes over cushions of Histopaque 1077 (Sigma) in 
capped tubes, and leucocytes recovered from the interface. Adherent cells were 
removed by culturing the cells in RPMI 1640 + 10% FCS in plastic tissue culture 
flasks for 1 hr at 37 °C. For activation studies, PBL were cultured in RPMI FCS + 100 
ytg/ml PHA (Wellcome) at 37 °C in an atmosphere of 5% CO2 in air, and harvested at 
24 hour intervals over a 3 or 5 day period for immunofluorescence staining. 
2.3 Immunohistochemistry. 
The immunohistochemical staining technique described below was used to stain the 
tissue sections described in chapters 4, 6 and 7. 
2.3.1 Immunohistochemical Staining Of Tissue Sections. 
Paraffin- embedded tissue samples were cut into 3 pm thick sections and mounted on 
glass slides. Sections were deparaffinised by immersion in xylene for 10 mins. They 
were re- hydrated by immersion in decreasing concentrations of ethanol in water 
(Absolute alcohol -> 74% -> 64% -> water). Endogenous peroxidase activity was 
blocked by removing sections from the absolute alcohol bath and immersing in 1% 
H2O 2 (Sigma) in methanol for 10 mins before continuing with the rehydration 
process. Hydrated sections were washed in running tap water for 5 mins and 
trypsinised if necessary. (Sections were immersed in 0.1% trypsin, 0.1% CaC12 in 
distilled water pH 7.6 - 7.8 at 37 °C for 20 mins). Sections were washed twice for 5 
mins in TBS (see appendix A) before incubating in 20% normal rabbit serum 
(NRS)(SAPU) in TBS for 10 mins to reduce non -specific staining. Serum was 
drained off, and 100 ysl aliquots of primary mAb (diluted optimally in 20% NRS) 
carefully pipetted on to each section and incubated for 30 mins. Slides were washed 
twice for 5 mins in a bath of TBS, drained and sections incubated in biotinylated 
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rabbit -anti -mouse -Ig (DAKO) diluted 1/400 in 20% NRS for 30 mins. Slides were 
washed twice in TBS as before and incubated in avidin- biotin -peroxidase or avidin- 
biotin- alkaline phosphatase complexes (DAKO) in TBS for 30 mins. Sections were 
washed twice more as before, and stained using the appropriate enzyme substrate (see 
appendix A). Stained sections were counterstained by incubation in a bath of 5% 
Mayers Haematoxylin for 10 mins and washed in slightly alkaline tap water to allow 
the blue colour to develop. Sections were dehydrated by immersion in increasing 
concentrations of ethanol in water (reverse of hydration process described) and left in 
xylene for at least 30 mins before mounting using a synthetic resin (DPX) to fix 
coverslips. Stained sections were analysed by light microscopy, and photographed 
using a 35mm camera attached to the microscope. Magnification given on each 
photographic plate is that of the microscope objective. 
2.4 Biochemical Techniques. 
The following techniques were used in the experiments described in chapter 5. Cells 
were solubilised in detergent prior to electrophoretic separation using SDS PAGE. 
Separated proteins were then transferred to nitrocellulose by Western blotting and then 
detected using enzyme labelling. Where immunoprecipitations were performed, whole 
cells were surface labelled using biotin or metabolically labelled using radioactively 
labelled methionine and cystein prior to solubilisation. Once separated and transferred 
to nitrocellulose, these labelled proteins were detected using enzyme labelling or 
autoradiography. The radioimmunoassay was used to test the integrity of cell -surface 
epitopes after possible damage by detergent treatments. Likewise, dot -blotting was 
used to test the integrity of detergent solubilised CDw75 epitopes. 
2.4.1 NHSS -Biotinylation Of Whole Cells. 
Cells were resuspended to 108 per ml in PBS (see appendix A). 50 pl per 1 ml of cells 
of a 44 mg /ml sulpho -N- hydroxysuccinimide ester of biotin (NHSS- biotin) (Pierce) in 
PBS solution was added, and the suspension incubated on ice.(Cole, S.R., Ashman, 
L.K. and Ey, P.L., 1987) After 30 mins, -5 ml PBS was added and the suspension 
was mixed by inversion. Biotinylated cells were washed three times in PBS prior to 
solubili sation. 
2.4.2 Metabolic Radiolabelling. 
Cells were harvested from tissue culture flasks, washed in methionine and cysteine- 
free culture medium (DMEM, ICN Flow), and resuspended at 107 cells /ml in the same 
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medium. 35S- labelled methionine and cysteine (Amersham) was added ( -100 jCi/ml 
of cells) and cells were cultured at 37 °C in an atmosphere of 5% CO2, 95% humidified 
air for 3 hrs. (A tray of water was routinely placed in the incubator with the cells in 
order to absorb any radioactive sulphide gases emitted from the medium. Samples of 
this water were tested for radioactivity after each labelling session). Cells were 
harvested and washed prior to solubilisation. (All washings and spent medium were 
stored for disposal at a later date once radioactivity had decayed to a safe level). 
2.4.3 Solubilisation Of Cells. 
Cells were washed twice in PBS and counted. After centrifugation to pellet the cells, 
the supernatant was discarded before gently resuspending the cells in their own pellet 
volume. Cells were placed on ice and 1 ml of 0.5% detergent in lysis buffer(Baecher, 
C.M., Infante, A.J., Semcheski, K.L. and Frelinger, J.G., 1988) (see appendix A) 
containing protease and glycosidase inhibitors (1 x 50 µl vial of each per 1 ml of 
detergent) was slowly added per 107cells. Cells were gently resuspended and 
incubated on ice for 30 minutes. Cells were centrifuged in capped tubes at 175g for 10 
mins at 4 °C and 1 ml aliquots of supernatant fluid were carefully removed into 
Eppendorf tubes and centrifuged at 5000g for 30 mins to remove any residual 
intracellular vesicles. The supernatant was carefully removed and stored in aliquots at 
-20 °C. Protease and glycosidase inhibitors were stored at -20 °C as pre -prepared 
cocktails at 20 x normal working concentration. The contents of each cocktail, and 
their normal working concentrations are given in appendix A (Table A 1). 
2.4.4 Immunoprecipitation. 
Protein -A Method. 
Bead Arming. 
10 mg of Protein A Sepharose (Sigma) was added to 40 µl of PBS and left to swell 
for 2 hrs, before adding 40 µl of 1% detergent in lysis buffer. 160 µl of rabbit anti - 
mouse immunoglobulins (DAKO) was then added to the beads, and incubated on a 
roller at 4 °C for 2 hrs. The armed beads were washed 3 times in 0.5% detergent 
solution and resuspended in 400 µl to give a 10% volume /volume (v /v) armed bead 
suspension. 
Preclearing. 
65µl of 10% v/v armed bead suspension was added to 500 µl aliquots of biotinylated 
or radiolabelled cell lysate, and incubated on a roller at 4 °C for 1 hr. Beads were 
centrifuged at 6000g for 20s and the supernatants transferred to new tubes containing 
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fresh 65 pl aliquots of 10% v/v armed bead suspension, and the above preclearance 
step was repeated twice more. (SDS PAGE analysis of the 3 pellets from these steps 
showed that all 3 steps were necessary to remove all cross -reacting material from cell 
lysates). After step 3, supernatants were transferred to fresh tubes for 
immunoprecipitation. 
Immune complex formation. 
4 yrl aliquots of ascites fluid was added to 250 JAl aliquots of precleared biotinylated or 
radiolabelled lysate and incubated overnight at 4 °C on a roller mixer. 
Immunoprecipitation. 
Complexed lysate was transferred to fresh tubes containing 65 pl of 10% v/v armed 
beads and incubated on a roller for 1 hr at 4 °C. The beads were centrifuged as before, 
and washed x 1 in 1% detergent, x 2 in 0.1% detergent, and x 2 in detergent -free lysis 
buffer. Pellets were then either analysed immediately by SDS PAGE or stored at 
-40 °C for later analysis. 
Biorad Inununobeads Method. 
Preclearing. 
50 pl of Biorad immunobeads was added to each 1 ml of biotinylated or radiolabelled 
lysate at 4 °C for 1 hr. These were centrifuged at 500g 
for 2 mins and supernatant decanted to fresh Eppendorf tubes containing 50 pl of 
beads. This step was carried out three times. 100 pl of supernatant was aliquoted into 
fresh Eppendorf tubes for immunoprecipitations and primary mAb added (2 pl neat 
ascites or 10 pl culture S /N). These were incubated on a rotary mixer overnight at 
4 °C. 
Immunoprecipitation. 
30 pl of immunobeads were added to each tube of complexes and incubated at room 
temperature for 1 hr on a rotary mixer. Beads were pelleted by centrifuging at 500g for 
2 mins and the supernatant was removed. The beads were then washed twice in high 
salt buffer (see appendix A), twice in low salt buffer, and finally in the same buffer 
with no added NaCl. 40 pl of reducing sample buffer (see appendix A) was added and 
samples incubated at 100 °C on a hot block for 5 mins before loading onto SDS 
polyacrylamide gels. 
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Immunoprecipitation - Dynabeads Method. 
Bead arming. 
M -450 Tosylactivated Dynabeads (Dynal) were used. Beads were washed in sterile 
distilled water and resuspended to 4 x 108 beads /ml. An equal volume of this 
suspension was added to a 150 ug /ml solution of purified goat- anti -mouse IgM 
(Sigma) in 0.05M borate buffer, to give an antibody to bead ratio of approximately 
5:1. This was incubated at 22 °C for 24 hrs with slow end over end rotation. The 
Dynabeads were collected using a magnetic particle collector (MPC, Dynal), and the 
supernatant discarded. The beads were washed sequentially in PBS 0.1% BSA: 3 x 10 
mins, 1 x 30 mins, and 1 x overnight at 4 °C. The beads were collected using an MPC, 
the supernatant discarded and the beads resuspended in PBS BSA at a concentration of 
4 x 108 beads /ml. Beads were stored at 4 °C as recommended by the manufacturer. 
Bead arming with primary mAbs. 
1 ul of ascites was added to each 150 µl aliquot of armed Dynabead suspension and 
incubated overnight on a roller at 4 °C. The beads were washed x 4 for 30 mins at 4 °C 
in PBS 0.1% BSA and stored in PBS BSA 0.02% NaN3 until use. 
Immunoprecipitation. 
150 pl of primary mAb coated beads (first washed in PBS 0.1% BSA for 30 mins) 
was added to 250 pl aliquots or radiolabelled cell lysate and incubated 
on a roller at 4 °C for 24 hrs. Beads were recovered using the MPC and washed x 2 for 
30 mins in PBS BSA before analysis by SDS PAGE. 
2.4.5 Sodium Dodecyl Sulphate Polyacrylamide 
Gel Electrophoresis (SDS PAGE). 
(Method based on íLaemmli, U.K., 1970)). Samples were incubated in reducing 
sample buffer (see appendix A) at 100 °C for 4 mins before loading on to 10% or 12% 
gels. 15 µl and 20 pl samples were used for 10 -well mini -gels, 30 pl samples for S- 
well mini gels, and 200 -400 pl samples for single sample -well gels. Molecular weight 
markers ( Amersham International Rainbow markers or 14C- labelled markers) were 
also diluted 1:1 and boiled in sample buffer and loaded on to each gel. The loaded gels 
were saturated in tank buffer (see appendix A) in a Biorad Miniprotean 2 TM11 SDS 
PAGE tank. A voltage of 200V was applied for 45 mins until the solvent front had 
reached the bottom of the gel. Gels were removed from between the glass plates and 
immersed in transfer buffer (see appendix A) for 60 mins before Western blotting. 
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2.4.6 Western Blotting. 
Western blotting was carried out using a Pharmacia dry- blotting system. Gels were 
placed face up on the cathode on a pad of filter paper saturated in transfer buffer (see 
appendix A). Transfer buffer -soaked nitrocellulose was then smoothed on top, taking 
care to eliminate any residual air bubbles from between the layers as they can interfere 
with the passage of current. Another pad of transfer buffer -soaked filter paper was 
then smoothed on top before sandwiching the layers together by clamping on the 
anode. A voltage of 100V was applied for 60 mins in order to transfer the SDS PAGE 
separated proteins to transfer to the nitro -cellulose. Western blots were blocked by 
incubation in PBS 5% dried milk powder for 2 hrs at room temperature with rocking, 
or overnight at 4 °C before developing. 
2.4.7 Enzyme Labelling Of Western Blots. 
Unlabelled Proteins. 
Blots were washed x 3 for 5 mins in TBS 0.02% Tween 20 before incubating in 
primary mAbs optimally diluted in PBS 1% BSA for 1 hr at room temperature. Blots 
were washed as before in TBS 0.05% Tween 20. Washed blots were incubated in 
horse -radish -peroxidase (HRP) labelled rabbit anti -mouse Ig (Sigma) diluted 1 /1000 
in TBS Tween for 1 hr at room temperature, and then washed x 3 in TBS Tween 
before developing. 
Biotinylated Proteins. 
Blots were washed as described above and then incubated in avidin- biotin -HRP 
complexes (DAKO - ABC -HRP kit) made up according to the manufacturers 
instructions and diluted a further 1/5 in ABC buffer (see appendix A). Blots were then 
washed x 3 as before and then developed using the DAB or ECL method. 
2.4.8 Antigen Detection. 
Diaminobenzidine (DAB) Method. 
Washed blots were bathed in a minimum volume of substrate solution (see appendix 
A) and colour development was observed within a few minutes. The reaction was 
stopped by washing in TBS Tween + NaN3. 
Enhanced Chemiluminescence (ECL) Method. 
After labelling of specific protein bands with horse radish peroxidase, blots were 
incubated with 10 ml of mixed E.C.L. reagents (Amersham International) which 
contain H202 + luminol (cyclic diacylhydrazide) + a light enhancer, at room 
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temperature for 1 min. ECL regents were removed, and the blots exposed to 
photographic film ( Hyperfilm - Amersham International) for 1 - 120 seconds 
depending on light intensity. Films were developed using a Kodak automatic 
developing machine. 
2.4.9 Autoradiography. 
After SDS PAGE of radiolabelled samples, gels were dried on an electric gel drier. 
Dried gels were exposed to Kodak Scientific Imaging Film (X -OMAT AR) in a 
cassette in the dark room for as long as was necessary in order to see clear bands on 
the developed film. Films were developed by immersion in Kodak LX24 developer 
with shaking for 5 mins, washed for 30 seconds in running tap water, and fixed by 
immersion in Kodak FX -40 liquid fixer for 3 mins until they became transparent. 
Films were then washed for 5 - 10 mins in running tap water and dried carefully 
before analysis. 
2.4.10 Radioimmunoassay Of Detergent- Treated Cells. 
5 x 105 formaldehyde -fixed CDw75 positive cells were incubated with 50 j l of 
primary mAb + 50 yíl 0.5% detergent solution for 45 mins at room temperature. Cells 
were washed x 2 in PBS 0.1% BSA 0.02% NaN3 and resuspended in the pellet 
volume. They were incubated in 50 ycl aliquots of 1/100 diluted NEM 1251- anti -mouse- 
IgM (80,000 cpm/well), (containing 25 ycl of human serum /ml to block cross - 
reactivity with human Ig on cell surfaces) for 30 mins at room temperature. Cells were 
washed twice as before, resuspended to 100 ill in the same buffer and transferred to 
sealed tubes before counting radioactivity in a gamma counter. 
2.4.11 Dot Blotting. 
Nitro -cellulose membrane was soaked in TBS and fitted into the dot -blot apparatus 
(Biorad). It was then re- wetted and vacuum -dried before adding 100 ycl aliquots of 
coating antigen dissolved in TBS. This was allowed to drain through the membrane by 
gravity for 1 hr before washing and blocking the membrane in PBS 1% BSA 0.05% 
Tween 20. 100 p i aliquots of primary mAbs optimally diluted in PBS 1% BSA were 
added, and allowed to drain through by gravity for 30 mins. Blots were washed 
overnight in TBS 0.05% Tween 20 at 4 °C. Washed blots were incubated in 
peroxidase -labelled rabbit anti -mouse Ig (Sigma) diluted 1 /1000 in TBS Tween for 1 
hr at room temperature. They were then washed x 3 in TBS Tween before addition of 
DAB substrate solution (see appendix A). After colour development, the reaction was 
stopped by washing in TBS Tween + 0.02% NaN3. 
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2.5 Monoclonal antibody production. 
The following techniques were employed in the production of the Pst mAbs as 
described in Chapter 6. Synthetic peptides were constructed from the amino acid 
sequence of human a- 2,6- sialyltransferase and used as immunogens for the 
production of a- 2,6- sialyltransferase specific mAbs. mAbs produced were screened 
using the anti -peptide ELISAs and the Raji -cell -bound ELISA. 
2.5.1 Synthetic Peptide Production. 
A computer structure prediction program written by E.E.Eliopoulos, (Secondary 
Structure Prediction Suite Version 2.2, March 1986), was used to analyse the 
secondary structure of a- 2,6- sialyltransferase. The resulting profiles were used to 
determine which regions of the protein were most likely to a) protrude from the 
surface of the molecule and b) not be adjacent to glycosylation sites. Three regions 
were found to fit these criteria, and the amino acid sequences of these regions were 
used in the construction of 3 Multiple Antigenic Peptides (MAPs) by Peptide and 
Protein Research at the University of Exeter. Each MAP contains 8 copies of the 
peptide linked by a poly -lysine core (Illustrated in Figure 2.1). The advantage of using 
this system is that the complexes are large enough to be used as immunogens without 
the need for a carrier protein, thus eliminating unnecessary immune reactions to any 
carrier protein. 
Figure 2.1 Diagrammatic Representation Of A MAP. 
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2.5.2 Antibody Production From Synthetic Peptides. 
Immunizations. 
Female BALB /C mice were initially immunised intraperitoneally with 50 µg of peptide 
JP3 in 100 pi 50% Inject Alum (Pierce) in normal saline. 4 booster injections of 100 
pl of 500 pg /ml JP3 in saline were given over a period of eight weeks. Serum samples 
were tested for anti -peptide activity by peptide ELISA, and mice were reboosted twice 
more at 2 week intervals with 100 pg JP3 in 200 pl of 50% Alum in normal saline. 
Sera were retested, a final boost of 100 pl of 500 pg /ml peptide in saline given, and 
the most highly responsive mouse sacrificed 2 days later for fusion. 
Fusions. 
Macrophages were collected, washed twice, and the suspension made up to 50 ml 
with HAT medium. Cells were plated out onto 5 x 96 -well tissue culture plates 
(Costar) at a density of 103 /well and cultured at 37 °C in an atmosphere of 5% CO2. . 
Splenocytes from the sacrificed mouse (typically - 108 cells /spleen), Sp10 (a HAT - 
sensitive mouse myeloma cell- line), and fresh murine macrophages were washed 
twice in serum -free RPMI. The splenocytes were resuspended in 5 ml of ice -cold 
0.17M NH.CI for 2 mins in order to lyse any red blood cells present in the sample. 
This was topped up with serum -free medium and cells were washed once more to 
remove the lysed cells. Cells were mixed in a ratio of 10 spleen cells : 1 Sp20 cell and 
centrifuged at 175g for 5 mins. The supernatant was carefully removed and the pellet 
tapped loose from the side of the tube. 0.5 ml of 54% polyethylene glycol (PEG -1500 
- Koch -Light) in PBS (previously sterilised by autoclaving) was slowly overlayered 
onto the pellet. The mixture was gently swirled to resuspend the pellet and mix the 
cells. After 2 mins stirring, 1 ml of warm serum -free medium was slowly added and 
stirring continued over 1 -2 mins. Another 1 ml of warm serum -free medium was 
added, and stirring continued for a further 1 -2 mins. Finally a further 1 ml of warm 
serum -free medium was added, stirred for 2 mins and the volume made up to 10 mis 
with warm serum -free medium. This suspension was centrifuged at 175g for 5 mins, 
the supernatant was carefully removed and 5 ml of plating medium (DMEM (ICN 
Flow) + 10% FCS + HAT (Sigma)) added slowly without disturbing the pellet. This 
was swirled gently to resuspend the cells. The suspension was then made up to 50 ml 
with warm HAT medium and plated immediately onto macrophages in 5 x 96 -well 
tissue culture plates (Costar). 
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Screening and Cloning. 
Plates were fed every 3 days and examined daily 7 days after fusion for the presence 
of colonies of cells. Supernatants from "positive" wells were carefully removed and 
tested for the presence of antibody by peptide -ELISA or cell -bound ELISA (using Raji 
cells). Wells were topped up with fresh DMEM -HAT. Large colonies of antibody 
secreting cells were transferred to larger wells in 24 -well plates to allow further 
growth. Supernatants were re- screened, and positive colonies were cloned by dilution 
of cells to 10 cells /ml and seeded into 96 well plates in 100 pl aliquots (1 cell /well). 
Plates were checked daily for cell growth, and colony supernatants were rescreened by 
ELISA. Positive clones were expanded by transferring to larger wells and then 
sequentially larger tissue culture flasks, freezing down samples in liquid nitrogen at 
each stage to prevent loss of clones in the event of infection. 
2.5.3 Peptide ELISAs. 
Alkaline phosphatase method. 
96 well ELISA plates were coated overnight at 4 °C with 100 pl /well of 50 pg /ml of 
peptide dissolved in Carbonate -Bicarbonate coating buffer pH 9.6 (capsules - Sigma). 
Plates were washed x 3 in PBS 0.05% Tween 20, and blocked by incubation in PBS 
1% BSA for 30 mins at room temperature. Antibody samples were loaded into wells 
in triplicate in 100 pl aliquots, and incubated at room temperature for 90 mins. Normal 
mouse serum or irrelevant hybridoma supernatant were used as negative controls. 
Plates were washed x 3 in PBS Tween before addition of 100 pl aliquots of 1 /100 
diluted alkaline phosphatase labelled anti -mouse -IgG (Sigma) in PBS 1% BSA. Plates 
were incubated at room temperature for 90 minutes, and washed x 3 as before. A 200 
Id aliquot of substrate solution (see appendix A) was then added to each well and 
plates were read at 405 nm in a Dynatech MR5000 ELISA plate reader after 30 -45 
mins. 
Horse radish peroxidase (HRP) method. 
Plates were coated, blocked and incubated in primary antibody as described above. 
After washing plates, a 100 pl aliquot of HRP- labelled rabbit -anti -mouse -Ig (DAKO) 
diluted 1/2000 in PBS 1% BSA was added to each well, and incubated for 90 mins at 
room temperature. Plates were washed x 3 as before and a 100 aliquot of substrate 
solution (see appendix A) added to each well. When a colour change from clear to 
yellow was observed (typically within 1 -5 minutes) the reaction was stopped by the 
addition of 100 pl of 4M H2SO4/well. Plates were then read on a Dynatech MR5000 
ELISA plate reader using a 490 nm test filter and a 630 nm reference filter. 
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2.5.4 Cell -Bound ELISA. 
Adherent cells (e.g. RAJI -A) were grown to confluence, and removed from the 
culture flask by vigorous pipette action. Cells were counted and made up to 106 
cells /ml in fresh medium (DMEM, 10% FCS, P /S, Glu). 10 pl of Phorbol Myristate 
Acetate was added to 50 ml of cell suspension and 100 pd aliquots of cells were seeded 
into five 96 well flat -bottomed microtitre plates. Cells were grown overnight until they 
were close to confluence. The plates were then washed twice in PBS pH 7.2 and fixed 
with 100 pl aliquots of 1% paraformaldehyde in PBS for 30 mins (or until use after 
storing at 4 °C). After fixing or storage, the plates were washed once with TBS 1% 
BSA and 50 -100 pl of mAb was added to wells. Plates were incubated overnight at 
4 °C and washed twice in TBS 1% BSA before adding 100 µl of biotin -conjugated 
anti -mouse Ig (1/400 in TBS 1% BSA) per well. After 1 hr at 20°C, plates were 
washed twice in TBS BSA and two drops of avidin- biotin -HRP complexes (DAKO 
ABC -HRP kit) in ABC buffer (see appendix A) were added to each well. Plates were 
incubated at room temperature for 30 mins, and washed twice in TBS BSA before 
addition of -200 p1 /well of filtered DAB substrate solution (see appendix A). When 
staining of the cells was evident, they were washed in TBS and examined under an 
inverted microscope. 
2.6 Development of an Assay For a- 2,6- Sialyltransferase. 
The following assay was developed to specifically measure a- 2,6- sialyltransferase 
activity in Pst immunoprecipitates and in serum samples. Unfortunately, attempts at 
immunoprecipitation of enzymatically active a- 2,6- sialyltransferase were not 
successful, and are therefore not described in the thesis. 
2.6.1 Assay For a -2,6 -S ialyltransferase. 
This method is adapted from that of Mattox et al (Mattox, S., Walrath, K., Ceiler, D., 
Smith, D.F. and Cummings, R.D., 1992). 96 well ELISA plates were coated 
overnight at 4 °C with 100 p1 /well of 1 pg /ml asialofetuin (Sigma) in coating buffer. 
Plates were then washed x 3 in PBS 0.05% Tween 20 (Sigma) and blocked in PBS 
0.05% Tween 20 1% Gelatin (Sigma) for 30 mins at room temperature. Plates were 
washed x 3 in PBS Tween before setting up the assay. The assay mix in each well 
consisted of 50 pl of enzyme + 50 pl of 100 itM CMP -NANA (Boehringer Mannheim 
or Sigma) in 50 mM cacodylate buffer pH 6.5. Standard samples of purified rat a- 
2,6-sialyltransferase (Sigma) were used in order to obtain a standard curve. Negative 
controls consisted of wells containing sialic acid + no enzyme, or buffer with no 
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enzyme or sialic acid present. The mixture was incubated at room temperature for 1 hr. 
Plates were then washed x 3 in PBS Tween before adding 100 ytl aliquots of 1 pg /m1 
biotinylated Sambucus Nigra Agglutinin (SNA) in PBS Tween. Plates were incubated 
at room temperature for 1 hr and then washed x 3 as before. 3 drops of avidin- biotin- 
peroxidase complexes (DAKO) in TBS were then added to each well, and incubated at 
room temperature for 30 mins. Plates were then washed a further x 3 before addition 
of 100 pl aliquots of substrate solution (see appendix A). When a colour change from 
clear to yellow was observed (typically within 1 minute) the reaction was stopped by 
the addition of 100 pl aliquots of 4M H2SO4. Plates were then read on a Dynatech 
MR5000 ELISA plate reader using a 490 nm test filter and a 630 nm reference filter. A 
standard curve was obtained by plotting the log of sialyltransferase concentration 
against the optical density (O.D.) detected by the reader after subtracting the O.D. 
values of negative controls. Unknown enzyme concentrations were then estimated 
from the curve. This assay was tested for specificity for a- 2,6- sialyltransferase by 
substitution of SNA with Maackia Amurensis Agglutinin (MAA) - a lectin specific for 
a-2,3 -linked sialic acid residues. O.D. values obtained were lower than those of the 
negative controls using SNA. 
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CHAPTER 3 
Expression and Structure of CDw75 
on Lymphocytes. 
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3.1 Distribution of CDw75 on Lymphocytes. 
As described in chapter 1, all CDw75 mAb have previously been shown to react 
specifically with mature B lymphocytes which are sIg +, as well as sIg+ B -cell lines, 
leukaemias and lymphomas. Also, mAbs have not been found to react to pre -B -cell 
lines or to sIg- B- lineage lymphoblastic leukaemias or sIg- B -cell lines(Mittler, R.S., 
Talle, M.A., Carpenter, K., Rao, P.E. and Goldstein, G., 1983; Epstein, A.L., 
Marder, R.J., Winter, J.N. and Fox, R.I., 1984; Smeland, E., Funderud, S., Ruud, 
E., Blomhoff, H.K. and T, G., 1985; Dorken, B., Moller, P., Pezzutto, A., 
Schwartz -Albiez, R. and Moldenhauer, G., 1989; Erikstein, B.K., Beiske, K., 
Smeland, E.B., Davies, C.D.L., Blomhoff, H.K. and S, F., 1989; Gramatzki, M., 
Burger, R., Kraus, J., Lauer, U., Rohwer, P., Eger, G., Kalden, J.R. and 
Henschke, F., 1991). Interestingly CDw75 is not expressed on sIgM+ B -cells from 
foetal samples which implies that CDw75 is expressed at a later stage of B -cell 
development than sIg, and as CDw75 is not expressed on EBV transformed 
lymphoblastoid cell lines or on plasma cell tumours, it has been suggested that CDw75 
is lost from the cell surface at a late stage of terminal B -cell differentiation(Dorken, B., 
Moller, P., Pezzutto, A., Schwartz -Albiez, R. and Moldenhauer, G., 1989). There 
are also some reports of mAbs HH2, EBU -141, EBU -65 and LN -1 binding to normal 
peripheral blood T- cells, but no reactivity with T -cell lines or T -cell leukaemias or 
lymphomas has previously been described(Dorken, B., Moller, P., Pezzutto, A., 
Schwartz -Albiez, R. and Moldenhauer, G., 1989; Gramatzki, M., Lauer, U., Burger, 
R., Huber, C., Rohwer, P., Kalden, J.R. and Henschke, F., 1989; Gramatzki, M., 
Burger, R., Kraus, J., Lauer, U., Rohwer, P., Eger, G., Kalden, J.R. and 
Henschke, F., 1991). 
In order to further characterise CDw75 expression patterns already observed, in 
sections 3.1.1 and 3.1.2 respectively, I have looked at CDw75 expression on PBL 
from a number of normal healthy donors and from patients with B -CLL. In section 
3.1.3, sublines of the Namalwa Burkitt lymphoma cell -line were also stained with 
CDw75. These sublines are thought to resemble B -cells arrested at different stages of 
differentiation(Guy, K., Ross, J.A. and Steel, C.M., 1989; Guy, K., Middleton, 
P.G., Bansal, N.S., Ross, J.A. and Steel, C.M., 1990), and thus may be of use in 
further determination of the stage of B -cell differentiation at which CDw75 expression 
occurs. In addition, as the epitope recognised by the LN -1 mAb is reported to be 
highly susceptible to neuraminidase treatment(Epstein, A.L., Marder, R.J., Winter, 
J.N. and Fox, R.I., 1984), I have also looked at the effects of neuraminidase 
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treatment of cells on mAb binding in most of the samples tested. Neuraminidase 
catalyses the removal of sialic acid groups from sialylated glycosides of glycoproteins 
and glycolipids. By pre- treating cells with neuraminidase prior to staining with mAbs, 
we can assess which, if any of the CDw75 epitopes contain sialylated carbohydrate. 
3.1.1 CDw75 Expression on Normal Lymphocytes. 
Normal peripheral blood lymphocyte (PBL) samples were obtained from laboratory 
staff and from leucocyte concentrates (buffy coats) from normal blood donors at the 
Blood Transfusion Service. Cells were stained by indirect immunofluorescence using 
3 mAbs from the CDw75 panel from the 4th International Leucocyte Typing 
Workshop (Dorken, B., Moller, P., Pezzutto, A., Schwartz -Albiez, R. and 
Moldenhauer, G., 1989). HH2, OKB4 and EBU -141 are mAbs which were assigned 
to this cluster. EBU -65 was also used. Although not formally included in the CDw75 
cluster, it was in the same preliminary statistical cluster as the others, and does exhibit 
similar staining characteristics (Gramatzki, M., Lauer, U., Burger, R., Huber, C., 
Rohwer, P., Kalden, J.R. and Henschke, F., 1989; Guy, K., Ross, J.A. and Steel, 
C.M., 1989; Johnson, G.D., MacLennan, I.C.M., Khan, M., Hardie, D.L. and 
Richardson, P.R., 1989). Unfortunately, the fourth mAb of the cluster (LN -1) was 
not available for us to use. 
10 PBL samples were stained using HH2, EBU -141, EBU -65 and OKB4 as well as 
CD 19, CD43, CD4, CD8, CD45RA and CD45RO. Cells were also treated with 0.05 
U /ml neuraminidase to remove sialic acid prior to staining. The amount of 
neuraminidase used was determined by a titration. The results of this titration are 
illustrated in figure 3.1.1. CDw75 staining patterns were very similar for all normal 
donors tested, and flow cytometry histograms for cells from three donors are shown 
in figure 3.1.2. A small percentage of cells (4 -7 %) correlating roughly with the 
percentage of B -cells in each sample, were stained with high intensity using HH2 and 
EBU -141. A small proportion of cells in these samples was also weakly stained with 
these mAbs. This may be a small subpopulation of T- cells. This subpopulation was 
more apparent in EBU -65 stained samples. As with HH2 and EBU -141, EBU -65 
stained a small number of cells with high intensity. However, a much larger 
population of cells was found to be weakly stained with this mAb. Binding of all three 
mAbs was completely abrogated by neuraminidase treatment of cells. OKB4 staining 
was negligible in all samples tested, and was only slightly increased producing dimly 
stained cells, after neuraminidase treatment. 
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Figure 3.1.1 PNT cells were treated with different concentrations of 
Neuraminidase Type X (Clostridium peifringens) in the range 0 - 0.2 
U /ml prior to immunofluorescence staining, and were analysed by 
flow cytometry. Mean fluorescence intensities of stained cells 
indicated that 0.05 U /ml was the lowest concentration of 
Neuraminidase that should be used. 
Total numbers of positively stained cells was found to vary a great deal from donor to 
donor. However, the general pattern of staining was always the same, with EBU -65 
staining highest numbers of cells with low intensity, and similar numbers of cells as 
HH2 and EBU -141 with high intensity. These subpopulations of lymphocytes were 
examined in more detail later on in the project and are described in section 3.3. 
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3.1.2 CDw75 Expression in CLL Patients. 
Blood samples from 23 patients with B -cell Chronic Lymphocytic Leukaemia (B- 
CLL) were studied for CDw75 expression. Cells were also stained with CD2, CD19 
and CD5 to determine the proportion of T -, B- and CLL cells in each blood sample. 
Histograms of typical fluorescence levels of stained samples from two patients are 
shown in figure 3.1.3(a,ó), along with histograms of data from another patient 
3.1.3(c) whose cells were treated with neuraminidase before staining. Results 
obtained from a panel of 13 CLL patients are given in table 3.1.1 below. 















1 92 ND 98 ND 96 ND 3 ND 3 97 
2 97 ND 96 ND 94 ND 8 ND 6 95 
4 78 ND 89 ND 90 ND 1 ND 32 89 
5 95 ND 92 ND 92 ND 4 ND 5 95 
9 87 1 75 1 88 1 33 77 11 67 
11 81 2 72 3 82 2 38 67 16 74 
16 92 0 94 1 91 0 16 70 4 94 
17 87 1 83 8 84 6 8 72 6 89 
18 44 1 44 1 40 1 1 24 40 51 
19 77 0 97 2 92 1 3 33 0 98 
20 48 0 48 1 36 3 6 50 3 44 
21 56 1 63 0 62 0 2 42 26 55 
22 58 1 56 1 61 2 6 73 21 60 
* -N = before neuraminidase treatment; + N = after neuraminidase treatment. 
EBU -141 and EBU -65 staining patterns were found to be virtually identical in all 
samples tested. A major population of cells, similar in number to the B -cell population 
were brightly stained with both of these mAb. HH2 exhibited similar staining patterns, 
but in some cases (e.g. Patient 4 in figure 3.1.3) the number of brightly stained cells 
was slightly lower than for EBU -141 and EBU -65. OKB4 stained a few cells at low 
intensity in some patients (9, 11, 16), but in most patients binding levels were 
negligible. However, after treatment with neuraminidase, OKB4 stained similar 
numbers of cells to HH2, although at slightly lower intensities. This may indicate that 
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3.1.3(b) CDw75 Expression in CLL Patients. 
Patient 5. 
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the epitope recognised by OKB4 is masked by sialic acid, and may even be the non - 
sialylated version of the HH2 epitope. In contrast, HH2, EBU -141 and EBU -65 
binding was completely abolished by neuraminidase treatment, confirming that sialic 
acid forms a major part of these epitopes. In addition to B -cell staining, all four mAbs 
dimly stained a small population of non -B- cells. The number of cells in this population 
varied between patients and with the mAb used. From this study alone, it would 
appear that all four mAbs do not recognise the same epitope, despite reports indicating 
that they do (Dorken, B., Moller, P., Pezzutto, A., Schwartz -Albiez, R. and 
Moldenhauer, G., 1989). Further analysis of these epitopes was carried out using 
tunicamycin - an inhibitor of N- linked glycosylation. Results of these experiments are 
given in section 3.2. 
3.1.3 CDw75 Expression on Namalwa Cell- lines. 
It has been suggested that the variant sublines of the Namalwa Burkitt lymphoma cell - 
line are representative of B -cells at different stages of maturation.(Guy, K., Ross, 
J.A. and Steel, C.M., 1989; Guy, K., Middleton, P.G., Bansal, N.S., Ross, J.A. 
and Steel, C.M., 1990) Five of the six available sublines (NK, CSN /70, IPN /45, 
PNT & KN2 - in increasing order of maturation) were tested using the four CDw75 
mAb on four occasions throughout the duration of the project. The results of flow 
cytometric analysis were consistent, and typical percentage values of positively stained 
cells both before and after neuraminidase treatment are given in table 3.1.2 below. 















NK ND ND 1 1 1 1 1 9 
CSN /70 3 0 0 0 0 0 2 17 
IPN /45 79 0 25 1 16 0 42 88 
PNT 78 2 40 2 21 1 38 69 
KN2 10 0 0 0 0 0 1 16 
NK cells did not bind any of the CDw75 mAbs tested. CSN /70 was negative with 
EBU -141 and EBU -65. OKB4 only stained a few cells weakly, and slightly more 
after neuraminidase treatment. HH2 also dimly stained a very small percentage of 
CSN /70 cells. IPN /45 and PNT cells were brightly stained by all mAbs, with PNT 
cells expressing slightly higher levels of all epitopes than IPN /45 cells. Interestingly, 
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OKB4 bound to both sublines in significant amounts even prior to neuraminidase 
treatment, although binding was substantially increased after treatment. This suggests 
that the epitope may be only partially shielded by sialic acid on these cells, perhaps 
because it is expressed at such high levels. KN2 cells were found to express very low 
levels of the HH2 epitope and the sialylated OKB4 epitope (only detectable after 
neuraminidase treatment). Neither EBU -141 nor EBU -65 was found to bind to this 
cell -line. 
CSN /70 cells do not express membrane Ig, whereas both IPN /45 and PNT cells do 
express this, but do not secrete Ig. KN2, the most mature subline not only expresses 
surface Ig, but also secretes it, mimicking mature B -cells in an activated state. NK 
cells are thought to be even less differentiated than CSN /70 cells(Guy, K., Middleton, 
P.G., Bansal, N.S., Ross, J.A. and Steel, C.M., 1990). CDw75 therefore seems to 
be expressed mostly on resting, mature B -cells which synthesise membrane Ig but do 
not secrete it, but not on immature non -Ig- expressing B -cells or on activated Ig- 
secreting cells. These observed cellular expression patterns correlate with those 
described previously at the Fourth International Leucocyte Typing Workshop(Dorken, 
B., Moller, P., Pezzutto, A., Schwartz -Albiez, R. and Moldenhauer, G., 1989). 
3.2 Carbohydrate Structure of CDw75. 
As discussed above, it is clear that the epitopes of CDw75 recognised by the mAbs 
HH2, EBU -141 and EBU -65 contain sialic acid, and that the OKB4 epitope is masked 
by sialic acid. It has also been shown previously that the epitope recognised by LN -1 
is sialylated(Epstein, A.L., Marder, R.J., Winter, J.N. and Fox, R.I., 1984). In 
order to discover more about the carbohydrate structure of the epitopes, I attempted to 
determine if this was N- or 0-linked carbohydrate, and if the OKB4 epitope was also 
composed of non -sialylated N- or 0-linked carbohydrate. This was done by inhibition 
of synthesis of N- linked carbohydrate using tunicamycin. Tunicamycin is an antibiotic 
which blocks N- linked glycosylation of proteins and lipids by inhibiting the enzyme 
UDP-G1cNAc : dolichylphosphate- G1cNAc -l- phosphate transferase. This enzyme 
catalyses the first step of N- linked glycosylation - the transfer of GlcNAc -1- phosphate 
from UDP -N- acetylglucosamine to dolichyl phosphate to form N- acetylglucosamine 
pyrophosphoryl dolichol(Tkacz, J.S. and Lampen, J.O., 1975; Duksin, D. and 
Mahoney, W.C., 1982; Humphries, M.J., Matsumoto, K., White, S.L. and Olden, 
K., 1986; Broquet, P., George, P., Geoffroy, J., Reboul, P. and Louisot, P., 1991). 
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I also attempted to determine if the type of neuraminidase used to remove sialic acid 
had any effect on antigen recognition, as neuraminidase from Vibrio cholerae is 
reported to remove only terminal sialic acid residues, whilst neuraminidase from 
Clostridium perfringens removes both terminal and internal residues (Conzelmann, A. 
and Lefrancois, L., 1988). 
3.2.1 Effect of Tunicarnycin on CDw75 Expression. 
PNT cells were stripped of their sialic acid by neuraminidase treatment and then 
cultured in varying concentrations of tunicamycin dissolved in normal RPMI for 
varying lengths of time with or without monensin (an inhibitor of sialyltransferase 
(Waibel, R., O'Hara, C.J. and Stahel, R.A., 1991)). This experiment was repeated 
on eight occasions with slight variations, producing consistently repeatable results 
(results not shown). It was found that tunicamycin effectively inhibited synthesis of 
the CDw75 epitopes recognised by all four available mAb. 
A typical example of data is given in figure 3.2.1. In this experiment, PNT cells were 
cultured in 20jig /m1 tunicamycin + 2 ysg /ml monensin. The yellow histograms 
represent the fluorescence levels of the negative control - cells stained with the IgM 
anti -CD14 mAb VIM13. The red histograms show the fluorescence levels of 
neuraminidase treated cells stained with the CDw75 mAb indicated. The purple curves 
indicate CDw75 staining levels of neuraminidase treated cells cultured overnight in 
normal medium after treatment (i.e. recovered cells). The green histograms show 
fluorescence levels of CDw75 stained cells after culturing in the presence of 20 ytg /m1 
tunicamycin + 2 yig /ml monensin. Binding levels of all CDw75 mAb were visibly 
reduced after culturing in tunicamycin when compared to those of the control 
experiment (purple) in which normal glycosylation and CDw75 expression has been 
restored. 
3.2.2 Effect of Tunicamvcin Concentration. 
It is possible that the reduced levels of CDw75 binding observed in this experiment 
could be due solely to the inhibition of sialyltransferase activity by monensin. 
However, as demonstrated in figure 3.2.2, the tunicamycin effect is increased when 
increasing concentrations are used. In figure 3.2.2, the purple histograms again 
represent fluorescence levels of CDw75 stained control, recovered cells, and the red 
and green curves show CDw75 binding levels on PNT cells treated with 5 ycg/ml and 
20 ysg/ml tunicamycin respectively. 2 ysg/ml of monensin was used in all experiments. 
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= ISOTYPE MATCHED NEGATIVE CONTROL 
= RE- SIALYLATED CELLS (TUNICAMYCIN = 0 /cg /ml) 
= CELLS TREATED WITH 20 pg /m1 TUNICAMYCIN 
= NEURAMINIDASE- TREATED CELLS 
3.2.1 Tunicamvcin Inhibition of CDw75 Expression on PNT Cells. 
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It is particularly interesting to note the effect of tunicamycin on the expression of the 
OKB4 epitope. Fluorescence levels of control cells are reduced due to masking of the 
epitope by sialylation of newly synthesised epitopes. However, fluorescence levels of 
tunicamycin treated cells are even lower than those of the re- sialylated control cells. 
The data suggests that the OKB4 epitope is composed of N- linked carbohydrate, as its 
expression is inhibited by tunicamycin, even in the presence of monensin. In the 
presence of monensin, we would expect fluorescence levels to remain high as masking 
of the epitope by sialic acid is prevented. However, fluorescence is decreased 
indicating that tunicamycin effectively inhibits synthesis of the OKB4 epitope, 
suggesting that it contains N- linked carbohydrate. 
3.2.3 Effect of Tunicamycin Alone on CDw75 Expression. 
HH2, EBU -141 and EBU -65 binding levels were all reduced after culturing cells in 
tunicamycin and monensin. The dependence on tunicamycin concentration indicates 
that these epitopes are also made up of N- linked sialylated carbohydrate, and that the 
reduction in staining is not solely due to the effects of monensin. To add further 
credence to this data, cells were cultured in the presence of tunicamycin alone without 
monensin, and then stained with CDw75 as before. To check the level of inhibition, 
cells were also stained with lectins Sambucus Nigra Agglutinin (SNA) and Maackia 
Amurensis Agglutinin (MAA), specific for a- 2,6- linked sialic acid (only present on 
N- linked carbohydrate), and for a- 2,3- linked sialic acid (found on both N- and O- 
linked carbohydrate) respectively (Shibuya, N., Goldstein, I.J., Broekaert, W.F., 
Nsimba -Lubaki, M., Peeters, B. and Peumans, W.J., 1987; Shibuya, N., Goldstein, 
I.J., Broekaert, W.F., Nsimba -Lubaki, M., Peeters, B. and Peumans, W.J., 1987; 
Wang, W.C. and Cummings, R.D., 1988). In one experiment, cells were treated with 
neuraminidase prior to staining in order to eliminate the effect of resialylation on 
epitope structure. The results of two experiments are given in tables 3.2.1 and 3.2.2 
below. Even in the absence of monensin, CDw75 expression is inhibited, proving that 
all epitopes are composed at least in part of N- linked carbohydrate. In particular it 
should be noted that the level of OKB4 binding after treatment with 1 µg /ml and 2 
µg /ml tunicamycin is unaffected by neuraminidase, providing further evidence that the 
reduction in OKB4 staining is due to inhibition of synthesis of the epitope and not 
simply to masking by sialic acid. 
The percentages of cells stained with the EBU -65 mAb were particularly low in this 
experiment due to deterioration of the mAb. I have had to rely on the generosity of the 
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clone originators for all CDw75 mAb used, and it has been particularly difficult to 
obtain sufficient amounts of the mAbs EBU -141 and EBU -65. It would have been 
impossible to obtain fresh stocks of these mAbs at the stage in the project when these 
experiments were conducted. 
Table 3.2.1Percentages of CDw75 Positive Tunicamycin- treated Cells. 
Day Zero Tunicam cin Concentration 
mAb control + neur 0µg /ml 0.25µg /m10.511.g /m1 lµg /ml 214/ml 
HH2 57 1 38 17 6 2 1 
OKB4 25 64 40 31 27 24 22 
EBU -141 50 18 42 29 18 11 8 
EBU -65 10 1 6 1 0 0 0 
SNA 100 8 81 66 35 14 2 
MAA 84 94 , 90 99 94 93 72 
Table 3.2.2 Percentages of CDw75 Positive Tunicamycin- treated Cells 
Before and After Neuraminidase Treatment. 
Day Zero Tunicamycin Concentration 
mAb control + neur 014/m1 0.251.1g /m 
1 
0.511g /m1 lµg /ml 21.1g/ml 
HH2 44 0 39 27 18 8 2 
OKB4 16 48 35 32 29 30 22 
OKB4(N) 48 48 50 45 39 32 20 
EBU -141 40 9 41 34 27 29 11 
EBU -65 7 1 8 4 3 2 1 
SNA 89 9 94 82 67 29 15 
SNA(N) 9 9 6 6 3 1 0 
MAA 6 91 97 96 94 94 94 
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3.2.4 Comparison of Effects of Neuraminidase from 
Vibrio cholerae and Clostridium perfringens. 
PNT cells were treated with 0.05 U /ml neuraminidase Type X from Clostridium 
perfringens as before, and with increasing concentrations of neuraminidase from 
Vibrio cholerae over the range 0 - 0.2 U /ml. Cells were then stained using the CDw75 
mAb OKB4, EBU -141 and EBU -65 as well as with an isotype- matched negative 
control mAb (VIM13) and a known positive control mAb (4F2 - directed against an 
activation marker). This experiment was carried out on 2 occasions, producing similar 
results. Percentages of positively stained cells obtained from 1 experiment are given in 
table 3.2.3 below, and illustrated in figure 3.2.3. 
From the results it can be seen that at Vibrio cholerae neuraminidase concentrations 
greater than 0.05 U /ml, the OKB4 epitope is exposed to the same extent as with 0.05 
U /ml Clostridium perfringens neuraminidase, and epitopes EBU -141 and EBU -65 are 
destroyed equally effectively by both enzymes. This indicates that the sialic acid 
residues involved in the EBU -141 and EBU -65 epitopes, and those which mask the 
OKB4 epitope are terminal sialic acid residues. Had they been internal residues, the 
neuraminidase from Vibriocholerae would not have removed them. 
Table 3.2.3 Percentages of CDw75 Positive C.perfringens and 
V.cholerae Neuraminidase- treated PNT Cells. 
fNeuraminidaseJ 
(U/ml) OKB4 EBU-141 EBU-65 4F2 
0.016 V.c.* 150 23 14 98 
0.003 V.c. 22 20 10 98 
0.006 V. c. 28 13 6 98 
0.0125 V.c. 35 5 2 98 
0.025 V.c. 35 4 1 99 
0.05 V.c. 38 2 0 99 
0.1V.c. 46 3 1 99 
0.2 V.c. 43 3 0 100 
0.05 C.p.T 43 2 0 98 
0 13 24 15 98 
*V.c. = Neuraminidase from Vibriocholerae. 
0 All values are adjusted to compensate for background and non -specific binding. 
¡C .p. = Neuraminidase from Clostridium perfringens. 
Figure 3.2.3 Percentages of CDw75 Positive C.perfringens and 
V.cholerae Neuraminidase- treated PNT cells. 
-5 
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3.3 CDw75 Expression on Resting and PHA -Activated 
Peripheral Blood T- Lymphocyte Subsets. 
CDw75 expression on all mature slg+ B -cells has been well documented. However, 
as discussed in section 3.1, and as previously noted(Dorken, B., Moller, P., 
Pezzutto, A., Schwartz -Albiez, R. and Moldenhauer, G., 1989), CDw75 is also 
expressed to a certain extent on peripheral blood T- cells. This expression seemed to be 
poorly characterised, with levels of expression being much lower than those observed 
on B- cells, and percentages of T -cells stained varying from donor to donor. It 
appeared that subsets of T -cells were stained with different intensities, and the 
variation from donor to donor suggested that the activation state of the T -cells may 
also be a factor in CDw75 expression. There is a report of OKB4 binding to PHA 
activated T -cells in T- enriched samples(Mittler, R.S., Talle, M.A., Carpenter, K., 
Rao, P.E. and Goldstein, G., 1983). The author reports no significant increase of 
OKB4 expression on activated T- cells. However, the results given hint at possible 
OKB4 induction since expression was increased by almost 3 -fold on activation, and 
staining with OKB4 was done without prior treatment of cells with neuraminidase. 
T -cells express a number of other cell -surface markers which allow us to identify 
various subsets according to their specific functions in the immune response. CD4+ T- 
cells are long established as the helper /inducer T -cell subset, whereas CD8+ T -cells 
represent the cytotoxic cell subset. Other markers such as CD58 and CD29 are 
expressed on memory T- cells, and expression of CD54 is a good indicator of T -cell 
activation(Sanders, M.E., Makgoba, M.W., Sharrow, S.O., Stephany, D., Springer, 
T.A., Young, H.A. and Shaw, S., 1988). More recently it has become apparent that 
different isoforms of CD45 are expressed on T -cells at different stages of maturation. 
Naive T -cells initially express only CD45RA, but when stimulated with PHA or any 
soluble antigen, cells begin to express CD45RO(Akbar, A.N., L, T., Timms, A., 
Beverley, P.C.L. and Janossy, G., 1988; Wallace, D.L. and Beverley, P.C.L., 
1990). There is a stage at around day 3 of activation where both isoforms can be 
detected on the cell surface, and then eventually by day 7, only CD45RO is expressed. 
These CD45RO+ T -cells show an increased response to the same soluble antigen with 
kinetics typical of a secondary response. They do not revert to CD45RA expression. 
This primed CD45RO+ T -cell subset has therefore been identified as the memory 
cell subset (Smith, S.H., Brown, M.H., Rowe, D., Callard, R.E. and Beverley, 
P.C.L., 1986; Akbar, A.N., L, T., Timms, A., Beverley, P.C.L. and Janossy, 
G., 1988; Sanders, M.E., Makgoba, M.W., Sharrow, S.O., Stephany, D., 
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Springer, T.A., Young, H.A. and Shaw, S., 1988; Wallace, D.L. and Beverley, 
P.C.L., 1990). 
In this section, both resting and PHA -activated T -cells were examined for expression 
of each of the CDw75 epitopes and for other markers of specific T -cell subsets 
including those discussed above. The aims of this section were to determine if CDw75 
expression is increased on T -cell activation as previously suggested(Mittler, R.S., 
Talle, M.A., Carpenter, K., Rao, P.E. and Goldstein, G., 1983), to discover which 
T -cell subsets express CDw75 epitopes, and to ascertain if each CDw75 epitope is 
expressed on the same T -cell subsets. 
3.3.1 CDw75 Expression on Resting T-Cells 
In order to identify which resting lymphocyte subpopulations were CDw75 positive, 
normal peripheral blood lymphocytes (PBL) were double- stained with each of the four 
CDw75 mAb available, and with the cell surface markers CD3, CD4, CD8 and CD19. 
When OKB4 was used, cells were first treated with neuraminidase to expose the 
epitope. In all cases studied, OKB4 binding was negligible before this treatment. 
Typical results from a study involving six donors are shown in figure 3.3.1. In the 
resting state, B -cells (CD19+ cells) express CDw75 with highest intensity. HH2 and 
OKB4 stain relatively few T lymphocytes in the resting state. However, a small 
subpopulation of T -cells express high levels of those epitopes recognised by the mAbs 
EBU -141 and EBU -65. The majority of these T -cells are of the CD4+ type, but a 
proportion of CD8+ cells also expressed these epitopes. 
3.3.2 EBU -141 and EBU -65 Staining of 
TJ- nstimulated T- Cells. 
Further analysis of these EBU -141+ and EBU -65+ populations using markers of T- 
cell activation such as CD45RO, CD45RA, CD54, CD58 and CD29, indicate that 
these T -cells belong to the naive T -cell population rather than the memory cell 
population.(Akbar, A.N., L, T., Timms, A., Beverley, P.C.L. and Janossy, G., 
1988; Wallace, D.L. and Beverley, P.C.L., 1990) This reinforces the findings of our 
previously published study which indicated that EBU -65+ T -cells belong to this naive 
population(Guy, K. and Andrew, J.M., 1991). Representative results from one 
experiment where cells were stained with each of these two CDw75 mAb and the 












Figure 3.3.1 CDw75 staining of resting PBL. 
2- colour immunofluorescence dot -plots of cells stained using FITC -anti- mouse -IgM to 
detect CDw75 mAbs (HH2, OKB4, EBU -141 and EBU -65), and biotinylated anti - 
mouse-IgG and streptavidin P.E. to detect IgG mAbs. Fluorescence is shown in log 
scale, and the gates superimposed indicate the limits of fluorescence intensities 







Figure 3.3.2 EBU -141 and EBU -65 staining of unstimulated T- cells. 
2- colour immunofluorescence of resting T -cells stained with CDw75 and other T -cell 
markers of activation. EBU -141+ and EBU -65+ T -cells are mainly highly positive for 
CD45RA, and negative or weakly positive for CD45RO, CD54, CD58 & CD29. 
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EBU -65 positive cells are CD45RA+ and CD45RO, CD54, CD58, and CD29 negative 
or weakly positive - a staining pattern characteristic of naive T- cells. (Wallace, D.L. 
and Beverley, P.C.L., 1990) 
3.3.3 CDw75 Expression on PHA -activated T- cells. 
T -cells were stimulated by culturing with PHA over a three day period, and were 
subsequently stained with CDw75 and CD3 mAbs in order to examine changes in 
levels of expression of CDw75 upon T -cell activation. This experiment was repeated 
using PBL from eight donors. The results from one representative donor are shown in 
Figure 3.3.3. After stimulation for three days, the number of HH2+ and OKB4+ T- 
cells increased 5 -10 fold, whereas binding of EBU -141 and EBU -65 mAbs was 
reduced. Both the number of EBU -141 and EBU -65 positive cells and the 
fluorescence intensity of those cells stained was reduced, with the fluorescence 
intensity of PHA- activated cells being approximately 10% of that of unstimulated 
cells. 
3.3.4, CDw75 Staining of CD54+ Cells. 
CD54 (ICAM -1) is a marker of activatedT -cells.(Sanders, M.E., Makgoba, M.W., 
Sharrow, S.O., Stephany, D., Springer, T.A., Young, H.A. and Shaw, S., 1988) 
When resting and activated T -cells are stained with CD54 and CDw75 mAbs, it is the 
cells with the highest levels of CD54 that express the CDw75 epitopes recognised by 
mAbs HH2 and OKB4 (figure 3.3.4). In contrast, although EBU -141 and EBU -65 
mAb do bind to some CD54+ T- cells, they do so with much less intensity than to 
resting (CD54 -) T- cells. 
3.3.5 CDw75 staining of CD45RO+ Cells 
The correlation between CDw75 expression and CD45RO expression was also 
examined. Figure 3.3.5 illustrates typical results of PBL stained for both antigens 
before and after PHA activation. Before stimulation, most EBU -141 and EBU -65 
positive cells are CD45RO -. However, after PHA stimulation, as most 
cells become 
CD45RO +, the intensity of EBU -141 and EBU -65 staining on these cells 
is greatly 
reduced. HH2 binding levels were, in contrast, increased on these CD45RO+ 
cells. 
Staining intensities of OKB4 on CD45RO+ cells could not be investigated 
as 
neuraminidase destroys the epitope recognised by the CD45RO 

















Figure 3.3.3 CDw75 staining of PHA -stimulated T- cells. 
2- colour immunofluorescence of PBL before and after PHA activation. There is little 
or no HH2 or OKB4 staining of resting T- cells, but there is a considerable increase in 
the number of stained cells after activation. In contrast, EBU -141 and EBU -65 stain a 
large proportion of resting T- cells, but when these are activated, staining intensity and 
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Figure 3.3.4 CDw75 staining of CD54+ cells. 
2- colour immunofluorescence of resting and PHA -activated cells using CDw75 mAbs 
and anti -CD54. HH2 and OKB4 were found to weakly stain the most activated 
(CD54high+) T- cells. Whereas EBU -141 and EBU -65 binding levels were greatly 
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Figure 3.3.5 CDw75 staining of CD45RO+ cells. 
2- colour immunofluorescence of resting and PHA -activated cells using CDw75 mAbs 
and anti- CD54RO. HH2 binding was observed mainly on activated CD45RO+ cells, 
whereas EBU -141 and EBU -65 staining were at highest levels on resting CD45RO- 
T- cells, with decreased expression of these epitopes being observed after activation 
(on CD45RO+ cells). 
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3.4 Discussion. 
As previously mentioned, CDw75 has been detected mainly on the surface of mature 
B -cells expressing surface Ig and on B -cell leukaemias and lymphomas derived from 
mature B- cells(Mittler, R.S., Talle, M.A., Carpenter, K., Rao, P.E. and Goldstein, 
G., 1983; Epstein, A.L., Marder, R.J., Winter, J.N. and Fox, R.I., 1984; Smeland, 
E., Funderud, S., Ruud, E., Blomhoff, H.K. and T, G., 1985; Dorken, B., Moller, 
P., Pezzutto, A., Schwartz -Albiez, R. and Moldenhauer, G., 1989; Erikstein, B.K., 
Beiske, K., Smeland, E.B., Davies, C.D.L., Blomhoff, H.K. and S, F., 1989; 
Gramatzki, M., Burger, R., Kraus, J., Lauer, U., Rohwer, P., Eger, G., Kalden, 
J.R. and Henschke, F., 1991). These findings were confirmed in section 3.1 by 
examining CDw75 expression on normal PBL, B -CLL cells and on the Namalwa 
Burkitt lymphoma cell lines. CDw75 was detected at high levels on the surface on 
normal B- cells, and also at low levels on normal peripheral blood T -cells when stained 
with the mAbs EBU -141 and EBU -65. As expected, all mAbs also brightly stained 
PBL of patients with B -CLL, but also dimly stained additional subpopulations of non- 
B- cells. The percentages of these dimly stained cells varied from patient to patient, and 
also with the mAb used. It is likely that these cells are also peripheral blood T- cells. Of 
the Namalwa sublines tested, the sIg+ sublines IPN /45 and PNT CDw75 expressed 
CDw75 with highest intensity. It was found however, that HH2 and OKB4 mAbs 
dimly stained a small percentage of CSN /70 cells which do not express surface Ig and 
KN2 cells which are sIg+ but also secrete Ig. From these experiments alone, it can be 
seen that there are some minor differences in expression levels and tissue distribution 
of the four epitopes studied. It has previously been suggested that all CDw75 mAbs 
recognise a single epitope(Dorken, B., Moller, P., Pezzutto, A., Schwartz -Albiez, R. 
and Moldenhauer, G., 1989). However, these observations alone indicate that this 
cannot be the case. Further evidence against this theory was found by looking at 
individual epitope structures, and by looking at expression of each epitope on resting 
and stimulated T -cell subsets. 
Previous studies with the mAb LN -1 have shown that this epitope of CDw75 is 
sialylated(Epstein, A.L., Marder, R.J., Winter, J.N. and Fox, R.I., 1984). In this 
chapter I have shown that the epitopes recognised by HH2, EBU -141 and EBU -65 are 
also sialylated as staining of CDw75+ cells with these mAbs is completely abolished 
when cells are pre- treated with neuraminidase. In contrast, OKB4 staining of CDw75 
positive cells is markedly enhanced in cells pre -treated with neuraminidase, indicating 
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that this epitope is not sialylated and that sialylation of this epitope actually inhibits 
OKB4 binding. MAb binding to all four epitopes was also compared after treatment of 
cells with two different types of neuraminidase from Clostridium perfringens and 
Vibrio cholerae. It was thus shown that the sialic acid residues involved in all four 
epitopes are terminal sialic acid residues connected to the very edges of the glycosidic 
groups. In addition, inhibition of N- linked glycosylation by treatment of cells with 
tunicamycin also decreased binding levels of all four mAbs. It was therefore surmised 
that all four epitopes contain N- linked carbohydrate. 
These experiments were carried out at a stage in the project prior to the discovery that 
CDw75 was not in fact a cell- surface sialyltransferase(Munro, S., Bast, B.J., Colley, 
K.J. and Tedder, T.F., 1992). Knowing now that CDw75 expression is dependant on 
the activity of the enzyme a- 2,6- sialyltransferase, it would seem logical that each 
epitope contains N- linked carbohydrate as this enzyme specifically sialylates terminal 
galactose residues of N- linked carbohydrate, and does not act on 0-linked 
carbohydrate groups. The issue of the epitope recognised by OKB4 however remains 
a puzzle, as although this epitope is composed of N- linked carbohydrate, its sialylation 
prevents recognition by this mAb. It seems strange that an epitope which is masked by 
the activity of sialyltransferases should be dependent on the activity of a -2,6- 
sialyltransferase for its expression. It has however been reported that COS cells only 
express the OKB4 epitope once transfected with the gene for a -2,6- 
sialyltransferase(Stamenkovic, I., Asheim, H.C., Deggerdal, A., Blomhoff, H.K., 
Smeland, E.B. and Funderud, S., 1990). 
From the work carried out so far, it would appear that the CDw75 story is by no 
means a simple one, and that the "w" status is more than justified. Examination of T- 
cell subsets only proved to complicate the picture yet further, with different epitopes 
being upregulated and downregulated by the same stimulus. From dual staining 
experiments, it was shown that EBU -141 and EBU -65 dimly stain a large proportion 
of resting T -cells which were mostly of the CD4+ type. The size of the T -cell 
subpopulation varied from donor to donor, and this was established to be influenced 
by the activation state of the T- cells. In unstimulated samples of normal PBL, EBU - 
141 and EBU -65 were found to stain CD45RA+ T -cells i.e. naive unstimulated T- 
cells. Binding of HH2 and OKB4 mAbs to this T -cell population was found to be 
negligible. However, after stimulating cells with PHA, the expression pattern was 
very different. After stimulation with PHA, this CD45RA+ T -cell population begins to 
lose CD45RA from the cell surface and start to express CD45RO(Akbar, A.N., L, T., 
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Timms, A., Beverley, P.C.L. and Janossy, G., 1988). During this activation, the 
intensity of staining and the number of cells stained with EBU -141 and EBU -65 is 
reduced and that of HH2 and OKB4 is increased to levels similar to those of EBU -141 
and EBU -65. Dual staining experiments showed that the HH2+ cells are CD45RO +. It 
was not possible to determine if the OKB4+ cells also expressed CD45RO as 
neuraminidase treatment also destroys the CD45RO epitope recognised by UCHL -1. 
These CD45RO+ and HH2+ cells also express high levels of CD54 which confirms 
the theory that HH2 binds to activated T- cells. Also, CD45RO+ T -cells expressed 
much lower levels of EBU -141 and EBU -65 than the unstimulated CD45RA+ cells. 
Further study of these T -cell subsets over a longer period of stimulation would be 
needed in order to assess exactly which T -cell subsets express which epitopes of 
CDw75 and how this expression fits into the T -cell response to antigenic challenge, 
but it can be seen that HH2 and OKB4 epitopes are preferentially expressed on 
activated T -cells whereas the epitopes recognised by EBU -141 and EBU -65 are 
preferentially expressed on unchallenged naive T- cells. It may even be possible that 
these differences in expression separate the naive T -cell population from the memory 
T -cell population in a similar manner to the isoforms of CD45. 
The results of this study clearly indicate that CDw75 is not a single antigen. Some 
forms are preferentially expressed by different cells and in different states of 
differentiation and activation on B -cells and T- cells. Although all four mAbs tested 
preferentially stained mature slg+ B- cells, HH2 and OKB4 also stained some pre -B- 
cell -like cells and some more differentiated B -cells which not only express sIg but also 
secrete it. In addition, HH2 and OKB4 do not stain resting T- cells, whereas EBU -141 
and EBU -65 stain these cells very brightly. After PHA activation however, all four 
mAbs appear to stain T -cells with similar intensity indicating that an induction of the 
HH2 and OKB4 epitopes and a reduction in the expression of EBU -141 and EBU -65 
epitopes is produced by the same stimulus. In addition, the physical structure of the 
epitopes of CDw75 are not identical, as HH2, EBU -141, EBU -65 and LN -1 are 
sialylated carbohydrates, whereas the OKB4 epitope is masked when sialylated. It is 
possible that this epitope does not belong in the cluster at all, and this will be 
discussed at length in the ensuing chapters. 
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CHAPTER 4 
Tissue Distribution of CDw75. 
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4.1 A comparison of CDw75 distribution in 
solid- tumour and normal tissue sections. 
As discussed in chapter 1, the oligosaccharide portion of glycoproteins and glycolipids 
is thought to play a very important role in the processes of invasive tumour growth 
and metastasis. Metastasis involves the dissemination of tumour cells into distant 
organs and is a complex and multi -step process. This requires the release of cells from 
the primary tumour, invasion into blood vessels, transport and survival of blood - 
borne tumour cells, homing to preferred organs, extravasion from capillaries and 
infiltration of the target tissue(Smets, L.A. and Van Beek, W.P., 1984). Many 
observations are consistent with the idea that changes in the glycosylation of cell - 
surface molecules may account for the ability of tumour cells to implant and 
metastasise. Correlations have been shown to exist between levels of fucosylation of 
cell- surface glycoproteins and glycolipids and malignant transformation of 
cells(Yamashita, K., Ohkura, T., Tachibana, Y., Takasaki, S. and Kobata, A., 
1984), but it is perhaps of more importance that the occurrence of increased branching 
and sialylation of membrane -bound carbohydrate has also been confirmed in various 
solid tumour cells grown and labelled in vivo(Smets, L.A. and Van Beek, W.P., 
1984). In addition, several groups have shown a correlation between levels of cell - 
surface sialylation and tumour aggression(Yogeeswaran, G. and Salk, P.L., 1981; 
Hakomori, S., Patterson, C.M., Nudelman, E. and Sekiguchi, K., 1983; Smets, 
L.A. and Van Beek, W.P., 1984; Dennis, J.W., 1986; Humphries, M.J., 
Matsumoto, K., White, S.L. and Olden, K., 1986; Cohen, A.M., Allalouf, D., 
Djaldetti, M., Weigl, K., Lehrer, N. and Levinsky, H., 1989; Dall'Olio, F., 
Malagolini. N., di Stefano, G., Minni, F., Marrano, D. and Serafini -Cessi, F., 1989; 
Francina, A., Gateau -Roesch, O., Couprie, N., Leculier, C., Col, J.F., Archimbaud, 
E., Campos, L., Louisot, P. and Richard, M., 1989; Springer, G.F., 1989; Bresalier, 
R.S., Rockwell, R.W., Dahiya, R., Duh, Q.Y. and Kim, Y.S., 1990; Easton, E.W., 
Bolscher, J.G.M. and van den Eijnden, D.H., 1991; Sasaki, H., Momoi, T., 
Yamanaka, C., Yorifuji, T., Kaji, M. and Mikawa, H., 1991; Harvey, B.E., Toth, 
C.A., Wagner, H.E., Steele, G.D.J. and Thomas, P., 1992; Vandamme, V., 
Cazlaris, H., Le Marer, N., Laudet, V., Lagrou, C., Verbert, A. and Delannoy, P., 
1992). The alterations in glycosylation patterns of cell- surface glycoproteins and 
glycolipids are usually explained by altered levels of specific glycosyltransferases in 
tumour cells. It has been suggested that the same core protein on the cell surface can 
be differently glycosylated in different tissues and in tumour cells as compared with 
normal cells(Taylor -Papadimitriou, J., 1991). Some studies have indicated that 
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increased levels of ( 3- 1, 4- galactosyltransferase(Uemura, M., Sakaguchi, T., Uejima, 
T., Nozawa, S. and Narimatsu, H., 1992), or alternative transcripts of this 
enzyme(Uejima, T., Uemura, M., Nozawa, S. and Narimatsu, H., 1992) are 
associated with ovarian cancer. In another study, divergent expression of different 
fucosyltransferases was observed in certain colon carcinomas(Stroup, G.B., 
Anumula, K.R., Kline, T.F. and Caltabiano, M.M., 1990). Others have also 
suggested that the branching enzyme N- acetylglucosamine transferase may play a 
crucial role in the cell surface changes associated with transformation and tumour 
development(Smets, L.A. and Van Beek, W.P., 1984). Blood group antigens such as 
Ga1NAca -O (the basis of blood group A) have also been implicated in oncogenic 
transformations, and have even been linked with aggressive tumour 
behaviour(Springer, G.F., 1989; Wolf, G.T., Carey, T.E., Schmaltz, S.P., 
McClatchey, K.D., Poore, J., Glaser, L., Hayashida, D.J.S. and Hsu, S., 1990; 
Brooks, S.A. and Leathem, A.J.C., 1991). However, this antigen has also been 
shown to be protective in some lung cancers(Lee, J.S., Ro, J.Y., Sahin, A.A., Hong, 
W.K., Brown, B.W., Mountain, C.F. and Hittelman, W.N., 1991). In a number of 
studies, increased levels of sialyltransferase activity has been associated with cell 
transformation(Yamashita, K., Ohkura, T., Tachibana, Y., Takasaki, S. and Kobata, 
A., 1984; Cohen, A.M., Allalouf, D., Bessler, H., Djaldetti, M., Malachi, T. and 
Levinsky, H., 1989; Cohen, A.M., Allalouf, D., Djaldetti, M., Weigl, K., Lehrer, N. 
and Levinsky, H., 1989; Dall'Olio, F., Malagolini, N., di Stefano, G., Minni, F., 
Marrano, D. and Serafini -Cessi, F., 1989; Francina, A., Gateau -Roesch, O., 
Couprie, N., Leculier, C., Col, J.F., Archimbaud, E., Campos, L., Louisot, P. and 
Richard, M., 1989; Ledinko, N. and Fazely, F., 1989; Kanani, A., Sutherland, D.R., 
Fibach, E., Matta, K.L., Hindenburg, A., Brockhausen, I., Kuhns, W., Taub, R.N., 
van den Eijnden, D.H. and Baker, M.A., 1990; Dall'Olio, F., Malagolini, N., Di 
Stefano, G., Ciambella, M. and Serafini -Cessi, F., 1991; Sasaki, H., Momoi, T., 
Yamanaka, C., Yorifuji, T., Kaji, M. and Mikawa, H., 1991; Harvey, B.E., Toth, 
C.A., Wagner, H.E., Steele, G.D.J. and Thomas, P., 1992; Kobayashi, H., Terao, 
T. and Kawashima, Y., 1992; Vandamme, V., Cazlaris, H., Le Marer, N., Laudet, 
V., Lagrou, C., Verbert, A. and Delannoy, P., 1992). Many of these studies do not 
distinguish between the different sialyltransferases which may be involved, but other 
studies have specifically shown that 13- galactoside- a -2,6- sialyltransferase activity is 
upregulated in comparison to a- 2,3- sialyltransferase on metastatic cell 
lines(Hakomori, S., Patterson, C.M., Nudelman, E. and Sekiguchi, K., 1983; 
Dall'Olio, F., Malagolini, N., di Stefano, G., Minni, F., Marrano, D. and Serafini- 
Cessi, F., 1989; Bresalier, R.S., Rockwell, R.W., Dahiya, R., Duh, Q.Y. and Kim, 
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Y.S., 1990; Dall'Olio, F., Malagolini, N., Di Stefano, G., Ciambella, M. and 
Serafini -Cessi, F., 1991; Dall'Olio, F., Malagolini, N. and Serafini -Cessi, F., 1992; 
Dall'Olio, F., Malagolini, N. and Serafini -Cessi, F., 1992; Jiang, M., Passaniti, A., 
Penno, M.B. and Hart, G.W., 1992; Kobayashi, H., Terao, T. and Kawashima, Y., 
1992) and in ras- transformed cells(Easton, E.W., Bolscher, J.G.M. and van den 
Eijnden, D.H., 1991; Vandamme, V., Cazlaris, H., Le Marer, N., Laudet, V., 
Lagrou, C., Verbert, A. and Delannoy, P., 1992). 
As previously described, CDw75 was thought to be a cell -surface form of the enzyme 
ß- galactoside- a- 2,6- sialyltransferase which has been shown to be expressed at high 
levels on various transformed cell -lines of B -cell origin as discussed in chapter 3. 
Since sialyltransferases have also been shown to play a role in so many different types 
of solid tumours as discussed above, it seemed a logical step to compare CDw75 
expression in a number of samples of normal and cancerous tissues. It was hoped that 
the CDw75 mAbs may provide some sort of prognostic marker for tumour 
aggressiveness in some tissues. 
Table 4.1Number ofTissue samples analysed for CDw75 expression. 
Lymphoid Tissues Non -Lymphoid Tissues 
Tonsil (1) Liver (11) 
Lymph Node (2) Pancreas (9) 
Spleen (1) Intestine (12) 
Thymus (1) Breast (4) 
Lung (1) 
Samples of various lymphoid and non -lymphoid tissues (listed in table 4.1) were 
stained with the four available CDw75 mAbs (HH2, OKB4, EBU -141 & EBU -65) 
using immunohistochemical techniques. It was aimed to stain and analyse ten sample 
of each tissue type (5 normal and 5 tumour). However, the number of samples 
analysed was restricted by availability and by the quality of the samples available. 
Tissue samples were obtained from patients suffering from various forms of cancer, 
and others were normal samples, or apparently normal samples taken from a site 
distant from the cancerous tissue in the same patient. This is by no means a 
comprehensive comparison of CDw75 expression on normal and tumour tissue, as the 
study was very much limited by the quality and quantity of tissue available. However, 
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the results obtained in this study do serve to confirm and expand on those findings 
already described in the existing literature. 
4.1.1 CDw75 Expression on Tonsil. 
Only one tonsil sample was studied (block RL91 -630). This was a normal tonsil 
sample, and sections of this were routinely used as positive controls when staining 
other tissue samples. The staining pattern observed using CDw75 mAb on this tissue 
was very similar to that described in the literature (Epstein, A.L., Marder, R.J., 
Winter, J.N. and Fox, R.I., 1984; Dorken, B., Moller, P., Pezzutto, A., Schwartz - 
Albiez, R. and Moldenhauer, G., 1989; Gramatzki, M., Lauer, U., Burger, R., 
Huber, C., Rohwer, P., Kalden, J.R. and Henschke, F., 1989). Photographs of 
HH2 and EBU -141 staining on this tonsil can be seen in plates 4.1.1 and 4.1.2. Both 
HH2 and OKB4 stained cells of the B -cell follicles with high intensity, with a staining 
pattern like that shown in plate 4.1.1. Both mAb also stained occasional mantle zone 
cells as can be seen in a higher magnification of the same section in plate 4.1.1b. As 
can be seen in photograph 4.1.2, EBU -141 staining indicates low levels of CDw75 
expression throughout the tonsil, with higher levels of expression in the cells of the B- 
cell follicles where staining is very intense. EBU -65 staining was also weak and was 
limited to the B -cell follicles. 
4.2 CDw75 Expression on Lymph Node. 
F 
Lymph node samples from two patients were studied. One (8180/89) with follicular 
hyperplasia, and another (16069/89) with paracortical hyperplasia. Both samples 
produced similar staining patterns with the four CDw75 mAbs tested. 
HH2 produced a similar pattern in lymph node to that found on tonsil, with B -cell 
follicles in the outer cortex staining strongly and occasional mantle zone cells also 
positive. The other three mAbs tested did not produce any staining at all. A lymph 
Photographic Plate 4.1.1 
(a) 1--TH2 staining of normal tonsil RL91 -630. B -cell follicle (x 10 magnification). 
(b) HH2 staining of normal tonsil RL91 -630. Mantle zone (x 40 magnification). 
Photographic Plate 4.1.2 
(a) EBU -141 staining of normal tonsil RL91 -630. B -cell follicle (x 10 magnification). 
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node stained with HH2 and with a pan -B -cell mAb against CD 19 is shown in 
photograph plate 4.2.1. As can be seen in 4.2.1a, HH2 staining is confined mainly to 
the B -cell follicles, with very little staining of the mantle zone. This contrasts with the 
pattern found when the same lymph node was stained with a B -cell marker, CD 19, 
(4.2.1b) where positive B -cells were found throughout the follicles and the 
surrounding mantle zones. 
LN -1 has been reported to give a similar staining pattern to that observed with HH2 
(Epstein, A.L., Marder, R.J., Winter, J.N. and Fox, R.I., 1984). EBU -141 and 
EBU -65 have also been reported to stain the normal B -cell areas in lymph node 
(Gramatzki, M., Burger, R., Kraus, J., Lauer, U., Rohwer, P., Eger, G., Kalden, 
J.R. and Henschke, F., 1991). I did not find this, but it is possible that the activity of 
the antibodies used had deteriorated at the stage of the project when this tissue was 
studied. Fresh mAb supplies were obtained for later work. 
4.3 CDw75 Expression on Spleen. 
Only one, sample of normal spleen (8064/87) was obtained and stained with the four 
CDw75 mAbs available. All four mAbs stained the marginal zone of the white pulp, 
and HH2 and EBU -141 also stained occasional cells in the germinal centres. i.e. 
CDw75 is found in the normal B -cell areas of the spleen. The T -cell areas of the 
spleen are clearly demonstrated in photographic plate 4.3.1b - a section of spleen 
stained with the T -cell marker, CD3. Photographs of OKB4- and EBU- 141- stained 
sections are shown in plates 4.3.1a & 4.3.2. OKB4 mainly stains the area 
surrounding the T -cell follicles (4.3.1 a) and contrasts with the CD3 -stained example 
of the same section (4.3.1b). An example of EBU -141 staining is shown in 4.3.2a, 
where staining is mainly confined to the area outwith the T -cell follicles, and in higher 
magnification (4.3.2b) we can see occasional EBU -141 staining of follicular cells. 
EBU -65 produced a similar staining pattern to EBU -141, but did not stain any of the 
cells of the germinal centres. LN -1 has been reported to stain germinal centres of the 
white pulp in spleen (Epstein, A.L., Marder, R.J., Winter, J.N. and Fox, R.I., 
1984). 
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4.4 CDw75 Expression on Thymus. 
Only one sample of normal thymus was obtained (RL91 -582) and stained as before. 
Only occasional cells and clumps of medullary thymocytes were stained with all four 
mAbs. The vast majority of thymocytes were CDw75 negative. Photographs of a 
section stained with HH2 and with the B -cell marker CD19 are shown in plate 4.4.1. 
CDw75 distribution in the thymus appeared to be very similar to that of B- cells, which 
seems to suggest that CDw75 is expressed on the B -cells of the thymus and not on the 
immature T -cells of the thymus. Photographs of OKB4 and EBU -141 staining of 
thymus are shown in plate 4.4.2. There are no other previous reports of CDw75 
binding to thymocytes. 
4.5 CDw75 Expression on Liver. 
The liver was perhaps the most interesting of the tissues studied. 11 samples were 
tested, 5 of which came from liver tumours and another 5 which came from more 
normal parts of liver from these same patients. A summary of staining patterns 
observed on normal liver and tumour tissue is given in table 4.5.1 below. The 5 liver 
tumour samples were of various different types of tumours. Unfortunately, no data 
was obtained for EBU -65 staining as no EBU -65 mAb was available at the time of this 
study. 
Zonal staining was observed with at least one of the three mAb tested in all normal 
tissues studied. In all cases zone one is stained most intensely. This is the area of the 
liver closest to the hepatic artery. It seemed very unusual to find increased levels of the 
products of a sialyltransferase enzyme in this location as most hepatic transferases are 
found in zone 3 which is further away from the artery and has lower oxygen levels. In 
all cases studied, CDw75 expression was markedly disrupted in tumour tissue when 
compared with normal tissue. Plates 4.5.1, 4.5.2 and 4.5.3(a) show examples of the 
normal staining pattern observed on normal liver with HH2 and EBU -141. In all 
cases, there is strong canalicular staining which is more concentrated in zone 1. If we 
look at plate 4.5.3(b) we see an example of EBU -141 binding to tumour tissue. Most 
cells are unstained, with occasional positive cells being found at the edges of the 
tumour. This looks like an immature attempt at zonal focality. In most cases, there is 
little or no binding at all of HH2 and EBU -141 to tumour tissue sections. Plate 4.5.4 
shows an unusual example of zonal cytoplasmic staining of a normal liver by OKB4. 
In most sections studied, OKB4 staining was very weak or non -existent. 
Photographic Plate 4.2.1 
(a) E-1H2 staining of lymph node 8180/69. B -cell follicles only (x 10 magnification). 
(b) CÚ19 staining of lymph node 8180/69. Follicles and mantle zones 
(x 10 magnification). 
Photographic Plate 4.3.1 
(a) 01034 staining of spleen 8064/87 (x 10 magnification). 
(b) CD3 staining of spleen 8064/87 (x 10 magnification). 
Photographic Plate 4.3.2 
(a) EBU -141 staining of spleen 8064/87 (x 10 magnification). 
(b) EBU -141 staining of spleen 8064/87 (x 40 magnification). 
Photographic Plate 4.4.1 
(a) HH2 staining of thymus RL91 -582 (x 10 magnification). 
(b) CD19 staining of thymus RL91 -582 (x40 magnification). 
Photographic Plate 4.4.2 
(a) OKB4 staining of thymus RL91 -582 (x 40 magnification). 
(b) EBU -141 staining of thymus RL91 -582 (x 40 magnification). 
Photographic Plate 4.5.1 
(a) HH2 staining of liver I (normal) (x 40 magnification). 
(b) HH2 staining of liver 3 (normal) (x 10 magnification). 
Photographic Plate 4.5.2 
(a) HH2 staining of liver 4 (normal) (x 10 magnification). 
(b) EBU -141 staining of liver 4 (normal) (x 10 magnification). 
Photographic Plate 4.5.3 
(a) EBU -141 staining of liver 3 (normal) (x 10 magnification). 
(b) EBU -141 staining of liver 3 (tumour) (x 20 magnification). 
Photographic Plate 4.5.4 
(a) OKB4 staining of liver 6 (normal) (x 10 magnification). 
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Table 4.5.1 Results of CDw75 staining on liver. 
Sample HH2 OKB4 EBU -141 
strong canalicular 
staining esp. in zone 1 
negative strong canalicular 
staining esp. in zone 1 
1(t) negative 
background stroma and 
cells at edges of malignant 








2 (t) strong staining at edges o( tumour only 
negative strong staining at edges of 
tumour only 
strong canalicular 





3 (t) mostly negative, few stained cells at edges of 
tumour 
negative 
as HH2, immature attempt 
at zonal focality? 
strong canalicular 
staining esp. in zone 1 
weak cytoplasmic staining, 
stronger on bile ducts 
strong canalicular 
staining esp. in zone 1 
4(t) stains duct -forming cells stains tumour cells stains duct -forming cells 
zonal staining 
of canaliculae 
negative zonal staining 
of canaliculae 
5 (t) few small cells with cytoplasmic staining, 
membranes of large 
multi -nucleate cells 
few small cells with 
cytoplasmic staining, 
membranes of large 
multi -nucleate cells 
few small cells with 
cytoplasmic staining, 
membranes of large 
multi -nucleate cells 
zonal staining 
of canaliculae 
Pale cytoplasmic, much 




It is also curious that the canaliculae of the liver are stained with CDw75. This was 
previously unreported. LN -1, EBU -141 and EBU -65 mAb have been reported to bind 
to hepatocytes (Epstein, A.L., Marder, R.J., Winter, J.N. and Fox, R.I., 1984; 
Gramatzki, M., Burger, R., Kraus, J., Lauer, U., Rohwer, P., Eger, G., Kalden, 
J.R. and Henschke, F., 1991), but the pattern of expression in tissue sections is not 
described. There are no reports of HH2 binding on liver cells. 
4.6 CDw75 Expression on Pancreas. 
Nine samples of pancreas tissue were studied from normal and cancerous parts of 
pancreas from five patients. Sections were stained with four CDw75 mAb - HH2, 
OKB4, EBU -141 and EBU -65. Some sections were also stained with SNA, using a 
biotinylated conjugate of this lectin. Results of pancreatic staining by CDw75 are 
summarised in table 4.6.1. In the normal samples studied, CDw75 expression was 
found to be mainly confined to the cytoplasm of ductal cells and acini. Examples of the 
normal CDw75 expression pattern can be seen in photographic plates 4.6.1 and 
4.6.2(a), and of HH2 staining of tumour tissue in plate 4.6.2(b). 
Photographic Plate 4.6.1 
(a) OKB4 staining of pancreas 2 (normal) (x 40 magnification). 
(b) EBU -141 staining of pancreas 2 (normal) (X 40 magnification). 
Photographic Plate 4.6.2 
(a) EBU -65 staining of pancreas 2 (normal) (x 40 magnification). 
(b) HH2 staining of pancreas 2 (tumour) (x 10 magnification). 
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HH2 was not found to strongly stain any of the normal tissue samples studied, but as 
can be seen in the photograph, bound to some cells in the tumour -damaged ducts. 
SNA staining was variable, but mainly restricted to the ductal cells of normal pancreas 
tissue. Islet cells were stained in one sample studied. LN -1 has been reported to bind 
to ductal cells in many organs, including the pancreas (Epstein, A.L., Marder, R.J., 
Winter, J.N. and Fox, R.I., 1984), but no staining of pancreatic ducts or acini is 
reported for EBU -141 or EBU -65 (Gramatzki, M., Burger, R., Kraus, J., Lauer, U., 
Rohwer, P., Eger, G., Kalden, J.R. and Henschke, F., 1991). 
Table 4.6.1 Results of CDw75 staining on pancreas. 








ducts, acini and 
islet cells 
cytoplasmic 
staining of ducts, 
acini and islet 
cells 
negative 



















ducts & acini 
cytoplasmic 
staining of 
ducts & acini 
cytoplasmic 
staining of ducts 
& acini, (stronger 
on ducts) 
N.D. 






































ducts & acini 
cytoplasmic 
staining of 
ducts & acini 
cytoplasmic 
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In all cases studied, CDw75 expression was very disrupted in the tumour samples 
when compared with the normal samples. Staining of tumour cells was always much 
weaker and patchier than on normal cells. It appears that CDw75 is not synthesised 
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properly in pancreatic tumour cells. It is either not expressed at all or is improperly 
glycosylated. In some cases its expression is increased in focal areas. 
4.7 CDw75 Expression on Small Intestine and Colon. 
Two samples of small intestine tissue were obtained from a patient with a fibroma 
(4013/88) and from another patient with a leiomyoma. OKB4 was the only CDw75 
mAb to stain sections of either of these samples. The results of OKB4 staining of 
tissue sample 4013/88 are shown in plate 4.7.1. OKB4 stained the epithelial cells of 
this section only. 
Ten samples of colon tissue from a variety of sources were studied (some normal, 
some diseased, and some cancerous). Results from CDw75 staining of these samples 
were mainly negative except in two abnormal samples. These came from a patient with 
a rectal polyp(4), and from another patient with acute ulcerative colitis induced by a 
benign gastric tumour(3). In both cases, the endothelial cells of the villi were stained 
by all four CDw75 mAb tested. Staining was most intense at the tips of the villi. This 
can be seen in photographic plates 4.7.2 - 4.7.4. A summary of results obtained is 
given in table 4.7.1. 
LN -1 staining of the superficial epithelium has been reported, as well as staining of 
epithelium- derived tumour cells of the colon (Epstein, A.L., Marder, R.J., Winter, 
J.N. and Fox, R.I., 1984). EBU -141 and EBU -65 have also been reported to stain 
intestinal mucosa and endothelial cells (Gramatzki, M., Burger, R., Kraus, J., Lauer, 
U., Rohwer, P., Eger, G., Kalden, J.R. and Henschke, F., 1991). It is not clear 
from these reports if CDw75 was found to be expressed in all intestine samples tested. 
Certainly from my own results, it would appear that expression is only induced in 
abnormal intestinal cells. 
Photographic Plate 4.7.1 
(a) OKB4 staining of small intestine 4013/88 (x 10 magnification). 
(b) OKB4 staining of small intestine 4013/88 (x 40 magnification). 
Photographic Plate 4.7.2 
(a) EBU -65 staining of colon 3 (x 10 magnification). 
(b) HH2 staining of colon 3 (x 10 magnification). 
Photographic Plate 4.7.3 
(a) OKB4 staining of colon 3 (x 10 magnification). 
(b) EBU -65 staining of colon 3 (x l0 magnification). 
Photographic Plate 4.7.4 
(a) HH2 staining of colon 4 (x 40 magnification). 
94 
Table 4.7.1 Results of CDw75 staining on colon and small intestine. 
Sample HH2 OKB4 EBU -141 EBU -65 
I normal negative negative negative negative 
2 
rectal ca negative negative negative negative 
3 
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5 
colorectal ca negative negative negative negative 
6 
caecal ca negative negative negative negative 
7 
normal negative negative negative negative 
8 
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4.8 CDw75 Expression on Breast. 
Breast tissue was very difficult to study as samples often consisted of mainly fatty 
tissue with very few distinguishable cells. Of the ten samples studied, four produced 
results which could be analysed. All four of these samples were taken from breast 
tumours. "Normal" samples taken from the same patients were in too poor a condition 
for useful study. 
Where staining was found, it was mainly on ductal cells, and clear examples of this 
ductal staining on breast tissue are demonstrated in plates 4.8.1 and 4.8.2. In one 
sample (4.8.3), weaker cytoplasmic staining of all tumour cells was found, with 
comparatively stronger staining on the ducts. Results of breast tissue staining are 
summarised in table 4.8.1. 
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Table 4.8.1 Results of CDw75 staining on breast. 
Sample HH2 OKB4 EBU -141 EBU -65 
3 ducts stained only ducts stained only ducts stained only ducts stained only 
5 
tumour negative, 
normal cells and 
ducts only stained 
tumour cells and 
ducts stained 
tumour cells and 
ducts stained 
tumour cells and 
ducts stained 
7 negative negative negative negative 
9 negative negative negative 
ducts and lobules 
stained 
Staining of ducts and lobules of the breast with LN -1 has been reported (Epstein, 
A.L., Marder, R.J., Winter, J.N. and Fox, R.I., 1984). However, EBU -141 and 
EBU -65 were not found to stain breast tissue (Gramatzki, M., Burger, R., Kraus, J., 
Lauer, U., Rohwer, P., Eger, G., Kalden, J.R. and Henschke, F., 1991). 
Photographs on plate 4.8.2 show clear examples of EBU -141 and EBU -65 staining of 
breast tumour which contradicts these findings. Perhaps expression is limited only to 
tumour tissue which may not have been tested by Gramatzki et al. It is unfortunate that 
no useful samples of normal tissue were available for comparative staining in this 
study. 
4.9 CDw75 Expression on Lung. 
Only one sample of normal lung tissue was stained (block 23104/90). HH2 appeared 
to stain the epithelium of bronchioles. OKB4 staining of the epithelium was stronger 
than that of HH2, and stained with even greater intensity after neuraminidase treatment 
of the section. These results are illustrated in photographic plate 4.9.1. No staining of 
this sample was observed with EBU -65 and only very weak epithelial staining was 
achieved with EBU -141. 
LN -1 is not reported to stain lung tissue, but staining of the ciliated epithelial cells of 
the bronchus is reported (Epstein, A.L., Marder, R.J., Winter, J.N. and Fox, R.I., 
1984). There are no reports in the literature of staining of lung tissue with any of the 
other CDw75 mAbs. 
Photographic Plate 4.8.1 
(a) HH2 staining of breast 3 (x 40 magnification). 
(b) OKB4 staining of breast 3 (x 40 magnification). 
Photographic Plate 4.8.2 
(a) EBU -141 staining of breast 3 (x 40 magnification). 
(b) EBU -65 staining of breast 9 (x 40 magnification). 
Photographic Plate 4.8.3 
(a) HH2 staining of breast 5 (x 40 magnification). 
Photographic Plate 4.9.1 
(a) OKB4 staining of lung 2310/90 (x 40 magnification). 
(b) OKB4 staining of lung 23104/90 after neuraminidase treatment (x 40 magnification). 
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4.10 Discussion. 
It is generally accepted that carbohydrates are of major importance in all areas of 
embryogenesis, cell- differentiation and malignancy. For example, vital cell functions 
such as growth can be completely disrupted when oligosaccharide chains are disturbed 
by the action of anti -carbohydrate mAbs causing autophosphorylation of epidermal 
growth factor receptors(Feizi, T., 1990). More specifically, increased levels of cell - 
surface sialylation have been linked with cell transformation and increased 
metastasising potential(Yogeeswaran, G. and Salk, P.L., 1981; Hakomori, S., 
Patterson, C.M., Nudelman, E. and Sekiguchi, K., 1983; Smets, L.A. and Van 
Beek, W.P., 1984; Dennis, J.W., 1986; Humphries, M.J., Matsumoto, K., White, 
S.L. and Olden, K., 1986; Cohen, A.M., Allalouf, D., Djaldetti, M., Weigl, K., 
Lehrer, N. and Levinsky, H., 1989; Dall'Olio, F., Malagolini, N., di Stefano, G., 
Minni, F., Marrano, D. and Serafini- Cessi, F., 1989; Francina, A., Gateau -Roesch, 
O., Couprie, N., Leculier, C., Col, J.F., Archimbaud, E., Campos, L., Louisot, P. 
and Richard, M., 1989; Springer, G.F., 1989; Bresalier, R.S., Rockwell, R.W., 
Dahiya, R., Duh, Q.Y. and Kim, Y.S., 1990; Easton, E.W., Bolscher, J.G.M. and 
van den Eijnden, D.H., 1991; Sasaki, H., Momoi, T., Yamanaka, C., Yorifuji, T., 
Kaji, M. and Mikawa, H., 1991; Harvey, B.E., Toth, C.A., Wagner, H.E., Steele, 
G.D.J. and Thomas, P., 1992; Vandamme, V., Cazlaris, H., Le Marer, N., Laudet, 
V., Lagrou, C., Verbert, A. and Delannoy, P., 1992). It has been suggested that 
increased sialylation of cell- surface glycoconjugates, whether glycoprotein or 
glycolipid, may contribute to the metastatic behaviour of tumour cells through (a) an 
increased adhesiveness leading larger tumour cell emboli or to an increased capacity to 
adhere to vascular endothelium at secondary sites of implantation; or (b) an increased 
capacity to aggregate blood platelets; or (c) a decrease in the susceptibility of the cells 
to destruction by host immune mechanisms(Yogeeswaran, G. and Salk, P.L., 1981). 
Although the significance of the findings of this study is somewhat limited due to the 
quality and quantity of tissue samples available, several differences were observed in 
the distribution of CDw75 in normal and tumour tissues which correlate with 
previously observed differences in enzyme activities observed in these tissues. 
Samples of lymphoid tissue were very scarce, but on those studied, CDw75 
expression was limited to the B -cell areas. However, in tonsil and lymph node mAbs 
did not stain all B- cells, as staining tended to be restricted to follicular areas. In spleen, 
likewise staining was restricted to the B -cells of the white pulp, and in thymus there 
101 
was no significant staining. There were not enough samples available to make any 
comparisons between sections of normal and cancerous lymphoid tissues. 
CDw75 expression on normal liver was almost always restricted to the canaliculae, 
whereas in liver tumour samples taken from the same patients, CDw75 staining was 
totally disrupted. It is not clear whether this is due to a morphological change in the 
cells of the tumour causing destruction of the network of canaliculae, or whether the 
enzyme ß- galactoside- a -2,6- sialyltransferase is downregulated in liver cancer. In two 
samples, only the cells at the edges of the tumour were CDw75 positive, almost as if 
the cells were attempting to form a canaliculae -like structure. It is known that there are 
receptors for serum galactose terminated glycoproteins in the liver(Cook, J., Hou, E., 
Hou, Y., Cairo, A. and Doyle, D., 1983), and it is possible that captured proteins are 
then sialylated here. However, CDw75 staining of canaliculae has not previously been 
reported. A further investigation of CDw75 expression on transformed hepatocytes 
coupled with an assay of sialyltransferase activities and mRNA levels would be 
necessary in order to draw any conclusions from these findings. However it is 
possible to speculate that although in many types of cancer there are increased levels of 
a- 2,6- sialyltransferase, in liver cancer this may not be the case. The reduced 
expression of CDw75 may reflect the upregulation of a different glycosyltransferase, 
possibly causing increased branching of the carbohydrate moiety and differential 
terminal glycosylation. It has been shown that the same core protein can be differently 
glycosylated in different tissues, and that yet more differences can be induced upon 
malignant transformation (Taylor -Papadimitriou, J., 1991). This may also be the case 
in pancreatic cancer. The differences in CDw75 staining between normal and 
malignant areas of the same pancreas were not as marked as in the liver samples 
studied. However as with the liver samples, CDw75 binding was reduced in the 
pancreatic tumour samples when compared to non -tumour samples. 
In the colon samples studied, CDw75 was only expressed on malignant cells. This 
may reflect an increase in a -2,6- sialyltransferase activity in transformed colon cells. 
Others have reported increased SNA binding to the surface of some metastatic colon 
cell lines when compared to parental lines(Bresalier, R.S., Rockwell, R.W., Dahiya, 
R., Duh, Q.Y. and Kim, Y.S., 1990) and a corresponding increase in a -2,6- 
sialyltransferase activity in these transformed cells. Others have monitored a -2,6- 
sialyltransferase activities in normal human colonic epithelium and in colorectal 
carcinomas and have also found increased levels of activity in the tumour 
cells(Dall'Olio, F., Malagolini, N., di Stefano, G., Minni, F., Marrano, D. and 
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Serafini -Cessi, F., 1989). This was reflected in an increased level of a- 2,6- sialylated 
cell -surface glycoproteins and glycolipids. These sialylated glycolipids have also been 
detected in corresponding foetal tissues, and therefore they may perhaps be described 
as oncofoetal antigens which arise due to the activation of a foetal enzyme during 
neoplastic transformation(Hakomori, S., Patterson, C.M., Nudelman, E. and 
Sekiguchi, K., 1983). Others have shown a direct correlation between a -2,6- 
sialyltransferase activities in colon cancer cells and their metastatic potential(Harvey, 
B.E., Toth, C.A., Wagner, H.E., Steele, G.D.J. and Thomas, P., 1992). Many of 
the samples used in this study did not express significant levels of CDw75. It may be 
that these samples were from patients with less aggressive tumours which may not 
have formed metastases. There are also reports of differential fucosylation of 
glycoproteins in certain colon carcinomas(Stroup, G.B., Anumula, K.R., Kline, T.F. 
and Caltabiano, M.M., 1990). It is possible that some of the samples used in this 
study may have been of a similar type, and thus had altered fucosylated structures and 
no changes in sialylation patterns. 
In another recent and more comprehensive study comparing CDw75 expression on 
human gastric carcinomas, it was found that in the majority of cases HH2 did not stain 
normal gastric tissue but did stain 47% of tumour samples tested(David, L., Nesland, 
J.M., Funderud, S. and Sobrinho- Simóes, M., 1993). Moreover, it was also found 
that HH2 expression on these tumours correlated with tumour aggression as measured 
by metastases of the primary tumour into the lymph nodes. The limited results of my 
own study and those of this more comprehensive study suggest the possibility that 
CDw75 is not normally expressed on gatrointestinal tissue, but that expression may be 
induced upon transformation of these cells into tumour cells. 
In breast tissue, the study was limited to four samples taken from breast tumours. It is 
not known if these were primary or secondary tumours. CDw75 staining was 
observed in three out of the four samples tested, and expression was limited to ductal 
cells and tumour cells. As previously mentioned, LN -1 mAb has been shown to stain 
ducts and lobules of normal breast tissue and to strongly stain cytoplasmic filaments of 
a breast carcinoma cell line(Epstein, A.L., Marder, R.J., Winter, J.N. and Fox, R.I., 
1984). EBU -141 and EBU -65 did not stain normal breast tissue in a previous 
study(Gramatzki, M., Burger, R., Kraus, J., Lauer, U., Rohwer, P., Eger, G., 
Kalden, J.R. and Henschke, F., 1991), but photographs on plate 4.8.2 clearly show 
that they do stain breast carcinoma cells. It is therefore possible that a -2,6- 
sialyltransferase is upregulated in some forms of breast cancer. Indeed in one study, 
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LN -1 was shown to stain the entire ductal epithelium of 7 different fibroadenoma 
samples, and the ductal remnants of samples of cysto sarcomas phyllodes 
samples(Mechtersheimer, G., Krüger, K.H., Born, I.A. and Möller, P., 1990). Other 
groups have shown a correlation between blood group antigen A expression and 
aggressive breast tumour behaviour, but also acknowledge that some other groups 
have shown that colorectal and breast cancers express a-2,6-sialylated forms of this 
antigen(Springer, G.F., 1989). 
Only one sample of normal lung tissue was available, and this produced epithelial 
staining with all CDw75 mAbs tested. There are reports of LN -1 staining of the 
ciliated epithelial cells of the bronchus, but not of lung tissue itself(Epstein, A.L., 
Marder, R.J., Winter, J.N. and Fox, R.I., 1984). It was unfortunate that all tumour 
samples of lung tissue were in too poor a state for immunohistochemical staining, as it 
is known that lung carcinoma cells with high levels of surface sialylation are much 
more aggressive in terms of invasion than cells with less sialylation(Ledinko, N. and 
Fazely, F., 1989). It has also been shown that inhibition of N- linked glycosylation of 
a melanoma cell -line reduces the capacity of these cells to form metastases in the lungs 
of injected mice(Humphries, M.J., Matsumoto, K., White, S.L. and Olden, K., 
1986). This is thought to be due to a decrease in the ability of these cells to adhere to 
lung tissue once the cell -surface carbohydrate has been altered. Blood group antigen A 
on non -small cell lung cancer cells has also been shown to be a protective factor as 
patients of blood group A or AB who express antigen A on these cells have a much 
better survival rate than those who have lost Blood group A from their cell - 
surfaces(Lee, E.U., Roth, J. and Paulson, J.C., 1989). Blood group A is non - 
sialylated, but can be sialylated, and it may well be the case that sialylation of this 
epitope causes the "disappearance" of the epitope and at the same time increases cell - 
adhesiveness and therefore metastatic potential. 
In summary, this small study has shown that there are differences in CDw75 
expression in different tissues, and also that expression is altered in some tissues 
when tumours develop. There are many reports which suggest that carbohydrate 
changes play a major role in tumour development and metastatic potential, and so it is 
not surprising that CDw75 expression is altered in so many tissues. In order to 
determine whether the differences observed correlate with altered expression of 13- 
galactoside-a-2,6- sialyltransferase expression, an attempt was made to produce mAbs 
specific for this enzyme, and these were used to immunohistochemically stain the 
same tissues tested here. This work will be discussed in chapter 6. 
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CHAPTER 5 
Biochemical Analysis of CDw75. 
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5.1 Initial Attempts at Molecular Weight Determination. 
Despite numerous attempts, the molecular weight of CDw75 has not been conclusively 
established. OKB4 has been reported to precipitate a band of mr 53kDa from JOK1 
cells(Dorken, B., Moller, P., Pezzutto, A., Schwartz -Albiez, R. and Moldenhauer, 
G., 1989), and of mr 87kDa from Raji cells(Mittler, R.S., Talle, M.A., Carpenter, 
K., Rao, P.E. and Goldstein, G., 1983). EBU -141 and EBU -65 have been reported 
to immunoprecipitate bands of mrs 34 -38kDa and 105kDa respectively from U266 
lysates(Gramatzki, M., Lauer, U., Burger, R., Huber, C., Rohwer, P., Kalden, J.R. 
and Henschke, F., 1989), although the bands were said to be very weak and therefore 
should only be considered as preliminary results. The 11112 and LN -1 epitopes have 
never been detected by Western blotting or immunoprecipitation. Attempts have even 
been made to detect the LN -1 epitope in lipid extracts from labelled Raji cells(Epstein, 
A.L., Marder, R.J., Winter, J.N. and Fox, R.I., 1984), but only weakly positive 
results were obtained. 
At this point in the project, it was generally accepted that CDw75 was a cell- surface 
form of the enzyme (3- galactoside- a- 2, 6- sialyltransferase(Stamenkovic, I., Asheim, 
H.C., Deggerdal, A., Blomhoff, H.K., Smeland, E.B. and Funderud, S., 1990) 
which has a predicted mr of around 47kDa. As discussed in chapter 1, there is 
considerable evidence to support the existence of cell -surface glycosyltransferases and 
their possible roles in cell -cell interactions (reviewed in(Shur, B.D. and Roth, S., 
1975; Shur, B.D., 1982)), which gives further credence to this suggestion. This being 
the case, CDw75 would be a glycoprotein, and it should therefore have been possible 
to obtain its molecular weight using standard biochemical techniques. 
It is well recognised that many detergents exist, each with slightly different properties, 
and that the detergent used can markedly effect the integrity of the protein 
solubilized(Womack, M.D., Kendall, D.A. and MacDonald, R.C., 1983). Some 
detergents can completely denature protein whereas others are gentler and are capable 
of solubilisation without disrupting the structure or activity of the protein concerned. 
In particular it has been shown that membrane -bound enzymes are most successfully 
solubilized in some of the newer synthetic detergents such as CHAPS, CHAPSO, 
Zwittergents 310 and 312, and octylglucoside(Womack, M.D., Kendall, D.A. and 
MacDonald, R.C., 1983). It is possible that the structure of CDw75 is affected by 
different detergents and this may explain why it has never been isolated. In this 
chapter I therefore attempted to isolate CDw75 using a variety of detergents and 
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techniques in order to obtain its molecular weight and thus either add to the existing 
evidence for CDw75 being a cell -surface a- 2,6- sialyltransferase, or disprove this 
theory. 
5.1.1 Western Blotting Using CDw75 mAbs. 
CDw75+ lymphocytes from CLL patients were solubilised in 0.5% Triton CF70 and 
in 0.5% NP40. Lysates were diluted and boiled in reducing sample buffer and 
separated on 12% SDS polyacrylamide gels. Protein were electrophoretically 
transferred to nitro -cellulose, cut into strips and incubated with either EBU -65 or an 
anti -MHC class II mAb DA6 -147. Bound mAb was detected using HRP- labelled goat - 
anti- mouse -Ig (Sigma) and colour developed using DAB as substrate. 
This experiment was repeated twice, but on both occasions no bands were observed 
on either of the two EBU -65 stained blots, and DA6 -147 was found only to have 
stained MHC Class II from the NP40 lysate. From this experiment, it was concluded 
that the structure of the EBU -65 epitope had been disrupted either by the presence of 
detergent, or by the reducing sample buffer and SDS PAGE. 
5.1.2 
Since the structure of CDw75 is altered by either SDS, reducing sample buffer or 
NP40, I decided to solubilise some more cells using different detergents, and to 
attempt to detect CDw75 by dot -blotting the lysates directly onto nitro -cellulose and 
staining with CDw75 mAbs. The nitro -cellulose strips were incubated in HH2, EBU - 
65, an IgM type CD19 mAb as a positive control and VIM13 (an IgM type CD14 
mAb) as a negative control. Blots were labelled with HRP and developed as before. 
The results of this experiment are given in table 5.1.1 below. 
CDw75 detection by dot - blotting 
DETERGENT HH2 EBU -65 CD19 CD14 
NP40 +* ++ ++ ± 
Triton X 100 + ++ ++ ± 
Triton CF -54 ± + + ± 
Zwittergent ± + + ± 
+ = moderate staining, ++ = strong staining, ± = low, background colour only. 
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Antigen was detected in both NP40 and Triton X 100 lysates, suggesting that the 
EBU -65 epitope might have been denatured during electrophoresis. I decided to try 
using these lysates again in SDS PAGE, using both a non -reducing sample buffer and 
the reducing sample buffer previously tried to determine if this was the damaging 
factor. However, no visible bands were detected on the Western blots from these non- 
reduced samples either. 
5.2 Immunoprecipitation of Labelled Proteins 
Using CDw75 mAb. 
It seemed logical at this point to attempt to label all cell- surface proteins prior to 
solublisation, and then to immunoprecipitate labelled CDw75 from cell lysates and 
identify the immunoprecipitated antigens by SDS PAGE. The advantage in using this 
method is that antigen recognition occurs before disruption of epitopes by SDS 
PAGE. Detection of previously labelled, immunoprecipitated proteins is then possible 
regardless of the state of the antigen after electrophoresis. 
5.2.1 
Lymphocytes from CLL patient 19 were biotinylated and solubilised in six different 
detergents, one cationic (cetylpyridinium chloride), one anionic (taurocholic acid), two 
non -ionic (n- octylglucoside & MEGA -8), and two zwitterionic (CHAPS & 
CHAPS O). Immunoprecipitations were carried out using the Protein A- Sepharose 
bead method, and precipitates were incubated in reducing sample buffer and run on 
12% SDS polyacrylamide gels. Proteins were electrophoretically transferred to nitro- 
cellulose, and detected using a streptavidin -HRP conjugate and developed using 
E.C.L.. However, many non -specific bands were detected on the film, making it 
impossible to identify any specific bands. CHAPS and CHAPSO lysates were 
observed to contain the highest number of protein bands indicating that they were the 
most efficient at solubilising membrane proteins. 
5.2.2 
PNT cells were found to express high levels of CDw75 (Chapter 3.1.3), which made 
them another ideal source of antigen for biochemical studies. PNT cells were 
biotinylated and solubilised in CHAPS, CHAPSO and MEGA -8. Lysates were 
precleared by incubation with rabbit -anti- mouse -Ig (RAMG) armed beads for 1 hr, 
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and the supernatant decanted and used in immunoprecipitations with HH2, EBU -141, 
DA6 -147 and DA6 -231. Precipitates were heated in reducing sample buffer and run on 
12% polyacrylamide gels as before, then blotted, labelled and developed using E.C.L. 
However, there were still too many non - specific bands detected, and no major specific 
bands could be seen. It was decided that further pre -clearance was necessary, and that 
lysates would also have to be analysed for the presence of non -denatured CDw75. 
5.2.3 
PNT cells were harvested from culture. Half were biotinylated and both biotinylated 
and nonbiotinylated cells were solubilised in 0.5% and 3% CHAPS. These lysates 
were used in an attempt to inhibit binding of CDw75 mAb to formaldehyde -fixed 
lymphocytes from CLL patient number 15. 50 gl of mAb (HH2, EBU -141 and EBU - 
65) were mixed with 50 p.1 of lysate of concentrations varying from 1 /100 - neat 
lysate, and incubated at room temperature for 45 mins prior to addition of the fixed 
cells. Cells were then treated as normal for immunofluorescence labelling and analysed 
by flow cytometry. 
The results of this experiment were difficult to analyse as the detergent itself affected 
fluorescence levels. This was thought to be due mainly to the disruption of the cell 
surface, as the forward and side scatter profiles of the detergent- exposed cells were 
noticeably changed. However, it did appear that HH2 binding was inhibited more by 
increasing concentrations of both biotinylated and unbiotinylated 0.5% CHAPS 
lysates. 
5.2.4 
Experiment 5.2.3 was repeated using 0.5% taurodeoxycholic acid, decanesulfonic 
acid and digitonin lysates of biotinylated lymphocytes from CLL patient 19 to inhibit 
mAb binding to fixed CDw75 positive cells. However, as before, the results were 
indecipherable as the cells were damaged by the effects of the detergents. 
5.2.5 
HH2 and DA6 -147 were used in an attempt to immunoprecipitate antigens from 
biotinylated 0.5% CHAPS PNT cell lysate. Lysates were precleared three times before 
immunoprecipitation. Pellets were denatured in reducing sample buffer and run on 
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12% polyacrylamide gels as before. Gels were Western blotted and blots labelled and 
developed using HRP and E.C.L. as before. The results of this experiment are shown 
in figure 5.2.1. As can be seen from the films, DA6 -147 cleanly immunoprecipitated 
two proteins with mr 33.9 kD and 29.1 kD - the expected weights for MHC Class II a 
and ß chains. There were also two fainter bands at mr 45.7 kD and 63.8 kD which 
were also found in the HH2 immunoprecipitate lanes and were suspected to be caused 
by the cross -reaction of human Ig with RAMG or with protein A. HH2 did not 
precipitate any specific bands. 
Figure 5.2.1 Western blot of Antigens Immunoprecipitated from 
Biotinylated PNT lysates by HH2 and MHC -II. 
4111.am. 
. 





Samples were run in duplicate (lanes 1,3,5,& 7 from 3% CHAPS lysates, and lanes 
2,4,6 & 8 from 0.5% CHAPS lysates). Lanes 1 & 2 and 5 & 6 contain remaining 
lysate preparations after immunoprecipitation with DA6 -147 and HH2 respectively. 
The results of this experiment demonstrate that the immunoprecipitation system works 
at least for DA6 -147. This is an IgG mAb, whereas the CDw75 mAbs are all of IgM 
isotype. It is possible that this system of immunoprecipitation does not work with IgM 
mAbs. It is also possible that the detergent itself interferes with the interaction between 
mAb and antigen, and that another detergent may be more suitable. 
5.2.6 
In order to check the effect of biotin on CDw75 epitope recognition, lymphocytes 
from CLL patient number 19 were biotinylated and immunofluorescently labelled 
using HH2, EBU -141, EBU -65, OKB4, DA6 -147, CD14, IgG1 AFP & IgG2a AFP. 
Unbiotinylated cells from this patient were stained in the same way, and fluorescence 
levels of the two sets of cells were compared. It was found that fluorescence levels of 
all biotinylated cells stained with all mAbs were no different to those of the 
nonbiotinylated cells. i.e. biotin does not interfere with antibody binding. 
5.2.7 
The mAbs HH2, OKB4 and DA6 -147 were used to immunoprecipitate antigens from 
Digitonin lysates of biotinylated lymphocytes from CLL patient 19. Lysates were pre - 
cleared three times before precipitation, and precipitates were denatured in reducing 
sample buffer and run on 12% polyacrylamide "ready- gels" (Biorad). These were 
Western blotted and blots were labelled and developed using E.C.L. One of the 
resulting films is shown in figure 5.2.2. The film is somewhat obscured due to the 
stickiness of the pre -made gels. It was impossible to observe the division between the 
running gel and the stacking gel, and much of the stacking gel became attached to the 
nitro -cellulose. It can also be seen that the pre -clearance does not seem to have been as 
effective as previously observed, as there are still many non -specific bands. However, 
it can be seen that DA6 -147 has precipitated the same two specific bands at 34 kD and 
29 kD as in experiment 5.2.5 (figure 5.2.1). 
Figure 5.2.2 Immunoprecipitation of HH2 and OKB4 from 
biotinylated CLL cells. 
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The bands in the HH2 and OKB4 precipitate lanes appear to be mainly non -specific, 
but there is one band at mr 30 kD which may be specific to these immunoprecipitates 
as it is not seen in the DA6 -147 immunoprecipitates, nor in any of the pre -clearance 
pellets. This experiment was repeated six times, but these were the clearest results 
obtained. A definitive answer is difficult without further pre -clearance to eliminate 
background non -specific binding. 
5.3 Effects of Different Detergents on 
Antibody -Antigen Interactions. 
A detergent may be defined as a soluble amphiphile (a molecule which is partially 
hydrophobic and partially hydrophilic) which effectively solubilizes membrane 
lipids(Keesey, J., 1987). In section 5.2 a random selection of different types of 
detergent were used to solubilise CDw75+ cells, in the hope that one would be found 
which solubilized the antigen without denaturing the epitopes recognised by the 
CDw75 panel of mAbs. As has been described in the previous section, this approach 
was largely unsuccessful, and it was deemed necessary to use a larger panel of 
detergents and to analyse each lysate for its ability to solubilise CDw75 without 
denaturing the epitopes necessary for identification. 
Ionic detergents although very effective at total disruption of membranes and 
separation of every component protein in its monomeric form, usually completely 
denature the protein at the same time, making them unlikely to be suitable for CDw75 
purification(Keesey, J., 1987). SDS is a good example of such a detergent and its 
denaturing properties no doubt explain why CDw75 is not detectable after 
electrophoretic separation by SDS PAGE. Non -ionic detergents such as n -octyl 
glucoside and NP40 however, are much gentler in their solubilisation of membrane 
proteins. They often allow the solubilized proteins to retain native subunit structure 
and even enzymatic activity(Womack, M.D., Kendall, D.A. and MacDonald, R.C., 
1983). Non -ionic detergents also frequently displace lipids and themselves provide a 
lipid -like environment to stabilise the solubilized protein. Due to their high 
hydrophobicity, some membrane proteins have a tendency to associate non- 
specifically with other proteins when solubilized by detergents. These associations can 
be overcome by ionic detergents, but not by non -ionic detergents. To avoid the 
denaturation problem of ionic detergents and at the same time prevent this non -specific 
protein aggregation, zwitterionic detergents such as CHAPS or CHAPSO can be used 
for protein solubilisation. These detergents have proved to be very effective in the 
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purification of other membrane -bound enzymes(Womack, M.D., Kendall, D.A. and 
MacDonald, R.C., 1983). 
In this section a panel of twenty two different detergents were tested for their ability to 
inhibit binding of HH2 and EBU -141 to formaldehyde -fixed lymphocytes from CLL 
patient 15. mAb binding was detected using a radio -immunoassay as an alternative to 
flow cytometry, as this is not affected by the damage to the fixed cell surface caused 
by detergent. Once it had been established which detergents did not interfere with mAb 
binding, these were used to make CDw75+ cell lysates which were in turn also tested 
for their ability to inhibit CDw75 mAb binding. 
Table 5.3.1 Panel of detergents used for inhibition studies. 
Detergent name N o . Type Source 
Cetyl pyridinium chloride 1 cationic Sigma 
Taurocholic acid 2 anionic Sigma 
N -octyl glucoside 3 non -ionic Sigma 
NP40 4 non -ionic Sigma 
CHAPS 5 zwitterionic Boehringer Mannheim 
CHAPSO 6 zwitterionic Boehringer Mannheim 
Taurodeoxycholic acid 7 anionic Sigma 
Decanesulfonic acid 8 anionic Sigma 
Triton WR -1339 9 non -ionic Sigma 
Triton CF -54 10 non -ionic Sigma 
Triton X -100 11 non -ionic Sigma 
Triton X -114 12 non -ionic Sigma 
N- dodecyl- N,N- dimethyl- 3- ammonio -1- 





Sigma N- dodecyl - 3 -D- maltoside 
Isotridecylpoly(ethylene glycol)n 15 non -ionic Boehringer Mannheim 
MEGA -8 16 non -ionic Boehringer Mannheim 
Thesit 17 non -ionic Boehringer Mannheim 
Dodecyltrimethylammonium bromide 18 cationic Sigma 
N- dodecylglucoside 19 non -ionic Sigma 
Digitonin 20 non -ionic Sigma 
MEGA -10 21 non -ionic Boehringer Mannheim 
Hexadecyltrimethylammonium bromide 22 cationic Sima 
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5.3.1 CDw75 Radioimmunoassay of Detergent- treated Cells. 
Fixed lymphocytes from CLL patient 15 were incubated in HH2 or EBU -141 (at the 
minimum concentration necessary for detectable labelling) in the presence of 0.5% 
detergent. A panel of 22 different detergents of various types (as described in table 
5.3.1) were used. mAb binding was detected using a radiolabelled secondary mAb in 
a radioimmunoassay. This experiment was repeated three times. 










(% of normal) 
Inhibition 
1 1084 9 1646 15 + ++ 
2 822 3 4560 60 ++ 
3 3848 70 6666 93 + 
4 212 0 278 0 + + ++ 
5 5848 >_ 100 6578 92 none 
6 6026 >_ 100 6960 98 none 
7 2060 31 1498 13 + ++ 
8 2620 43 5736 79 ++ 
9 4492 84 5962 82 + 
10 654 0 880 3 + + ++ 
11 560 0 646 0 + + ++ 
12 340 0 270 0 + + ++ 
13 366 0 534 0 + + ++ 
14 254 0 320 0 + + ++ 
15 468 0 496 0 + + ++ 
16 3984 73 5026 68 + 
17 362 0 708 1 + + ++ 
18 690 0 3382 42 + ++ 
19 1730 23 1572 14 + ++ 
20 6124 >_ 100 7892 >_ 100 none 
21 2810 47 4592 61 ++ 
22 856 4 1270 9 + ++ 
NONE 5197 100 7109 100 none 
of normal cpm in the absence of detergent after adjusting for bacKgrouna. 
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The results of each experiment indicated similar levels of binding inhibition by 
respective detergents. Representative results from one experiment are given in table 
5.3.2. 
The results of this experiment indicate that the detergents which cause least 
interference to mAb binding are Digitonin, CHAPSO, CHAPS, N- octylglucoside, 
Triton WR -1339, MEGA -8, MEGA -10, Decanesulfonic acid and Taurocholic acid. 
5.3.2 Determination of Epitope Structure Preservation 
in Non -inhibitory Detergents. 
In order to determine which detergents solubilised CDw75 without disrupting the 
epitopes recognised by the available mAbs, PNT cells were biotinylated and 
solubilised in 0.5% Digitonin, CHAPSO, CHAPS, N- octylglucoside, Triton WR- 
1339, MEGA -8, MEGA -10 and Taurocholic acid. These lysates and samples of 0.5% 
detergent alone were used to inhibit binding of HH2 and EBU -141 to fixed 
lymphocytes from CLL patient 15. Binding was detected by radioimmunoassay in the 
same way as before (5.3.1). Each inhibition was carried out in triplicate, and the mean 
cpm after adjustment for background levels of radioactivity (as determined by binding 
of IgM anti -CD 14 mAb VIM 13) are given in table 5.3.3 below. 
Table 5.3.3 Results of Lysate Inhibition of CDw75 Binding. 
Detergent 
No. 
Detergent Lysate % Inhibition Detergent Lysate % Inhibition 
HH2 EBU -141 
2 4268 1112 74 3150 1886 40 
3 3774 396 90 5444 504 91 
5 2124 236 89 5498 814 85 
6 4948 2282 54 4538 800 82 
9 4296 1502 65 5010 3214 36 
16 3932 0 100 4938 2826 43 
20 6376 864 86 5434 2342 57 
21 2198 894 59 2592 1036 60 
NONE 3908 3908 0 5547 5547 0 
These results indicate that intact, non -denatured CDw75 is present in all of the lysates 
tested. Detergent numbers 3, 5, 16 and 20 were observed to preserve both HH2 and 
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EBU -141 epitopes most successfully. These are N- octylglucoside, CHAPS, MEGA -8 
and Digitonin respectively, i.e. one zwitterionic and three non -ionic detergents. These 
detergents should make the best candidates for use in cell lysis for 
immunoprecipitation. The amalgamated results of section 5.3 are summarised in table 
5.3.4 below. 
Table 5.3.4 Summary of Results of Section 5.3. 
DETERGENT No. mAb Binding jpitope Preservation 
Cetyl pyridinium chloride 1 inhibited n .d.* 
Taurocholic acid 2 slightly inhibited disrupted 
N -octyl glucoside 3 normal preserved 
NP40 4 inhibited n.d. 
CHAPS 5 normal preserved 
CHAPSO 6 normal disrupted 
Taurodeoxycholic acid 7 inhibited n.d. 
Decanesulphonic acid 8 slightly inhibited n.d. 
Triton WR -1339 9 slightly inhibited disrupted 
Triton CF -54 10 inhibited n.d. 
Triton X -100 11 inhibited n.d. 
Triton X -114 12 inhibited n.d. 
N- dodecyl- N,N- dimethyl- 3- ammonio- l - 
propane sulphonate 13 inhibited n.d. 
N- dodecyl-f3-D- maltoside 14 inhibited n.d. 
Isotridecylpoly(ethylene glycol)n 15 inhibited n.d. 
MEGA -8 16 slightly inhibited HH2 preserved 
Thesit 17 inhibited n.d. 
Dodecyltrimethylammonium bromide 18 inhibited n.d. 
N- dodecylglucoside 19 inhibited n.d. 
Digitonin 20 normal preserved 
MEGA -10 21 slightly inhibited 
inhibited 
disrupted 
n.d. Hexadecyltrimethylammonium bromide 22 
n.d. = not determined. 
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5.4 Final Attempts at Immunoprecipitation of CDw75. 
Using the information gained about the various detergents, lysates were made using 
detergents least likely to disrupt the CDw75 epitopes, and further attempts were made 
to immunoprecipitate CDw75 using a variety of techniques in an attempt to formally 
identify "CD75" by determining its molecular weight. 
5.4.1 Protein -A Sepharose CDw75 Immunoprecipitations. 
Lysates were made of biotinylated PNT cells, using N- octylglucoside, CHAPS, 
Digitonin and MEGA -8. These were used in immunoprecipitations with the mAbs 
HH2, OKB4 and DA6 -147. The precipitated pellets and whole lysates were reduced in 
sample buffer, run on 12% gels and transferred to nitro -cellulose by Western blotting. 
Bands were labelled with HRP and detected using E.C.L. 
One major band of mr -34 kD was detected in all immunoprecipitates from N- 
octylglucoside lysates (not shown). This was also visible as a double band at the same 
molecular weight in all immunoprecipitates from MEGA -8 lysates. In CHAPS lysates 
the same band was detected in the HH2 immunoprecipitate, and was present as a 
double band in the DA6 -147 precipitate. No bands were detected in the OKB4 
immunoprecipitate from CHAPS. The pellets from the pre -clearance steps were also 
analysed by SDS PAGE and Western blotting, and this same band was weakly 
detected in the pre -clearance pellets from the above three detergent lysates. No specific 
bands were detected in any of the Digitonin lysate immunoprecipitates. This was 
thought to be due to the precipitation of many proteins with Digitonin itself which 
became insoluble when mixed with aqueous buffers. 
The 34 kD band did not appear to be specific as it was present in DA6 -147 
immunoprecipitates as well as CDw75 precipitates, unless CDw75 is around the same 
molecular weight as MHC Class II. It was therefore impossible to draw any definite 
conclusions from this experiment. 
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5.4.2 CDw75 Immunoprecipitation Using Dynabeads. 
Tosylactivated Dynabeads (Dynal) were covalently attached to goat- anti -mouse -IgM, 
and used to immunoprecipitate CDw75 (using HH2 and OKB4), CD20 (using an IgM 
mAb 019 B-Cl from the 3rd Leucocyte Typing Workshop) and CD21 (using an IgM 
mAb B46 -B2 from the 4th Leucocyte Typing Workshop) from water soluble 
Digitonin lysates of biotinylated lymphocytes from CLL patients 18 and 24. 
Immunoprecipitates were reduced in sample buffer and run on 12% SDS 
Polyacrylamide gels, transferred to nitro -cellulose by Western blotting, HRP labelled, 
and developed using E.C.L. The developed films are shown in figure 5.4.1. 
Figure 5.4.1 Dynabead immunoprecipitated CDw75 from 










4 am am or -no 14.4kD 
HH2 OKB4 NEGATIVE 
CONTROL 
As can be seen from figure 5.4.1, a single dominant band was detected in CDw75 
immunoprecipitates at a molecular weight of - 14 kD. However, this band was also 
detected in the negative control , and appeared to be the major constituent of the whole 
lysate. Other weaker bands were also detected, but these too were found to be non- 
specific. No specific bands were detected at mr 35 and 140 kD in the CD20 and CD21 
positive controls (not shown) either, contrary to expectations. It was therefore 
concluded that the affinity purified anti -IgM had not bound to the primary mAbs, and 
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that all bands detected were due to non -specific binding of anti -IgM- coated beads to 
major proteins in the lysates. 
5.5 Discussion. 
As discussed in 5.1, all previous attempts at isolating and definitively identifying 
CDw75 by biochemical means have been unsuccessful. Despite my rigorous efforts 
using different detergents and even different means of immunoprecipitation, CDw75 
was not isolated. CDw75 was undetectable after SDS PAGE and Western blotting, 
and 1 was unable to immunoprecipitate any specific antigens from any detergent lysates 
using these IgM mAbs. Unless an IgG mAb could be produced, I was unlikely to 
obtain any biochemical information about this elusive antigen. At this point in the 
project, it was still universally accepted that CDw75 was most likely to be a cell - 
surface sialyltransferase(Stamenkovic, I., Asheim, H.C., Deggerdal, A., Blomhoff, 
H.K., Smeland, E.B. and Funderud, S., 1990). I therefore decided to have synthetic 
peptides constructed from parts of the known amino acid sequence of ß- galactoside -a- 
2,6-sialyltransferase, and to use these as immunogens in order to raise IgG mAbs 
against CDw75, and this work is discussed in chapter 6. 
However, since this work was completed, it has been proved that CDw75 is unlikely 
to be a cell - surface sialyltransferase and is more likely to be a carbohydrate moiety on 
the cell- surface that is generated by the intracellular activity of the enzyme [3- 
galactoside-a-2,6-sialyltransferase(Munro, S., Bast, B.J., Colley, K.J. and Tedder, 
T.F., 1992). Since this information came to light, a more logical explanation for the 
lack of success described above may be that CDw75 is in fact a carbohydrate structure 
or ganglioside attached to the lipid bilayer of the cell -surface. 
Gangliosides are expressed ubiquitously on all cells and their pattern of expression is 
developmentally regulated. They are mainly located on the outer leaflet of the lipid 
bilayer, and composed of hydrophilic carbohydrate chains which are linked to the lipid 
by a covalent link with ceramide(Yuasa, H., Scheinberg, D.A. and Houghton, A.N., 
1990). Ceramide is the hydrophobic part of the complex which inserts into the plasma 
membrane. It is made up of a sphingoid base attached to a long chain fatty acid. The 
initial step in synthesis of the glycosphingolipids involves the attachment of a glucose 
or galactose residue to ceramide by a glycosidic (3- linkage to the primary hydroxyl 
group of the sphingosine. For the synthesis of gangliosides, a galactose residue is 
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then linked to glucose to form lactosyl -ceramide. This represents the core structure of 
most glycosphingolipids and is designated Gal(3- 1,4- G1c(3- 1,1 -Cer. The addition of 
further sugar groups to this core structure leads to the formation of five different series 
of glycosphingolipids. Some gangliosides bear terminal Gal13 -1,4- GlcNAc groups 
which can be sialylated by either a -2,3- or a- 2,6- sialyltransferase. The a -2,6- linked 
sialylated gangliosides are less common than the a- 2,3- linked residues, but they have 
been identified on human lymphoid tissue(Kiguchi, K., Henning- Chubb, C. and 
Huberman, E., 1993). Expression of these gangliosides is dependant on the regulation 
of the genes encoding the glycosyltransferases involved, and it is widely accepted that 
the same glycosyltransferase enzymes are capable of glycosylating both glycoproteins 
and glycolipids(Hakomori, S., Patterson, C.M., Nudelman, E. and Sekiguchi, K., 
1983; Feizi, T., 1985; Dall'Olio, F., Malagolini, N., di Stefano, G., Minni, F., 
Marrano, D. and Serafini -Cessi, F., 1989; Paulson, J.C. and Colley, K.J., 1989; 
Kanani, A., Sutherland, D.R., Fibach, E., Matta, K.L., Hindenburg, A., 
Brockhausen, I., Kuhns, W., Taub, R.N., van den Eijnden, D.H. and Baker, M.A., 
1990; Erikstein, B.K., Funderud, S., Beiske, K., Aas -Eng, A., De Lange Davies, 
C., Blomhoff, H.K. and Smeland, E.B., 1992; Shah, S., Lance, P., Smith, T.J., 
Berenson, C.S., Cohen, S.A., Horvath, P.J., Lau, J.T. and Baumann, H., 1992). 
Further evidence for the theory that CDw75 may be a glycolipid can be found in 
lymphocyte activation studies. As shown in chapter 3, when normal human T -cells are 
stimulated with PHA, CDw75 expression is increased. It has also been shown that 
phorbol esters lead to increased a- 2,6- sialyltransferase activity in the human pro - 
myelocytic leukaemia cell line HL- 60(Kiguchi, K., Henning- Chubb, C. and 
Huberman, E., 1993), and in Chinese hamster V79 cells(Burczak, J.D., Moskal, 
J.R., Trosko, J.E., Fairley, J.L. and Sweeley, C.C., 1983). In addition, it has been 
shown that expression of sialylated gangliosides is increased when lymphocytes are 
stimulated with PHA(Basu, S.K., Whisler, R.L. and Yates, A.J., 1986). These 
changes are consistent both with the theory that CDw75 is controlled by the 
expression of a- 2,6- sialyltransferase, and that the antigen may be present on 
glycolipids. 
In section 5.3 it was observed that 8/8 detergents tested did not denature the epitopes 
recognised by HH2 and EBU -141, and yet when these detergents were used to 
solubilise CDw75+ cells (in section 5.4), no antigen was detected after electrophoretic 
separation of CDw75 immunoprecipitates. At the time, this was thought to be due to 
the inability of the IgM CDw75 mAbs to immunoprecipitate antigen. However, if 
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CDw75 is not present on cell -surface glycoproteins to any great extent, and instead is 
present mainly on glycolipid, no antigen would have been detected after 
electrophoresis as glycolipid would not be labelled by the biotinylation technique 
employed, nor would it be separated by electrophoresis. 
Other workers have also suggested that CDw75 may be expressed predominantly on 
glycolipid as the CDw75 antigen is resistant to formalin fixation and paraffin 
embedding - processes which often denature cell -surface proteins(Bast, B.J., Zhou, 
L.J., Freeman, G.J., Colley, K.J., Ernst, T.J., Munro, J.M. and Tedder, T.F., 
1992; Munro, S., Bast, B.J., Colley, K.J. and Tedder, T.F., 1992). CD76 has also 
been shown to be such a glycolipid, whose expression is regulated by the same 
intracellular ß- galactoside- a -2,6- sialyltransferase(Munro, S., Bast, B.J., Colley, 
K.J. and Tedder, T.F., 1992). One report also states that solid phase 
radioimmunoassays of Raji cell lipid extracts gave weakly positive results, although 
TLC grams of these extracts failed to give positive results when probed with LN -1. 
Perhaps further research in this area is required in order to determine if the CDw75 
antigen is in fact a component of cell -surface glycolipid. 
The role of carbohydrate on both glycoproteins and lipids on the cell -surface is 
increasingly being recognised as one of great importance. The level of control over 
cell -cell interactions via specifically glycosylated receptors is immense as each 
individual glycosidic linkage is controlled by a separate enzyme. If we consider sialic 
acid alone, there are seven specific sialyltransferases necessary for synthesis of the 
following different attachments(Joziasse, D.H., Bergh, M.L.E., Hart, H.G.J.t., 
Koppen, P.L., Hooghwinkel, G.J.M. and Van den Eijnden, D.H., 1985): 
a-2,3-Ga113-1,3-Ga1NAc; 
a-2, 3 -Gal ß-1, 3/4-G1cNAc; 
a-2,4-Gal ß-1,4-G1cNAc; 
and a-2,8-NeuAca-2,3-Gal. 
a-2, 6-Gal ß -1, 3 -Ga1NAc; 
a-2,6-Gal13-1,4-G1cNAc; 
a-2,6-Gal13-1,3-G1cNAc; 
If we also consider that there are many other sugar residues such as glucose, N- acetyl 
glucosamine, fucose, galactose and galactosamine, all of which are in turn controlled 
by several transferase enzymes, we begin to appreciate the level of control and the 
specificity of carbohydrate structures on the cell- surface and in the circulation. The 
presence of carbohydrate can transform the surface of a cell and completely change its 
interactions with other cells and circulating cytokines. Carbohydrates are also 
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hydrophilic, charged moieties, and as a result, their presence on the cell - surface can 
therefore alter the charge of the cell which may also influence its interactions. 
CDw75 has been proposed to act as a receptor on B -cells for CD2213 on other B- 
cells(Stamenkovic, I., Sgroi, D., Aruffo, A., Sy, M.S. and Anderson, T., 1991). 
Interaction with CD22[3+ cells is therefore only possible when the enzyme 13- 
galactoside-a-2,6- sialyltransferase is expressed and active in receptor B- cells. An 
additional level of control over CDw75 interaction must also be possible since 
different sized mRNA transcripts for a single (3- galactoside- a -2,6- sialyltransferase 
gene have been detected in different cell types(Aasheim, H.C., Aas -Eng, D.A., 
Deggerdal, A., Blomhoff, H.K., Funderud, S. and Smeland, E.B., 1993). The 
differences appear to be in the 5' untranslated region of the same gene, indicating that 
alternate promoter sites operate in a complex level of additional control over sialylation 
of glycoproteins and glycolipids. Thus even though CDw75 is not a cell- surface ß- 
galactoside-a-2,6-sialyltransferase, and is likely to be a carbohydrate moiety on cell - 
surface glycolipids rather than on glycoproteins, it may still be of major importance in 
many processes such as protein targeting, cell -cell interactions including growth 
regulation and therefore in tumour progression, and in developmental processes. 
Indeed, elevated levels of a- 2,6- sialylated glycolipids have been observed in some 
cancers(Hakomori, S., Patterson, C.M., Nudelman, E. and Sekiguchi, K., 1983). 
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CHAPTER 6 
Production of Monoclonal Antibodies 
Against a- 2,6- Sialyltransferase. 
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6.1 Protein Structure Prediction for a- 2,6- Sialyltransferase. 
As mentioned in Chapter 1, the enzyme 0- galactoside- a -2,6- sialyltransferase was first 
isolated and characterised from bovine colostrum in 1973(Bartholomew, B.A., 
Jourdian, G.W. and Roseman, S., 1973). Since then, it has been found in a variety of 
tissues and in many different species. In rat where it has been most extensively 
studied, five different mRNA transcripts for the enzyme have been described, all 
arising from a single gene(Wang, X., O'Hanlon, T.P., Young, R.F. and Lau, J.T., 
1990; Wen, D.X., Svensson, E.C. and Paulson, J.C., 1992). However, much less is 
known about the enzyme in human tissues, and different isoforms have yet to be 
identified. 
The cDNA from the human form of the enzyme has been sequenced(Lance, P., Lau, 
K.M. and Lau, J.T., 1989; Grundmann, U., Nerlich, C., Rein, T. and Zettlmeissl, 
G., 1990; Stamenkovic, I., Asheim, H.C., Deggerdal, A., Blomhoff, H.K., 
Smeland, E.B. and Funderud, S., 1990), and has been shown to share 80 -87% 
homology with the amino acid sequence of rat 3- galactoside-a-2,6- sialyltransferase. 
The enzyme described by Stamenkovic et al is a 405 residue polypeptide (as illustrated 
in Figure 6.1.1) with a predicted mr of 46.367 kDa. Like other glycosyltransferase 
enzymes, the human form of this sialyltransferase consists of a short 9 amino acid 
NH2- terminal domain which is thought to be cytoplasmic followed by a series of 17- 
18 hydrophobic residues which are thought to constitute a transmembrane domain of 
the enzyme. The extracellular domain (or lumenal domain in Golgi expression) of 378 
residues is catalytically active(Stamenkovic, I., Asheim, H.C., Deggerdal, A., 
Blomhoff, H.K., Smeland, E.B. and Funderud, S., 1990). In rats, this domain has 
been detected on its own as a soluble form of the enzyme in plasma and 
colostrum(Nemansky, M. and Van den Eijnden, D.H., 1992). It is likely that 
proteolytic cleavage of the catalytic site also occurs in humans as enzyme activity has 
been detected in human plasma and colostrum(Bartholomew, B.A., Jourdian, G.W. 
and Roseman, S., 1973). 
As with the work described in the previous chapter, production of mAbs against 
human 13- galactoside-a-2,6- sialyltransferase was initiated at a stage in the project 
when it was believed that CDw75 was a cell -surface form of this enzyme. The main 
aim of this work was to produce mAbs against the protein component of this 
glycoprotein which were of IgG isotype in order to compare tissue distribution with 
the original CDw75 mAbs and thus to provide further evidence for the proposed 
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identity of the antigen. The new IgG mAbs would also be used in biochemical 
characterisation of CDw75 in the hope that these mAbs would successfully 
immunolabel the antigen on electrophoretically separated preparations of solubilised 
membrane proteins, or be able to immunoprecipitate it from such samples. However, 
before antibody production was completed, as previously mentioned, it became 
evident that CDw75 is more likely to be a carbohydrate moiety on the cell- surface 
which is generated by the activity of this enzyme(Munro, S., Bast, B.J., Colley, K.J. 
and Tedder, T.F., 1992). Since production of the mAbs was already well underway, 
it was decided to continue with the experiment and to use the 13- galactoside- a -2,6- 
sialyltransferase -specific mAbs to compare the tissue distributions of CDw75 and the 
a- 2,6- sialyltransferase enzyme. 
There are various methods of predicting antigenic sites on proteins(Stern, P.S., 
1991). Epitopes were originally classed as either sequential or conformational meaning 
that antigenicity was dependent only upon the amino acid sequence or that it was 
dependent on the actual shape of the epitope. Subsequently, hydrophilicity was used 
as a measure of antigenicity, as the most hydrophilic residues are more likely to be on 
external domains of the protein and are thus more exposed to the immune system. 
Mobility of particular domains was another indication of immunogenicity, but by 
definition, the most mobile domains of a protein are most likely to be external domains 
and thus be hydrophilic. Other methods used have involved protrusion indices, 
accessibility and hydropathicity measurements. In general however, the most reliable 
methods of predicting antigenicity involve a combination of the above. 
6.1.1 Synthetic Peptide Production. 
In this study, a computer structure prediction program written by E.E.Eliopoulos, 
(Secondary Structure Prediction Suite Version 2.2, March 1986) was used to predict 
the three- dimensional structure of the enzyme. The program searches for particular 
amino acid motifs in order to predict domains of the protein which are most likely to 
be helical, 13-sheets, turns or hydrophobic regions. The results of this prediction 
method are illustrated in figure 6.1.2. From the amino acid sequence of the enzyme 
(listed in figure 6.1.1)(Stamenkovic, I., Asheim, H.C., Deggerdal, A., Blomhoff, 
H.K., Smeland, E.B. and Funderud, S., 1990), it was also possible to predict all 
potential N- and 0-linked glycosylation sites. 
Figure 6.1.1 Amino Acid Sequence of Human ß- Galactoside 
a -2,6 -S ialyltransferase. 
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represent possible N -linked glycosylation sites, possible 0- linked sites are 
indicated by S and T, and peptide amino acid sequences are indicated by 
Figure 6.1.2 illustrates the results of the protein structure prediction. As can be seen 
from this chart, there appear to be three major turns (highlighted) on the protein which 
are also hydrophilic and which do not contain any possible glycosylation sites. The 
sequences of these three regions were chosen for the synthesis of peptide 
immunogens, as hydrophilic turns are most likely to be on external domains of the 
protein. It was also desirable to use regions of the protein which would not normally 
be masked by carbohydrate, as this may prevent binding of any mAbs raised to the 
enzyme in its native state. The amino acid sequences of the three peptides chosen are 
listed in table 6.1.1. 
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Table 6.1.1 Amino acid sequences of synthetic peptides. 
PEPTIDE SEQUENCE RESIDUE NUMBERS 
JP1 KAGPWGR 176 -182 
JP2 YKGPGPGIK 125 -133 
JP3 WYQNPDYN 268 -275 
The peptides were constructed in the form of Multiple Antigenic Peptides (MAPs) 
which consisted of eight copies of the peptide on a branched polylysine core 
(illustrated in figure 2.1). MAPs have been shown to be an extremely efficient way of 
producing mAbs against synthetic peptides in comparison to hapten- carrier 
systems(Tam, J.P. and Lu, Y.A., 1989; McLean, G.W., Owsianka, A.M., Subak- 
Sharpe, J.H. and Marsden, H.S., 1991). They are large enough to be immunogenic 
and only give rise to peptide- specific mAbs, whereas peptide -carrier constructs give 
rise to mAbs specific for the protein carrier in addition to peptide- specific 
mAbs(Posnett, D.N., McGrath, H. and Tam, J.P., 1988). In addition, the problems 
of peptide damage by harsh chemical conjugation procedures to protein carriers is 
avoided by using MAPs. All three MAPs were used individually in the immunisation 
of three batches of mice for the production of mAbs. 
6.1.2 Antibody Production. 
After three immunisations with the three different peptides, mice were test bled, and 
the serum samples tested for reactivity with their respective peptides using the Alkaline 
Phosphatase peptide ELISA. 
Peptides JP1 and JP2 were found to react strongly with all sera tested including 
serum from a normal mouse negative control, and with an irrelevant ascites sample. 
The JP3 peptide in contrast, was found to be very specific, and only reacted with 
serum samples from mice immunised with the JP3 peptide. Results from this initial 
screening of 12 mice are given in tables 6.1.2 - 6.1.4. 
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Table 6.1.2 JP1 ELISA Results. 
MOUSE 
Absorbance at 405 nm 
1 /100 1/200 
Serum Concentration 
1/400 1/800 1/1600 1/3200 
control 0.633 1.471 >2 >2 >2 >2 
1 1.883 >2 >2 >2 >2 >2 
2 1.240 >2 >2 >2 >2 >2 
3 1.469 >2 >2 >2 >2 >2 
4 >2 >2 >2 >2 >2 >2 
OKB4 asc* 1.488 >2 >2 >2 >2 >2 
* asc = ascites 
Table 6.1.3 JP2 ELISA Results. 
MOUSE 
Absorbance at 405 nm 
1 /100 1/200 
Serum Concentration 
1/400 1/800 1/1600 1/3200 
control 0.231 0.921 >2 >2 >2 >2 
1 1.056 1.621 >2 >2 >2 >2 
2 0.594 1.567 >2 >2 >2 >2 
3 0.577 >2 >2 >2 >2 >2 
OKB4 asc 0.767 1.309 >2 >2 >2 >2 
Table 6.1.4 JP3 ELISA Results. 
MOUSE 
Absorbance at 405 nm 
1 /100 1/200 
Serum Concentration 
1/400 1/800 1/1600 1/3200 
control 0.269 0.265 0.244 0.192 0.083 0.111 
1 0.980 0.793 0.539 0.441 0.194 0.187 
2 0.651 0.384 0.292 0.233 0.140 0.101 
3 0.593 0.472 0.446 0.300 0.190 0.126 
4 0.812 0.572 0.472 0.346 0.291 0.177 
5 0.607 0.367 0.334 0.257 0.152 0.133 
OKB4 asc 0.049 0.025 0.038 0.050 0.006 0.067 
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From these results it would appear that peptides JP1 and JP2 react non -specifically 
with the alkaline phosphatase- labelled anti -mouse -Ig antibody, and are thus of no use 
in this assay. It was therefore decided to use only JP3 immunised mice in the 
synthesis of monoclonal antibodies against sialyltransferase. 
6.1.3 Hybridoma Screening. 
After booster injections of JP3, mice were again test -bled and the spleen of the mouse 
with the highest antibody titre was used in the production of mAbs against 
sialyltransferase. Hybridomas were screened by testing cell culture supernatants using 
the JP3 ELISA and the RAJI cell -bound ELISA. Cells with supernatants which 
specifically bound to JP3 and exhibited peri- nuclear staining of RAJI cells were 
selected, cloned and cultured in larger volumes in order to produce more cells. 
Samples of cells from all cultures were also frozen down in liquid nitrogen for future 
use. Supernatants from these cultures were re- tested by JP3 ELISA and Raji -cell- 
bound ELISA. The results of these ELISAs are given in table 6.1.5 below. 
In the JP3 ELISA, the mean of the negative control values + 3 x standard deviation 
was 0.069 absorbance units. Cells in wells 3H12, 3C11, 1A6, 3F11, 2D5, 4G1, 3C8 
and 2D8 were found to secrete significant specific Ab. These cells were 
all re- cloned at this stage. Supernatants from 1F9 and 3E10 were weakly positive and 
were also cloned in the hope that a strong mAb secreting clone would emerge. Another 
cell culture in 3G1 was observed to be growing well at this stage and this was also 
cloned. 
Table 6.1.5 Results of JP3 and RAJI cell -bound ELISA's 













3H12 ++ 0.245 2D5 ++ 0.610 
3C11 ++ 0.116 4G1 ++ 0.241 
1A6 + ++ 0.763 3E10 + 0.066 
4A7 - 0.026 3C8 ++ 0.124 
3F11 ++ 0.244 1F9 + 0.033 
4A1 ± 0.030 2D8 ++ 0.266 
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The hybridomas produced from this fusion were named the Pst series (possible 
sialyltransferase). Clones were re -named as described in table 6.1.6 below, and 
supernatants from all 12 sets of clones were tested three days later using the RAJI cell - 
bound ELISA. At least one positive supernatant was obtained from each set. 
Table 6.1.6 New Clone Names. 
OLD NAME 4G1 1A6 1F9 2D5 2D8 3C8 
NEW NAME Pst 1.1 -8 Pst 2.1 -8 Pst 3.1 -8 Pst 4.1 -8 Pst 5.1 -8 Pst 6.1 -8 
OLD NAME 3C11 3E10 3F11 3G1 3H12 4A1 
NEW NAME Pst 7.1 -8 Pst 8.1 -8 Pst 9.1 -8 Pst 10.1 -8 Pst 11.1 -8 Pst 12.1 -8 
Supernatants from the most positive clones were re- tested after culturing for a further 
ten days using a RAJI cell -bound ELISA. Those clones found to secrete antibody 
exhibiting strong and/or perinuclear staining of RAJI cells were Pst 1.6, 2.2, 3.2, 4.2, 
5.2, 6.2, 6.5, 7.7, 8.6, 9.7, 11.5, and 12.4. 
Table 6.1.7 Results of JP3 and rat a- 2,6- sialyltransferase ELISAs. 
Pst mAb 
clone 
Mean Absorbance at 490 nm (adjusted for n.s.b. *) 
JP3 
rat a- 2,6- sialyltransferase 
50 mU /ml 25 mU /ml 12.5 mU /ml 
1.6 0.378 0.063 0.073 0.087 
2.2 2.519 0.091 0.099 0.314 
3.2 0 0 0 0 
4.2 0.187 0.064 0.047 0.079 
5.2 1.291 0.097 0.084 0.145 
6.2 0.337 0 0.011 0.016 
6.5 1.986 0.058 0.109 0.215 
7.7 0.597 0.073 0.099 0.135 
8.6 0.399 0.029 0.065 0.076 
9.7 0.409 0.245 0.260 0.377 
11.5 1.375 0.052 0.091 0.112 
12.4 0.136 0 0.028 0.036 
* n.s.b.= non -specific binding 
Supernatants from 12 clones were later tested for reactivity with the JP3 peptide and 
with purified rat a- 2,6- sialyltransferase using peptide ELISAs. Plates were coated 
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with JP3 or a- 2,6- sialyltransferase at 50 mU /ml, 25 mU /ml and 12.5 mU /ml, and the 
HRP- peptide ELISA carried out as normal. The results are expressed in table 6.1.7. 
Clones 2.2, 5.2, 6.5, 7.7, 9.7, and 11.5 were found to secrete high levels of JP3- 
specific mAb. Clones 2.2, 6.5, and 9.7 were found to secrete mAb which also appear 
to cross -react with rat a- 2,6- sialyltransferase. All clones were cultured for a further 3 
days and fresh supernatant samples were taken and isotyped using an HRP ELISA . 
The results of this isotyping process are given in table 6.1.8. 
Table 6.1.8 Results of Pst Isotvuing. 
mAb 
Absorbance at 405 nm 
IgG1 IgG2a IgG2b IgG3 IgM 
Pst 1.6 0.256 0.189 0.145 0.135 0.181 
Pst 2.2 0.238 0.111 0.373 0.115 2.367 
Pst 3.2 0.186 0.078 0.075 0.077 0.152 
Pst 4.2 0.221 0.146 0.121 0.118 0.435 
Pst 5.2 0.775 0.225 0.553 0.155 2.969 
Pst 6.2 0.226 0.113 0.409 0.092 2.425 
Pst 6.5 2.976 0.306 0.697 0.160 2.457 
Pst 7.7 0.253 0.187 0.149 0.160 0.184 
Pst 8.6 0.286 0.145 0.123 0.121 0.157 
Pst 9.7 OVER* 0.556 2.459 0.311 0.366 
Pst 11.5 0.310 0.378 0.584 0.194 0.290 
Pst 12.4 0.183 0.087 0.083 0.089 0.126 
mean( -ve) + 3 s. d. 0.335 0.059 0.110 0.076 0.099 
* OVER = above the limits of the plate reader i.e. >_ 3. 
Pst clones 1.6, 3.2, 7.7, 8.6, and 12.4 appeared to have stopped secreting Ab, as 
supernatants from these clones did not contain significant levels of any class of Ab 
(absorbance levels were not much greater than those of the negative controls + 3 x the 
standard deviation). Clones 2.2, 4.2, 5.2, and 6.2 were all found to secrete IgM. 
Clone 6.5 appeared to secrete a mixture of IgGI and IgM. This clone should be 
identical to clone 6.2, but it is possible that it was undergoing class switch at the time 
of testing. Clone 9.7 appears to secrete a mixture of IgG 1 and IgG2b, and clone 11.5 
secretes IgG2b. 
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Clones 2.2, 4.2, 5.2, 6.2, 6.5, 9.7 and 11.5 were transfused into the peritoneal cavity 
of BALB /C mice in order to produce murine ascites, but only 5.2, 9.7 and 11.5 were 
successful. Pst clone supernatants and ascites were used in immunohistochemical 
staining of the same liver and pancreas sections previously stained for CDw75 in order 
to compare staining patterns. The mAb were also used to stain Western blots of 
CDw75 positive cell lysates, and were used in immunoprecipitations. The results of 
these experiments are described in section 6.2. 
6.2 Molecular Weight Determination of Pst Antigen. 
6.2.1 Western Blotting with Psts. 
Several attempts were made to determine the molecular weights of the proteins 
recognised by the Pst mAbs on Western blots of electrophoresed cell lysates. The 
results were never clear -cut, as many non -specific bands were always stained by the 
control mAbs as well as the Psts. However, in every experiment, all Pst mAbs and 
ascites samples tested produced virtually identical protein banding patterns, staining 
one, and sometimes two prominent bands in each test. 
An example of the results obtained from one such experiment is given in figure 6.2.1. 
In this experiment, PNT cells were harvested from culture, and solubilised in 0.5% 
CHAPS. 200µl of lysate was diluted in 800µ1 of reducing sample buffer and boiled at 
100 °C for 4 mins. 400µ1 aliquots of this were loaded on to two single sample -well 
SDS (10% Polyacrylamide) gels with rainbow molecular weight markers in the marker 
lanes. Electrophoresis was carried out, and separated proteins transferred to nitro- 
cellulose by Western blotting. After blocking unbound sites by incubating in PBS 5% 
dried milk powder overnight at 4 °C, blots were washed and cut into strips. Individual 
strips were incubated in Pst culture supernatant or ascites diluted 1/1000 in PBS 0.5% 
Tween. Antibodies used are listed in table 6.2.1. 
Antibody- treated strips were stained by enzyme labelling with HRP and developed 
using DAB. Stained strips were reassembled and are shown in figure 6.2.1. Two 
specific major bands are visible on all Pst mAb- labelled strips. The positions of these 
specific protein bands were measured, and their molecular weights calculated using the 
formula of the standard curve generated by the molecular weight markers as illustrated 
in figure 6.2.2. 
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Figure 6.2.1 Western Blots Labelled with Pst mAbs 
Gel 1 
6106 'a 













2:2 - 6.5_. 
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Table 6.2.1 mAbs used to label Western blot 
shown in figure 6.2.1 
GEL 1 GEL 2 
negative control VPM30 Pst 6.2 supernatant 
Pst 4.2 supernatant Pst 5.2 supernatant 
Pst 11.5 supernatant Pst 2.2 supernatant 















Standard curve for blots in Fig 6.2.1 
y = 2.0877 - 0.020571x RA2 = 0.998 






The positions of the two specific bands detected (not found with control mAbs) are 
illustrated in figure 6.2.2. The molecular weights of these proteins were calculated 
using the formula of the curve, and are listed in table 6.2.2 below. 
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Table 6.2.2 Molecular weights of proteins detected in Fig 6.2.1 






Pst 2.2, 5.2, 6.5 20 1.68 47.5 
Pst 2.2, 5.2, 9.7 23 1.61 41.2 
The predicted molecular weight of the protein component of ß-galactoside-a-2,6- 
sialyltransferase is 46.367 kD(Stamenkovic, I., Asheim, H.C., Deggerdal, A., 
Blomhoff, H.K., Smeland, E.B. and Funderud, S., 1990). As the bands detected by 
the Pst mAbs are of molecular weights 47.5 and 41.2 kD, it is very possible that these 
mAbs do in fact recognise different forms of this sialyltransferase enzyme, especially 
since it is known that in animals, the enzyme can be differentially expressed in 
different tissues by utilisation of different transcriptional start sites(Wang, X., 
O'Hanlon, T.P., Young, R.F. and Lau, J.T., 1990). However, as none of the 
Western blots stained produced clear, clean bands, I decided to look for more 
conclusive proof of the molecular weight of the Pst antigen by immunoprecipitation. 
6.2.2 Immunoprecipitation with Psts. 
PNT cells were metabolically labelled with 35S -met + cys, and solubilised in 1% Triton 
CF -54 (it was not necessary to use CHAPS as the Pst epitopes should not contain 
carbohydrate). After several unsuccessful attempts at immunoprecipitation using Biorad 
immunobeads, precipitations were carried out using the Protein -A- Sepharose method. 
Beads were armed using Pst 6.5, 9.7 and 11.5 culture supernatants, and also Pst 5.2, 
9.7, and 11.5 and DA6 147 and WAC 70 ascites. Immunoprecipitations were carried 
out, and precipitates were run on an SDS 10% Polyacrylamide gel. The gel was 
Western blotted and exposed to film for several days before developing, and is shown 
in figure 6.2.3. 
A single major band was detected in the ascites immunoprecipitates only, and another 
weaker, but specific band was seen in lanes 4 & 7 (Pst 11.5 supernatant and Pst 9.7 
ascites precipitates). The positions of these bands were measured, and their molecular 
weights calculated using the formula of the standard curve generated by the molecular 
weight markers, as shown in figure 6.2.4. The values obtained are listed in table 6.2.3. 
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6.5 97 115 WAC 5-2A 9-7A 11.5A DA6 
70 147 
Arrows indicate Pst -specific bands at 112.4 kD and at 46.8 kD. 
Table 6.2.3 Molecular weights (m.w.) of Pst Immunoprecipitates. 
mAb Distance on gel log m.w. m.w. 
WAC70(CD11a) 9.5 mm 2.254 179.6 
DA6 147 (MHC II) 47.5 mm 1.533 34.1 
Pst 11.5 41 mm 1.67 46.8 
Pst 9.7 Ascites 41 mm 1.67 46.8 
Pst 5.2 Ascites 20.5 mm 2.05 112.2 
Pst 9.7 Ascites 20.5 mm 2.05 112.2 
Pst 11.5 Ascites 20.5 mm 2.05 112.2 
The molecular weights obtained for the CD11a and MHC class H antigens are correct, 
and the predicted molecular weight of human 13- galactoside- a- 2,6- sialyltransferase is 
around 46 kDa. It is therefore possible that the 46.8 kDa band precipitated by Pst 
mAbs 11.5 and 9.7 is in fact human a- 2,6- sialyltransferase. It is also possible that the 
112 kDa band detected may be a dimer of the sialyltransferase enzyme as it is known 
that in rats the enzyme probably operates as a dimer(Fleischer, B., McIntyre, J.O. and 
Kempner, E.S., 1993). 
137 
Figure 6.2.4 Standard curve for blot in Fig 6.2.3 
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6.3 Tissue Distribution of Pst Antigen. 
The same tissue samples of liver and pancreas as studied in chapter 4 were stained 
using immunohistochemical techniques in order to compare distribution of the Pst 
antigen(s) with that of CDw75, and to compare expression levels on normal and 
tumour tissue. As in chapter 4, the number and quality of the tissue samples available 
were limited, and results can only be interpreted as a preview to more exhaustive 
research. 
6.3.1 Liver Sections 
Ten of the same samples of liver tissue as used in chapter 4, were 
immunohistochemically stained with five clones of Pst mAbs. The results are indicated 
in table 6.3.1 below. Examples of some of the positively stained tissue samples are 
also shown in photographic plates 6.3.1 - 6.3.3. Texas red was used as the 
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developing substrate in these sections, and positive staining is therefore indicated by 
various shades of pink colouring. 
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* (t) indicates a sample of tumour tissue taken from the same patient. 
+/- indicates very weak staining, + indicates moderate staining, 
++ indicates strong staining, - indicates no staining. 
Photographic Plate 6.3.1 
(a) Pst 9.7 staining of liver 1(tumour). (x 20 magnification). 
(b) Pst 6.5 staining of liver 3 (normal). (x 40 magnification). 
Photographic Plate 6.3.2 
(a) Pst 6.5 staining of liver 3 (tumour). (x 10 magnification) 
(b) Pst 9.7 asc. staining of liver 3 (tumour). (X 10 magnification) 
Photographic Plate 6.3.3 
ti 
` 11 ` S 
e.lbe 4E) 
..i 
(a) Pst 5.2 asc. staining of liver 5 (normal). (x 40 magnification) 
(b) Pst 6.5 staining of liver 5 (normal). (x 40 magnification) 
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The results of this study indicate that there may be a reduction in expression of the 
antigen(s) recognised by Psts 5.2, 9.7 and 11.5 in tumour cells. These mAbs are the 
clones most likely to possess anti- a- 2,6- sialyltransferase activity, as discussed in 
sections 6.2.1 and 6.2.2. It is possible therefore that expression of this enzyme is 
reduced in tumour cells, as is that of CDw75. However, due to the limited number of 
samples used in this study, no significant conclusions may be drawn, and a much 
larger group of patient samples would be required in order to fully determine any 
significant difference in expression levels. In addition, the identity of the antigen(s) 
recognised by each mAb would need to be conclusively proved. 
It can also be seen from photographic plates 63.1 - 6.33 that the staining pattern 
produced by the Pst mAbs on liver is completely different to that produced by the 
CDw75 mAbs. If we compare stained sections of liver 3 as illustrated on photographic 
plates 4.5.1 and 4.53 with those on photographic plates 6.3.1 and 6.3.2 the cellular 
distribution of the two antigens is completely different. Whereas the CDw75 mAbs 
predominantly stain the liver canaliculae, the Pst mAbs produce a granular cytoplasmic 
staining pattern which is perinuclear in location when viewed at higher magnification 
(6.3.1b & 6.3.3a & b). Since the sialyltransferase enzyme is found mainly in the 
Golgi apparatus, the staining patterns produced give further evidence that the' Pst 
mAbs may indeed be specific for this enzyme. 
6.3.2 Pancreas Sections 
Four samples of normal pancreas and three samples of tumour pancreas were 
immunohistochemically stained with five Pst mAbs. The results are indicated in table 
6.3.2, and examples of positively stained sections are shown on photographic plates 
6.3.4 - 6.3.8. 
If CDw75 and Pst mAb staining of normal pancreas sections are compared 
(photographic plates 4.6.1 and 63.4 - 63.7 respectively), differences in expression 
patterns can again be seen. CDw75 mAbs in general produce a patchy staining pattern 
mainly on the cytoplasm of ductal cells, but also on the membranes of these cells. Pst 
staining in contrast is more uniformly distributed across the section, and as in liver 
samples tends to stain cytoplasmic granules. However, in tumour tissue, the staining 
pattern produced by both sets of mAbs is very similar (photographic plates 4.6.2 and 
6.3.8). With the Pst mAbs staining is much less uniform than in normal tissue, and 
Photographic Plate 6.3.4 
(a) Pst 6.5 staining of pancreas 2 (normal). (x 20 magnification) 
(b) Pst 9.7 staining of pancreas 2 (normal). (x 40 magnification) 
Photographic Plate 6.3.5 
(a) Pst 11.5 staining of pancreas 2 (normal). (x 40 magnification) 
(b) Pst 11.5 staining of pancreas 2 (tumour). (x 40 magnification) 
Photographic Plate 6.3.6 
(a) Pst 6.5 staining of pancreas 5 (normal). (x 20 magnification) 
(b) Pst 11.5 staining of pancreas 5 (normal). (x 20 magnification) 
Photographic Plate 6.3.7 
(a) Pst 6.5 staining of pancreas 4 (normal). t( .40 magnification) 
(b) Pst 11.5 staining of pancreas 4 (normal). (x 40 magnification) 













(a) Pst 9.7 staining of pancreas 4 (tumour). (x 10 magnification) 
(b) Pst 11.5 staining of pancreas 4 (tumour). (x 10 magnification) 
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membranous structures are also stained, indicating a total disruption of the Golgi - 
targeting mechanism of the sialyltransferase, and possibly production of a soluble 
form or a plasma- membrane -bound form of the sialyltransferase enzyme. 
Table 6.3.2 Results of Pst and CDzv75 staining on aucreas. 
Tissue 
Sample 
Pst 4.2 Pst 5.2A Pst 6.5 Pst 9.7A 
_ 
Pst 11.5A CDw75 
(HH2 & 
EBU -141) 
l(t)* - - - 
I 
- - +/ 
2 +7- +/- + + +/- +; 
2(t) - - +/- - +1- +/ 
4 - ++ ++ - + +/ 
4(t) +/- +1- +/ + + + + +/- 
5 +/- +/- + +/- + iv- 
* (t) indicates a sample of tumour tissue taken from the same patient. 
+/- indicates very weak staining, + indicates moderate staining, 
+ + indicates strong staining, - indicates no staining. 
It is unfortunate that these results are less conclusive than those on liver sections since 
they are more difficult to quantify, and a much larger specimen group would have to 
be studied in order to determine any significant and consistent differences in CDw75 
or Pst mAb staining patterns between normal and tumour tissues. 
6.4 Discussion. 
The results of the experiments described in this chapter indicate that at least some of 
the mAbs produced from the synthetic peptide MAPs may be specific for the elusive 
13- galactoside- a -2,6- sialyltransferase enzyme. The initial screening process by Raji 
cell -bound ELISA selected mAbs exhibiting perinuclear staining, and this was also 
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observed on immunohistochemical staining of liver and pancreas sections. In addition, 
all Pst mAbs immunolabelled protein bands of mr -47 kDa and 41 kDa on 
electrophoretically separated preparations of detergent solubilised PNT cells. Also, 
Psts 11.5 and 9.7 ascites immunoprecipitated bands of mr 46.8 kDa, and Pst ascites 
5.2, 9.7 and 11.5 immunoprecipitated bands of mr 112 kDa. The predicted mr of the 
human enzyme is around 46 kDa(Grundmann, U., Nerlich, C., Rein, T. and 
Zettlmeissl, G., 1990; Stamenkovic, I., Asheim, H.C., Deggerdal, A., Blomhoff, 
H.K., Smeland, E.B. and Funderud, S., 1990), and in rats isoforms have been 
detected with mrs of 43kDa and 47kDa(Weinstein, J., Lee, E.U., McEntee, K., Lai, 
P.H. and Paulson, J.C., 1987). In addition, it has been shown that in rats the enzyme 
probably functions as a dimer in the Golgi membrane(Fleischer, B., McIntyre, J.O. 
and Kempner, E.S., 1993). Taking all the evidence into account, it is possible that the 
Pst mAbs detect two different isoforms of 3- galactoside- a- 2,6- sialyltransferase with 
mrs of around 47 kDa and 41 kDa. The large proteins detected at 112 kDa by 
immunoprecipitation may represent dimers or trimers of the enzyme (although this is 
speculative). The perinuclear staining pattern observed in Raji cells and in liver and 
pancreas sections adds further credence to the argument. a- 2,6- sialyltransferase 
enzyme assays were performed on the Pst immunoprecipitates, but no activity' was 
detected. However, this may have been due to the fact that protease inhibitors 
leupeptin, pepstatin, EDTA, TLCK -HCL and TPCK were used in the preparation of 
the soluble membrane samples. It has since come to light that these are potent 
inhibitors of sialyltransferase activity(Melkerson -Watson, L.J. and Sweeley, C.C., 
1991). 
If time had not been limited, I would have liked to have further defined the intracellular 
staining patterns of the Pst mAbs using immunoelectron microscopy techniques. I 
would also have liked to more accurately compare this staining pattern with that of the 
CDw75 mAbs by means of double -labelling techniques using electron microscopy 
with different sized gold particles or immunofluorescence microscopy using different 
coloured dyes. If the Pst mAbs can be proven to be specific for 13- galactoside- a -2,6- 
sialyltransferase, they may have many applications in the future. Since sialylation 
levels, and even a -2,6- linked sialic acid levels have been shown to be directly related 
to tumour aggression in many cancers(Yogeeswaran, G. and Salk, P.L., 1981; 
Hakomori, S., Patterson, C.M., Nudelman, E. and Sekiguchi, K., 1983; Smets, 
L.A. and Van Beek, W.P., 1984; Dennis, J.W., 1986; Humphries, M.J., 
Matsumoto, K., White, S.L. and Olden, K., 1986; Cohen, A.M., Allalouf, D., 
Djaldetti, M., Weigl, K., Lehrer, N. and Levinsky, H., 1989; Dall'Olio, F., 
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Malagolini, N., di Stefano, G., Minni, F., Marrano, D. and Serafini -Cessi, F., 1989; 
Francina, A., Gateau -Roesch, O., Couprie, N., Leculier, C., Col, J.F., Archimbaud, 
E., Campos, L., Louisot, P. and Richard, M., 1989; Springer, G.F., 1989; Bresalier, 
R.S., Rockwell, R.W., Dahiya, R., Duh, Q.Y. and Kim, Y.S., 1990; Easton, E.W., 
Bolscher, J.G.M. and van den Eijnden, D.H., 1991; Sasaki, H., Momoi, T., 
Yamanaka, C., Yorifuji, T., Kaji, M. and Mikawa, H., 1991; Harvey, B.E., Toth, 
C.A., Wagner, H.E., Steele, G.D.J. and Thomas, P., 1992; Vandamme, V., 
Cazlaris, H., Le Marer, N., Laudet, V., Lagrou, C., Verbert, A. and Delannoy, P., 
1992), a quick and economic means of labelling and possibly quantifying a -2,6- 
sialyltransferase levels in tumour biopsies could prove to be of great prognostic value 
in the treatment of cancer patients. 
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CHAPTER 7 
Fifth International Leucocyte Typing 
Workshop. 
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7.1 B -Cell Panel Analysis. 
The function of the International Leucocyte Typing Workshop is to classify new mAb 
into clusters with identical binding patterns and tissue distribution and in this way 
assist in the identification of new markers of cell differentiation. New mAbs are sent to 
the workshop which distributes them in the form of panels of coded mAbs to be 
analysed against different cell lineages by numerous labs throughout the world. The 
information is collated by the workshop and the new mAbs are allocated to either 
existing clusters or to new unclassified clusters. I applied to the Workshop for the 
CDw75 and CD76 panels, but also accepted the new B -cell panel for analysis in an 
attempt to identify putative CDw75 mAbs. 71 mAb were sent with information limited 
purely to the isotype of mAb, its form (ascites or hybridoma culture supernatant) and 
suggested working concentration. The panel was tested immunohistochemically on 
normal tonsil sections and by flow cytometry on the Namalwa cell lines, some 
leukaemias and samples of normal peripheral blood lymphocytes. Selected mAb were 
also used in biochemical analyses of cell lysates in order to determine the molecular 
weight of the antigens to which they had been raised. 
7.1.1 B -Cell Panel Analysis by Flow Cytometry. 
Six Namalwa sublines, NK, CSN /70, IPN /45, PNT and KN2 (in ascending order of 
differentiation) were used to screen the B -cell panel. Samples of PBL from 2 normal 
donors and a patient with B -cell Chronic Lymphocytic Leukaemia were also used. 
Cells were labelled with FITC- labelled anti -mouse -Ig and analysed by flow cytometry. 
The results are expressed as % positive cells using gates set using isotype- matched 
negative controls, and are given in table 7.1.1 below. 7 mAb were missing from the 
panel and these have therefore been omitted from the table. mAb B000 was provided 
by the Workshop as a negative control, 2A4.5 and VIM13 are our own IgG and IgM 
matched negatives. CD 19.3 was used to label the B -cell population in each sample, 
and DR001, an IgG2a mAb specific for MHC class II was used as a positive control. 
Paraffin sections of normal tonsil were also stained immunohistochemically with each 
mAb, and a summary of these results is included in Table 7.1.1. The results were 
analysed for novel patterns of reaction and for recognisable patterns of existing 
clusters. Approximately 40 mAb in the B -cell panel reacted preferentially with one or 
more of the Namalwa sublines. There were six or seven discernible patterns of 
expression of surface antigens, one of which was similar to that of existing cluster 
CD45RA, and one which was similar to that of CDw75. 
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Table 7.1.1 B -Cell Panel Reactivity (% Positive Cells) 
mAb NK CSN/70IPN/45 PNT KN2 PBL 1 PBL 2 BCLL Tonsil* 
B000 1 1 1 1 1 3 4 2 - 
2A4.5 0 0 0 1 1 2 3 1 N.D.t 
VIVI13 2 4 1 2 2 3 4 2 - 
CD19.3 99 87 78 99 82 14 9 98 N.D. 
DR001 45 59 100 99 100 18 20 99 N.D. 
B O 1 1 5 27 36 77 12 9 44 - 
B02 3 2 2 3 3 0 3 2 + 
B 0 3 1 2 1 3 3 4 4 1 + dendritic 
B 0 4 1 2 1 1 1 4 3 1 + dendritic 
B05 1 2 1 1 1 3 3 1 + 
B06 34 85 100 99 99 63 74 86 +/- 
B07 2 1 1 2 1 14 4 86 +1- 
B08 53 94 93 99 59 7 6 86 ++ 
B09 0 1 0 0 1 2 4 1 - 
B10 47 34 99 90 72 21 17 99 + 
B11 8 22 2 5 13 1 4 3 + 
B12 1 3 67 40 5 33 60 97 - 
B14 0 2 0 1 3 2 4 2 - 
B15 0 1 1 1 2 1 2 1 - 
B16 100 98 99 100 100 1 2 1 + 
B17 0 2 1 1 2 1 3 1 - 
B18 0 1 0 1 1 1 3 1 - 
B19 100 100 100 100 100 96 94 38 +/- 
B20 1 2 3 5 1 11 9 0 - 
B21 1 1 1 1 1 1 4 1 - 
B24 1 2 0 1 0 1 4 1 - 
B25 93 89 100 98 89 9 70 98 + follicular 
B27 3 5 60 26 6 29 57 98 - 
B28 4 3 1 2 6 9 8 1 - 
B29 6 50 84 38 51 8 10 2 -1-F follicular 
B31 34 75 94 99 97 1 26 36 - 
B32 32 69 92 99 96 17 25 58 +/- 
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mAb NK CSN/70IPN/45 PNT KN2 PBL 1 PBL 2 BCLL Tonsil* 
B34 0 1 0 1 3 1 3 1 - 
B35 1 1 0 1 9 1 2 1 - 
B36 14 49 6 15 20 12 8 92 +/- 
B37 2 5 47 74 17 7 9 4 - 
B38 4 9 0 2 2 42 60 1 - 
B39 0 0 0 1 1 1 3 1 +1- 
B40 6 10 20 6 67 1 3 3 ++ 
B41 99 96 99 99 94 4 21 96 - 
B42 0 0 0 1 0 1 3 1 - 
B43 3 0 0 1 12 0 3 1 - 
B44 32 81 100 100 81 36 76 98 + 
B46 4 55 13 28 7 1 4 1 + 
B47 0 0 0 1 1 10 9 10 - 
B48 99 99 95 86 11 97 97 99 ++ 
B49 1 2 14 34 2 9 7 1 - 
B50 0 1 0 1 1 12 7 1 +/- 
B51 0 1 0 1 0 3 4 1 - 
B52 89 87 28 6 48 9 7 1 - 
B53 1 1 0 1 0 3 4 2 - 
B54 64 79 94 99 99 54 32 95 - 
B55 93 87 67 94 16 57 54 83 ++ 
B56 100 99 98 100 91 96 97 100 +T-ceIl areas 
B57 70 57 40 89 29 32 28 22 +T-ceIlareas 
B59 100 100 99 95 99 97 98 100 + 
B60 0 0 0 1 0 3 3 1 - 
B62 31 94 100 100 99 75 78 98 + dendritic 
B63 29 93 100 100 99 75 78 97 +T-ceIlareas 
B64 37 95 93 96 59 4 4 87 + 
B65 20 20 1 2 1 4 4 2 +/- 
B66 16 23 1 1 2 4 3 1 - 
B67 100 100 100 100 100 97 96 31 - 
B68 100 100 100 100 100 97 95 36 +1- 
B69 100 100 100 100 100 98 97 54 +/- 
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* 
tN.D.= not determined 
mAb NK CSN/70II'N/45 PNT KN2 PBL 1 PBL 2 BCLL Tonsil* 
B70 100 100 100 100 100 97 96 67 - 
B71 100 100 100 100 100 96 95 10 + 
mAb pairs with similar patterns and those mAbs of the panel which produced staining 
patterns similar to those of existing clusters are listed in table 7.1.2. Pairs producing 
similar staining patterns were B006 and B044, B008 and B064, B012 and B027, 
B019 and B071, B031 and B032, B065 and B066, B067 and B068, and B069 and 
B070. The mAbs B019, B071, B067, B068, B069 and B070 were all similar in 
reactivity. 
Table 7.1.2 Potential Cluster Members in B -cell panel. 
Percentage positive cells * 
Reactivity mAb NK CSN70 IPN45 PNT KN2 PBL1 PBL2 B-CLL 
B006 34 85 99 99 99 63 74 86 CD45RA 
B044 32 81 99 99 81 36 76 98 CD45RA 
B008 53 94 92 98 59 7 6 86 UC 
B064 37 95 93 96 59 4 4 87 UC 
B012 1 3 67 40 5 33 60 97 ?CDw75 
B027 3 5 60 26 6 29 57 98 ?CDw75 
B019 99 99 99 99 99 96 94 38 PC#2 
B071 99 99 99 99 99 96 95 10 ?PC#2 
B031 34 75 94 99 97 1 26 36 UC 
B032 32 69 92 99 96 17 25 58 UC 
B065 20 20 1 2 1 4 4 2 PC#1 
B066 16 23 1 1 2 4 3 1 PC#1 
B067 99 99 99 99 99 97 99 31 PC#2 
B068 99 99 99 99 99 97 95 35 PC#2 
B069 99 99 99 99 99 98 97 54 PC#2 
B 0 7 0 99 99 99 99 99 97 96 67 PC#2 
* UC, unclustered mAb; PC, possible cluster. 
Antibodies B012 and B027 have a similar expression pattern to CDw75, although the 
level of binding on PNT cells is a bit low. This work is published in the Workshop 
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Proceedings in which the codes for all mAbs are listed. mAb B012 is the possible 
CDw75 mAb EBU- 65(Ross, J.A. and Andrew, J.M., 1995). 
7.1.2 Biochemical Analysis of B -cell Panel. 
Selected mAb which had successfully labelled cells immunohistochemically and flow 
cytometrically were used in basic biochemical studies. All mAbs producing any level 
of staining were used to immunoprecipitate Ag from PNT cell lysates. 








_ r_C5_N 70 PNT KN2 
Immunoprecipitates were separated electrophoretically and transferred to nitro- 
cellulose by Western blotting. Protein bands were detected using India Ink. Weak 
bands were detected in precipitates of B29, B71 and B55. Unfortunately, the bands 
were not clear enough to calculate any molecular weights. The results were therefore 
used merely as an indicator of potential binding activity to denatured protein. Lysates 
were then made of 5 of the Namalwa sublines and these were separated on 3 
individual SDS polyacrylamide gels, transferred to nitro -cellulose by Western blotting 
and each probed with one of the above 3 mAb and developed using the DAB/HRP 
method. Only B29 produced positive protein bands as shown in figure 7.1.1. Double 
bands of molecular weights -50 and 60kD were detected. These were of highest 
intensity in cell lines CSN /70 and PNT, and more weakly in NK and KN2. This 
reflects to a certain extent, the extracellular binding detected on these cell lines by flow 
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cytometry, although the intensity of bands detected in KN2 cell lysates is not as high 
as would be predicted from the flow cytometry results. This may be due to a decrease 
in intracellular antigen in these more differentiated cells as compared to high 
intracellular and extracellular antigen levels in CSN /70 and PNT cells. IPN /45 lysates 
were not used in this analysis. 
7.2 CDw75 & CD76 Panel Analysis. 
CDw75 and CD76 mAb panels were specifically requested from the Workshop. At the 
Fourth International Leucocyte Typing Workshop, CDw75 mAbs were shown to be 
mainly reactive with mature sIg+ cells of the B -cell lineage, and with germinal centre 
B -cells in solid lymphoid tissue(Dorken, B., Moller, P., Pezzutto, A., Schwartz - 
Albiez, R. and Moldenhauer, G., 1989). Only a limited amount of information about 
the biochemical nature of the antigen was described at this workshop, with conflicting 
results of molecular weight determinations indicating molecular weights of 53 kDa 
(Dorken, B., Moller, P., Pezzutto, A., Schwartz -Albiez, R. and Moldenhauer, G., 
1989) and 87 kDa ( Mittler, R.S., Talle, M.A., Carpenter, K., Rao, P.E. and 
Goldstein, G., 1983) for the 0104 antigen. In addition, the LN -1 epitope has been 
shown to be destroyed by neuraminidase treatment(Epstein, A.L., Marder, R.J., 
Winter, J.N. and Fox, R.I., 1984). However, no further information regarding 
epitope structures was generated at the previous workshop. Since the last workshop, 
CDw75 and CD76 have both been shown to be generated by the activity of 13- 
galactoside-a-2,6- sialyltransferase(Bast, B.J., Zhou, L.J., Freeman, G.J., Colley, 
K.J., Ernst, T.J., Munro, J.M. and Tedder, T.F., 1992). However, previous 
experiments with the CDw75 mAbs (chapter 3) have shown that not all epitopes are 
sialylated, and I wanted the opportunity to repeat these experiments using fresh mAbs 
and to compare CDw75 epitope structures with those of CD76. Tunicamycin was used 
to inhibit N- linked glycosylation of CDw75+ and CD76+ cells, and neuraminidase 
was used to eliminate sialic acid. Expression of Ag of both clusters on Namalwa 
sublines was also compared. 
7.2.1 Titration of CDw75 and CD76 mAb on PNT cells 
Before and After Neuraminidase Treatment. 
Initial titrations were carried out on both sets of mAb and on previously obtained 
CD76 mAb HD66 to establish optimum concentrations for cell -labelling. Dilutions of 
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1 /100, 1/200, 1 /500 and 1 /1000 were used to label PNT cells. Half of the samples of 
PNT cells were untreated and the other half were pre- treated with neuraminidase to 
remove sialic acid. FITC -labelled secondary mAb was used and fluorescence detected 
by flow cytometry. Results are described as % positive cells (over a threshold 
determined using isotype- matched negative controls). The results are given in Table 
7.2.1 below. 
Table 7.2.1 CDw75 and CD76 Titration on PNT Cells. 
(% Positive Cells 
mAb 
1/100 1/200 1/500 1/1000 
-NX +N -N +N -N +N -N +N 
C D w 7 5 .1 66 99 61 98 50 97 44 94 
CDw75.2 99 7 100 7 100 4 99 8 
CDw75.3 100 5 99 7 99 5 96 5 
CDw75.4 90 16 94 12 91 11 91 8 
CDw75.5 95 6 92 7 85 4 76 6 
CD76.1 95 5 92 5 86 4 73 5 
CD76.2 94 90 72 55 36 22 13 9 
C D 7 6. 3 86 100 80 100 64 100 49 99 
C D 76.4 74 48 84 54 90 65 9 0 70 
HD66 38 5 22 4 7 7 7 
VPN130 1 3 2 3 1 4 
* -N indicates no treatment of cells before staining, 
+N indicates pre -treatment with neuraminidase. 
The minimum concentrations of each mAb required for optimal binding are 
represented by shading. These are the concentrations which were used in all 
subsequent experiments. Table 7.2.2 gives the comparative binding levels of the four 
CDw75 mAb used in all other chapters at their current activity levels. As previously 
mentioned, the activity of EBU -65 stocks would appears to have deteriorated with 
storage when compared with the activities of the fresh workshop mAb. 
CDw75 Expression on PNT cells.(% Positive Cells) 
mAb HI-12 OKB4 EBU-141 1 EBU-65 
- N 94 29 93 38 
+N 7 75 8 5 
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Neuraminidase sensitivity is a good indicator of the glycosylation state of each epitope 
(as previously discussed). Only one CDw75 epitope (CDw75.1) appeared to be 
masked by sialic acid. The number of positive cells detected by this mAb after 
neuraminidase treatment was increased by 94% at the optimum mAb concentration of 
1/500. mAb CDw75.1 was therefore identified as OKB4. All other CDw75 epitopes 
were destroyed by neuraminidase treatment, thus confirming previous findings. 
With the CD76 mAbs, the CD76.3 epitope was found to exhibit the same phenomenon 
as CDw75.1, in that it is also masked by sialic acid. The number of cells recognised 
by this mAb was also increased by 103% after treatment with neuraminidase. CD76.1 
and HD66 binding was completely abrogated by neuraminidase treatment, indicating 
that this epitope is sialylated. However, neuraminidase treatment had little or no effect 
on CD76.2 and CD76.4 binding. 
7.2.2 Investigation of N- Linked Glycosylation of Epitopes. 
Neuraminidase treatment provided an assessment of sialic acid involvement in each 
epitope. However, if CDw75 expression is under the control of the enzyme (3- 
galactoside-a-2,6-sialyltransferase as has been reported, then it would seem logical to 
determine if each epitope contains the N- linked glycosides necessary for this enzyme 
to act. As previously explained in chapter 3.2, tunicamycin is a potent inhibitor of N- 
linked glycosylation. If tunicamycin treatment causes a reduction in epitope 
recognition by any of the mAb studied, then we can assume that the epitopes 
recognised are expressed on N- linked carbohydrate. 
As in chapter 3.2, PNT cells were used in this study. Cells were harvested from 
culture, stripped of their sialic acid by treatment with neuraminidase, and then cultured 
overnight in varying concentrations of tunicamycin. Monensin was not used to inhibit 
re- sialylation in this study. Instead, where de- sialylation was deemed necessary (i.e. 
for sialic- acid -masked epitopes CDw75.1 and CD76.3), neuraminidase treatment was 
repeated before staining with these mAb. Cells were labelled with all mAb from both 
clusters, and also with the previously obtained samples of identified CDw75 mAb and 
the lectins SNA and MAA (which provide a gauge of glycosylation state). The 
experiment was repeated four times and gave consistent levels of staining for each 
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mAb in each repetition. The results of these four experiments were pooled, and mean 
percentages of positive cells are given in table 7.2.3 below. 
Table 7.2.3 Results of Tunicamycin Inhibition of PNT -Cell 
Glycosylation on CDw75 & CD76 Expression (% Positive Cell 
mAb 
Before treatment After treatment 
-N +N Otm* 0.25tm 0.5tm 1.0tm 2.0tm 
CDw75.1 39 87 55 57 58 54 54 
CDw75.1(N)t 87 81 84 74 70 66 
C D w 7 5 . 2 84 1 64 56 34 25 17 
C D w 7 5 . 3 69 1 48 41 24 16 10 
CDw75.4 43 16 36 31 22 22 19 
CDw75.5 42 1 26 17 8 4 2 
CD76.1 32 1 19 11 7 5 4 
CD76.2 29 37 54 33 38 32 26 
C D 7 6 . 3 2 95 66 77 77 78 77 
C D 7 6 . 3 ( N ) 95 90 89 87 90 95 
C D 7 6 . 4 74 61 73 69 62 60 57 
H H 2 47 0 34 24 14 8 6 
OKB4 19 49 28 26 24 23 22 
OKB4(N) 49 42 45 38 34 28 
EBU-141 45 16 36 31 24 25 19 
EBU-65 7 1 6 3 2 2 2 
S N A 99 36 90 82 53 36 25 
SNA(N) 36 34 33 28 24 10 
MAA 60 97 91 100 92 90 77 
MAA(N) 97 94 99 92 94 87 
*tm = tunicamycin concentration used in µg /ml 
t (N) indicates cells re- treated with neuraminidase 
SNA binding is a good indicator of N- linked glycosylation levels as it specifically 
binds to sialic acid in the a- 2,6- linkage on N- linked carbohydrate(Shibuya, N., 
Goldstein, I.J., Broekaert, W.F., Nsimba- Lubaki, M., Peeters, B. and Peumans, 
W.J., 1987). As can be seen from table 7.2.3 above, N- linked glycosylation of these 
cells was indeed inhibited by tunicamycin treatment. The results also show that the 
level of inhibition was directly proportional to the concentration of tunicamycin used. 
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MAA binds to 0- linked glycans, and the results also show that tunicamycin treatment 
had little or no effect on 0- linked glycosylation. 
It can be seen from table 7.2.3, that the most noticeable effect of tunicamycin on 
CDw75 and CD76 expression was on epitopes CDw75.2, CDw75.3, CDw75.4, 
CDw75.5 and CD76.1. Tunicamycin was observed to have no effect on the CD76.3 
epitope (after neuraminidase treatment), and there was only a moderate reduction in the 
numbers of cells recognised by CDw75.1, CD76.2 and CD76.4 after the treatment. 
These results indicate that epitopes CDw75.2, CDw75.3, CDw75.4, CDw75.5 and 
CD76.1 are all composed of N- linked carbohydrate. CDw75.1, CD76.2 and CD76.4 
epitopes may partially consist of N- linked carbohydrate, and the moderate binding 
levels observed after tunicamycin treatment may be due to reduced affinity of binding 
of the mAb to partial epitopes. CD76.3 binding was completely unaffected by the 
treatment, indicating that this epitope does not contain any N- linked carbohydrate. 
Another explanation for the observed differences may be that the epitopes are also 
expressed on glycolipids. CD76 mAbs have been shown to identify a carbohydrate 
antigen present on gangliosides(Bast, B.J., Zhou, L.J., Freeman, G.J., Colley, K.J., 
Ernst, T.J., Munro, J.M. and Tedder, T.F., 1992). Individual CD76 mAbs have also 
been shown to produce different staining patterns dependent on the polarity of the 
gangliosides stained. It is also possible that CDw75 
glycolipids in addition to glycoproteins. This theory is supported by the observation 
that tunicamycin does not produce 100% inhibition of synthesis of any of the epitopes 
studied. 
It was noticed that the CD76.1 epitope structure is more similar to that of the 
CDw75.2, CDw75.3, CDw75.4 and CDw75.5 epitopes than to the other CD76 
epitopes. It should also be noted that the CDw75.1 epitope seems more similar in 
structure to the CD76.2 and CD76.4 epitopes than to the other CDw75 epitopes. This 
will be discussed more fully in section 7.3. 
7.2.3 CDw75 and CD76 Expression on Namalwa Sublines. 
CDw75 and CD76 mAb were screened against the six available Namalwa sublines, 
G4, NK, CSN /70, IPN /45, PNT and KN2 (as described in Chapter 3) in order to 
compare the relative distribution of both antigens on B -cells at various stages of 
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differentiation. Cells were harvested and stained as before using FITC -labelled 
secondary mAb, and analysed by flow cytometry. Results are expressed as 
percentages of positive cells above a threshold determined by isotype matched negative 
controls, and are given in table 7.2.4 below. Namalwa sublines are presented in 
ascending order of differentiation. Where indicated, cells were treated with 
neuraminidase prior to staining. These results are published in the Workshop 
Proceedings(Andrew, J.M. and Ross, J.A., 1995). 
Table 7.2.4 CDw75 & CD76 Expression on Namalwa Sublines 
(% positive cells 
mAb 
l 
G4 NK CSN/70 IPN/45 PNT KN2 
HH2 7 6 1 75 94 6 
OKB4 (N)* 46 9 9 63 75 8 
EBU-141 8 2 1 66 93 2 
EBU-65 8 1 1 19 38 1 
CDw75.1 6 2 1 51 50 2 
CDw75.1 (N) 55 15 32 85 97 17 
CDw75.2 9 16 3 92 99 19 
CDw75.3 9 9 2 78 96 13 
CDw75.4 6 2 1 63 91 3 
CDw75.5 7 2 2 59 92 5 
CD76.1 9 4 2 17 92 14 
CD76.2 43 19 14 70 94 61 
CD76.3 10 1 1 7 49 4 
CD76.3 (N) 76 69 54 92 99 99 
CD76.4 98 36 80 18 90 9 
HD66 9 2 1 4 38 5 
VPM30 2 1 1 1 1 1 
2A4.5 4 2 1 2 1 2 
As previously established, all CDw75 epitopes were found on sublines IPN /45, and 
PNT. These are the more mature sublines and are slg +. Four of the CDw75 mAb did 
not label the immature B -cell precursors or the most mature KN2 cells to any great 
extent. The OKB4 (CDw75.1) epitope however was found on the very immature G4 
cells and on the remaining three sublines (NK, CSN /70 & KN2) to a lesser extent. 
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This suggests that the OKB4 epitope is expressed at different stages of cell 
differentiation from the other epitopes. The distribution of this epitope on Namalwa 
sublines actually more closely resembles that of the CD76 epitopes with the exception 
of CD76.1 which in turn resembles the distribution of the other CDw75 epitopes. In 
general the CD76 epitopes CD76.2, CD76.3 and CD76.4, like the CDw75.1 epitope 
were expressed on all cells, but to a greater extent on the more mature cell lines 
IPN /45, PNT and KN2 (with the exception of CD76.4). 
7.3 Discussion. 
Both CDw75 and CD76 have previously been shown to be expressed mainly on 
mature B -cells and on a subset of T- cells. In my analysis, I have concentrated mainly 
on cells of B -cell origin, and have confirmed that the antigens are indeed most strongly 
expressed on the more mature B- cells. In the case of CDw75, very little structural 
data is available for each of the epitopes, although it is assumed that they all consist of 
a- 2,6- sialylated structures on N- linked carbohydrate(Munro, S., Bast, B.J., Colley, 
K.J. and Tedder, T.F., 1992). However, as shown in chapter 3 and confirmed in this 
chapter, this cannot be the case for all epitopes of CDw75 since the OKB4 epitope is 
in fact masked by sialic acid, as is that of CD76.3. It is difficult to understand how 
transfection of cDNA for f3-galactoside-a-2,6-sialyltransferase into COS cells can 
give rise to these non -sialylated epitopes, unless expression of this enzyme in some 
way controls the expression of another glycosyltransferase enzyme which produces 
the epitopes recognised by these mAbs. 
To add a further complication, it is also possible that these epitopes are not only 
expressed on glycoproteins, but are also expressed on glycolipids. As discussed in 
chapter 5, this may explain why it has been so difficult to isolate CDw75 by 
biochemical means. There is a growing body of evidence which suggests that 
glycosyltransferase enzymes and in particular the a- 2,6- sialyltransferase enzyme are 
also capable of glycosylating gangliosides of the glycolipids in cell 
membranes(Hakomori, S., Patterson, C.M., Nudelman, E. and Sekiguchi, K., 1983; 
Feizi, T., 1985; Dall'Olio, F., Malagolini, N., di Stefano, G., Minni, F., Marrano, 
D. and Serafini -Cessi, F., 1989; Paulson, J.C. and Colley, K.J., 1989; Kanani, A., 
Sutherland, D.R., Fibach, E., Matta, K.L., Hindenburg, A., Brockhausen, I., 
Kuhns, W., Taub, R.N., van den Eijnden, D.H. and Baker, M.A., 1990; Gottfries, 
J., Percy, A.K., Mansson, J.E., Fredman, P., Wikstrand, C.J., Friedman, H.S., 
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Bigner, D.D. and L, S., 1991; Sasaki, H., Momoi, T., Yamanaka, C., Yorifuji, T., 
Kaji, M. and Mikawa, H., 1991; Erikstein, B.K., Funderud, S., Beiske, K., Aas- 
Eng, A., De Lange Davies, C., Blomhoff, H.K. and Smeland, E.B., 1992; Shah, S., 
Lance, P., Smith, T.J., Berenson, C.S., Cohen, S.A., Horvath, P.J., Lau, J.T. and 
Baumann, H., 1992). Indeed, CD76 mAbs have already been shown to bind to both 
glycolipids and glycoproteins(Bast, B.J., Zhou, L.J., Freeman, G.J., Colley, K.J., 
Ernst, T.J., Munro, J.M. and Tedder, T.F., 1992), and binding has also been shown 
to be dependent on the polarity of the gangliosides. The fact that tunicamycin does not 
produce 100% inhibition of synthesis of any of the CDw75 or CD76 epitopes 
suggests that they may be expressed on both N- linked carbohydrate and on 
glycolipids. This may also explain the variation in binding levels observed with the 
different mAbs. 
Another controversial result arising from this study is the fact that the OKB4 binding 
pattern on Namalwa cells seems to more closely resemble that of the CD76 mAbs 
CD76.2 - CD76.4 than that of the other CDw75 mAbs. Unlike the other CDw75 
mAbs, OKB4 stains the very immature B -cell subline G4, and to a lesser extent, 
sublines NK, CSN /70 and KN2. This expression is only detected after neuraminidase 
treatment, but the antigen is expressed on these cells never -the -less. This is more like 
the pattern of expression observed with the CD76 mAbs. Ironically, it was also 
observed that CD76.1 produces a staining pattern which is more akin to that of the 
remaining CDw75 mAbs than to the other CD76 mAbs, as it only stains mature B -cell 
sublines IPN /45 and PNT. CD76.1 binding is also completely abolished by 
neuraminidase treatment unlike the other CD76 mAbs. Since the two offending mAbs 
are coded CDw75.1 and CD76.1 it is possible that there was some mix up in their 
labelling at a previous workshop, and that they have been allocated to the wrong 
clusters. Admittedly, further proof in the form of detailed immunohistochemical 
characterisation of each antigen on a variety of tissues will have to be sought in order 
for this matter to be cleared up satisfactorily. There is also a case against epitopes 
CDw75.1 and CD76.3 being included in either cluster due to the fact that they cannot 
possibly be generated by the activity of the enzyme a- 2,6- sialyltransferase, since 
sialylation of these epitopes actually inhibits mAb binding. 
CDw75 and CD76 are not the only carbohydrate containing clusters. To give but two 
examples, leukosialin (CD43) is a major cell -surface sialo -glycoprotein of thymocytes 
and T- cells(Cyster, J.G., Shotton, D.M. and Williams, A.F., 1991), and CD44 is 
another glycoprotein expressed on leucocytes and red blood cells(Spring, F.A., 
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Dalchau, R., Daniels, G.L., Mallinson, G., Judson, P.A. and Parsons, S.F., 1988). 
As carbohydrate plays such a major role in antigen recognition, the question of "what 
defines a cluster of differentiation ?" must surely be addressed. Since the protein 
content of such carbohydrate- containing clusters often remains unknown or 
unidentifiable, and in the case of CDw75 and CD76, where some mAbs of the cluster 
do not recognise antigen until sialic acid has been removed, how can we be sure that 
the antigen recognised is the same for all mAbs of the cluster? In addition, if a mAb is 
found to be specific for a carbohydrate moiety which is expressed on a number of 
different glycoproteins and glycolipids whose individual expression is also 
developmentally regulated, how can this carbohydrate antigen be allocated to a cluster? 
As it becomes more accepted that the role of carbohydrate is of major importance in a 
number of functions such as receptor- binding, antigen recognition, growth regulation 
and development, fundamental questions must be asked as to the entire basis of the 





8.1 Tissue distribution of CDw75. 
It had previously been established that all CDw75 epitopes were expressed 
predominantly on the cell -surface of mature sIg+ B -cells and on B -cell leukaemias and 
lymphomas(Dorken, B., Moller, P., Pezzutto, A., Schwartz -Albiez, R. and 
Moldenhauer, G., 1989), and these findings have been confirmed in this project. 
However, very little was known about CDw75 expression outwith the mature B -cell 
population, and about the structure of the CDw75 epitopes. I have shown that the 
CDw75 mAbs do not recognise a single epitope, and that different epitopes are 
expressed at different levels on human peripheral blood T- cells. Epitopes recognised 
by HH2 and OKB4 are induced when T -cells are activated, whereas epitopes 
recognised by EBU -141 and EBU -65 are expressed on resting T -cells and expression 
of these epitopes is reduced upon T -cell activation. 
It was also known that CDw75 was expressed in the B -cell areas of lymphoid tissues, 
and particularly in follicular areas. In this study it has also been shown that CDw75 is 
expressed in other tissues such as liver, pancreas, breast and intestine. In normal liver, 
all mAbs preferentially stained the canaliculae. It is known that there are receptors for 
terminally galactosylated sugars in the liver, and it is therefore possible that the 
epitopes recognised by CDw75 have been sialylated in the liver and secreted into the 
canaliculae. 
In samples of intestinal tissue, CDw75 was only detected on malignant cells. Others 
have observed increased levels of a- 2,6- sialyltransferase activity in colon cancer 
cells(Dall'Olio, F., Malagolini, N., di Stefano, G., Minni, F., Marrano, D. and 
Serafini -Cessi, F., 1989; Bresalier, R.S., Rockwell, R.W., Dahiya, R., Duh, Q.Y. 
and Kim, Y.S., 1990), which may explain this increase in CDw75 expression. 
CDw75 expression was also detected in breast cancer samples. As previously 
discussed, it was expected that CDw75 expression would be increased in tumour 
samples as there are many accounts of increased sialylation of glycoproteins and 
glycolipids in cancer tissues. The results obtained using the Pst mAbs on liver and 
pancreas sections did not show increased staining levels on tumour tissues in 
comparison with normal tissues, however the samples used were from a variety of 
patients with different types of tumours, and so these results should be regarded as 
preliminary. It would have been of great interest to obtain a supply of breast and colon 
cancer specimens of the same type, and to compare sialyltransferase expression on 
these with normal tissue samples. 
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8.2 Epitope structure. 
It was previously thought that all CDw75 mAb recognised a single epitope(Dorken, 
B., Moller, P., Pezzutto, A., Schwartz -Albiez, R. and Moldenhauer, G., 1989). In 
this study, it has been conclusively proved that this is not the case. Epitopes HH2, 
EBU -141 and EBU -65 all contain sialic acid, whereas the OKB4 epitope is masked by 
sialic acid, although it does contain N- linked carbohydrate. In addition, as mentioned 
above, epitopes are expressed on different subsets of T- cells. It was therefore 
concluded that the four mAbs studied here do not recognise a single epitope. 
Another question raised by this study is whether CDw75 is expressed on 
glycoproteins or on glycolipids. Clearly, the epitope is expressed on at least one 
glycoprotein as its expression is inhibited by tunicamycin which inhibits N- linked 
glycosylation. However, the same glycosytransferase enzyme can glycosylate both 
glycoproteins and glycolipids, and it is possible that it is expressed on many different 
glycoproteins and glycolipids, as no specific protein band was detected with the 
CDw75 mAbs. The fact that the antigen is stable on paraffin sections also indicates 
that it may be expressed on glycolipid. 
8.3 Pst mAbs. 
The Pst mAbs produced in this study are more than likely to be specific for 13- 
galactoside-a-2,6- sialyltransferase as they are specific for the JP3 peptide. In 
addition, they exhibit perinuclear staining of RAJI cells, liver cells and pancreas cells 
in the Golgi area of the cell which is where the sialyltransferase is mainly located. 
Furthermore, in immunoprecipitation experiments, the mAbs precipitate a protein of 
molecular weight 47 kDa, and in Western blotting, pick out bands of 41 kDa and 47 
kDa. The predicted molecular weight for the human enzyme is around 46 
kDa(Grundmann, U., Nerlich, C., Rein, T. and Zettlmeissl, G., 1990), and it is 
expected that there are different isoforms of the enzyme, as in rats different forms have 
been detected with molecular weights of 43 kDa and 47 kDa(Weinstein, J., Lee, E.U., 
McEntee, K., Lai, P.H. and Paulson, J.C., 1987). 
8.4 Leucocyte Typing Workshop. 
At the Fifth International Leucocyte Typing Workshop, it was acknowledged that the 
OKB4 epitope is not the same as the other CDw75 epitopes, and that all epitopes have 
slightly different distributions(Engel, P. and Tedder, T.F., 1995). It was also noted 
that the OKB4 epitope may have to be removed from the cluster, but not until the 
cluster is biochemically defined. It was also acknowledged that there is considerable 
overlap between the CDw75 and CDw76 epitopes, all of which I have found in this 
study. 
From this study, it is clear that the basis for defining a CD antigen needs to be 
clarified. If the same carbohydrate group can be expressed on many different 
glycoproteins and glycolipids which are expressed at different stages of cell 
development, how can this be defined as a single antigen? In addition, if a cluster is 
defined by the maturity of the cells on which it is expressed, how can a carbohydrate 
determinant be included in this classification if it is expressed on different cell -surface 
components at different stages of differentiation? It may be that the glycosyltransferase 
enzymes are developmentally regulated, and that specific carbohydrates are only 
expressed at certain times, but it would seem logical that there should be a separate 
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APPENDIX A (RECIPES). 
A 1 Phosphate Buffered Saline (PBS) pH7.3. 
8g NaC1 
0.2g KC1 
1.15g Na2HPO4 (anhydrous) 
0.2g KH2HPO4 (anhydrous) 
1 litre distilled H2O 
Concentrated HC1 to adjust pH to 7.3. 
A 2 Lysis Buffer. 
10mM Tris HC1 pH 7.4 










PMSF* 174 µg/ml (1 mM) M-a-D-P* 19.42 mg/ml (0.1 M) 
EDTA* 37 µg/ml (10011M) DMNJ* 80 µg/ml (400 µM) 
Leupeptin 0.5 µg/ml (1 µM) DNJ* 65.6 µg/ml (400 µM) 
Pepstatin A 0.7 µg/ml (1 µM) swainsonine 1.7 µg/ml (101.1M) 
TLCK-HC1* 50 µg/ml (135 µM) yeast mannan 15 mg/ml - 
TPCK* 100 µg/ml (284 µM) 
*PMSF = Phenylmethanesulphonyl fluoride, EDTA = Ethylenediaminetetraacetic acid, 
TLCK -HC1= L- 1- Chloro- 3- [4- tosylamido] -7- amino -2- heptanone -HC1, TPCK = L -1- 
Chloro-3-[4- tosylamido] -4- phenyl -2- butanone, M -a -D -P = methyl -a -D- pyranoside, 
DMNJ = Deoxymannojirimycin, DNJ = Deoxynojirimycin. 
A 4 Immunoprecipitation buffers. 
A4.1 












Low Salt Buffer. 
A 5 Reducing Sample Buffer for SDS PAGE Samples. 
1m10.5M Tris -HC1 pH 6.8 
0.8 ml glycerol 
1.6 ml 10% SDS in distilled water 
0.4 ml ß- mercapto ethanol 
0.2 ml 0.05% Bromophenol blue 
4m1 distilled water 
A 6 Tris Buffered Saline (TBS) 
100m1 0.125 M TRIS pH7.6 
900m1 8.5g/1 NaCl 
A7 
24ml 0.2M Tris 
38ml 0.1N HC1 
38m1 distilled water. 
ABC Buffer (Tris -HC1 pH 7.6). 
A 8 Immunohistochemistry / Cell -Bound ELISA 
Substrate Solutions. 
A 8.1 Peroxidase Substrate. 
!mg /ml DAB (Sigma) in TBS 
200ml 1 % H2O2. 
A 8.2 Alkaline Phosphatase Substrate. 
Vector Red alkaline phosphatase substrate kit (Vector Laboratories). 
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A9 a -2,6- Sialyltransferase Assay / HRP ELISA Substrate. 
A9.1 
5mg OPD (Sigma) 
41.130% H2O2 
12.5 ml citrate buffer. 
9.2 Citrate buffer: 
25.7m1 0.2M Na2PO4 
24.3m10.1M citric acid 
50m1 distilled H2O. 
Substrate solution: 
A10 SDS PAGE Tank Buffer. 
3g Tris base 
14.4g Glycine 
lgSDS 
Make to 11 with distilled water 
A 11 SDS PAGE Transfer Buffer. 




Make up to 11 with distilled water. 
A 12 Western Blot DAB Substrate Solution. 
1mg /ml DAB(Sigma - tablets) 
1111/m130% H2O2 
4111/m180 mg /ml Cobalt Chloride. 
A 13 Alkaline Phosphatase ELISA Substrate. 
lmg /ml paranitrophenyl phosphate (Sigma) 
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B16.4 Modulation of CDw75 and CD76 following neuraminidase 
and tunicamycin treatments 
J. ANDREW and J. A. ROSS 
CDw75 is a cell- surface antigen that was assigned at 
the Fourth Workshop where four mAb, HH2, OKB4, 
LN1, and EBU -141, were clustered. A fifth mAb, 
EBU -65 was also found to exhibit CDw75 -like 
staining. The gene cloned by Stamenkovic using the 
COS cell system and the CDw75 mAb HH2 was found 
to be almost identical in sequence to that of the human 
13- galactoside- a -2,6- sialyltransferase. This enzyme 
catalyses the transfer of sialic acid from its sugar - 
nucleotide donor CMP -NeuAc to terminal G1cNAc- 
3 -1,4- galactose groups on N- linked carbohydrate. 
CDw75 and CD76 epitopes were later suggested to be 
the glycosylation products of this enzyme [I] acting 
on COS cell native proteins. This study identifies the 
effect of neuraminidase and tunicamycin on the ex- 
pression of these structures. 
The CDw75 and CD76 antibodies exhibited non - 
coordinate expression on the variant sublines of 
Namalwa. The Namalwa sublines are, in increasing 
order of phenotypic maturity, G4- 'NK-+CSN /70- 
IPN /45- +PNT--'KN2. G4 and NK display some lineage 
infidelity (for example, CD7 expression), CSN /70 has 
no surface Ig, PNT has surface Ig, and KN2 secretes 
Ig. CDw75.2, CDw75.3, CDw75.4, and CDw75.5 
reactivity was absent from G4 and NK, increased 
slightly on CSN /70, was high on IPN /45 and PNT, 
and was low on KN2. Expression of the CDw75.1 
structure was moderate on IPN /45 and PNT but was 
absent from all the other Namalwa lines. However, 
neuraminidase treatment (Clostridium perfringens) 
revealed CDw75.1 expression on G4 (moderate), NK 
and CSN /70 (low- -moderate), IPN /45 and PNT 
(high), and KN2 (low). 
Staining with CDw75.2, CDw75.3, CDw75.4 and 
CDw75.5 was markedly reduced or abolished following 
neuraminidase treatment of the Namalwa variant line 
PNT (Table 1). The expression partially recovered over- 
night in culture, which may indicate rapid turnover 
of the host molecule. The expression paralleled that 
seen after staining with Sambucus nigra lectin which 
Table 1 CDw75 and CD76 expression on the Namalwa variant subline PNT following neuraminidase and 
tunicamycin treatments 
Workshop mAb 
Percentage positive cells* 
Day 0 Tunicamycin concentration (µg /ml) 
Code Clone name Controlr NANA= Nil§ 0.251 0.51 1.01 2.01 
CDw75.1 OKB4 45 92 70 65 65 54 56 
CDw75.2 HH2 90 2 70 54 31 16 6 
CDw75.3 LNI 77 1 54 39 19 7 2 
CDw75.4 EBU-141 48 20 41 28 17 13 8 
CDw75.5 IZB55 48 3 30 16 5 1 1 
CD76.1 CRIS-4 39 1 21 9 3 2 1 
CD76.2 HD66 23 56 19 7 4 2 1 
B058 BL-OFX/B8 4 99 81 90 88 90 86 
B057 8H7 87 73 71 65 55 53 50 
SNA1 99 8 81 66 35 14 2 
'Indirect immunofluorescence using rabbit anti-mouse-fluorescein isothiocyanate (FITC) F(ab')2. Fluorescence signals were collected in 
logarithmic mode on a FACScan flow cytometer. Results are expressed as percentage positive cells after subtraction of background negative 
control values. 
'Control antibodies included L243 (HLA -DR), VIM13 (CDI4), VPM30 (putative ovine CDw75), and 2A4.5 (an anti- phycoerythrin antibody). 
'NANA, Cells treated with neuraminidase from Clostridium perfringens before staining. 
* Neuraminidase (from C. perfringens) treatment and then incubation in medium for 24 h. 
4Neuraminidase (from C. perfringens) treatment and then incubation in medium containing tunicamycin at the given concentration for 24 h 
before staining. 
SNA, The effect of neuraminidase and tunicamycin treatments were monitored using Sambucus nigra (SNA) staining. 
592 B-cell antigens 
recognizes a2,6 -linked sialic acid. Tunicamycin in 
the culture medium prevented re- expression of the 
structures recognized by CDw75.2- CDw75.5. These 
findings suggest that CDw75.2- CDw75.5 recognize N- 
linked glycosylation products and contain sialic acid. 
In contrast, CDw75.1 binding was revealed or 
increased by neuraminidase treatment suggesting 
that the structure recognized by CDw75.1 is at 
least partially masked by sialic acid. Incubation of 
neuraminidase- treated PNT cells in tunicamycin did 
not prevent re- sialylation of the CDw75.1 structure 
suggesting that the associated glycosylation may not 
be N- linked. 
The reactivity of the CD76 antibodies was extremely 
heterogeneous on the Namalwa lines. CD76.1 showed 
moderate high binding to PNT only; CD76.2 
showed moderate binding to G4, IPN /45 and KN2 and 
moderate -high binding to PNT; B058 (BL- OFX /B8) 
exhibited low- moderate binding with PNT only; and 
B057 (8A7) displayed high binding to G4, CSN /70, 
and PNT and low- +moderate binding to NK and 
IPN /45. ( `Unknown' B-cell Panel mAb B057 and 
B058 were thought to show a pattern of reactivity 
similar to that of CD76 mAb and were then submitted 
to the CD76 Panel for testing.) Neuraminidase treat- 
ment increased binding of CD76.2 on G4, NK, 
CSN /70 (and PNT in some experiments), increased 
B058 binding on all the Namalwa lines, and did not 
affect binding of B057. 
All the CD76 antibodies displayed some binding to 
the PNT line; B058 exhibited lower binding than the 
other antibodies. PNT was therefore selected for 
the neuraminidase and tunicamycin experiments. 
CD76.1 reactivity was abolished on PNT by neur- 
aminidase and partially recovered overnight in culture 
(Table 1). This recovery was prevented by tunicamycin. 
In most experiments CD76.2 was not greatly affected 
by neuraminidase treatment. An increase in binding 
of CD76.2 after neuraminidase treatment was noted 
in some experiments which returned to baseline after 
B 
overnight culture. Reduced binding of CD76.2 occurred 
after incubation with tunicamycin. B058 was revealed 
by neuraminidase treatment and was not remasked 
during incubation with tunicamycin. If dimethyl- 
sulfoxide (DMSO) was used as a vehicle for tunicamycin 
remasking of B058 occurred. B057 reactivity was 
slightly reduced after neuraminidase treatment but did 
not recover overnight in culture and showed a 
progressive decrease after incubation in increasing 
concentrations of tunicamycin. These results suggest 
that the CD76.1- associated glycosylation involves sialic 
acid residues and is probably N- linked. Some experi- 
ments indicated that CD76.2 expression increased after 
neuraminidase. The CD76.2 structure may therefore be 
at least partially masked by sialic acid and associated 
with N -linked glycosylation. The epitope recognized 
by B058 on PNT is masked by sialic acid and this 
structure is probably dependent on N- linked glyco- 
sylation. The B057 structure may be at least partially 
sialic acid -dependent and N- linked. 
This study indicates the similarity between 
CDw75.2, CDw75.3, CDw75.4, and CDw75.5 binding 
following neuraminidase and tunicamycin treatment. 
CDw75.1 appears to be a different but possibly 
related specificity. The extreme heterogeneity in the 
binding pattern of the CD76 antibodies following 
neuraminidase and tunicamycin treatment was 
confirmed. 
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SUMMARY 
Using monoclonal antibodies (mAb) characterized at the last International Workshop on Human 
Leucocyte Antigens, we examined the expression of CDw75 antigens (/ß- galactoside x 2,6- 
sialyltransferase) on normal peripheral blood cells and on cells from patients with B -cell chronic 
lymphocytic leukaemia (CLL). The mAb used (HH2. EBU.65. EBU.141 and OKB4) detect different 
epitopes of CDw75. Normal peripheral blood B cells expressed high levels of CDw75 detectable with 
HH2. EBU.65 and EBU.141 but did not react with OKB4. Cells from patients with B -cell CLL 
closely resembled normal B cells. All CDw75 epitopes, including OKB4. were strongly expressed on 
some Namalwa variant Burkitt lymphoma cell lines. The OKB4 epitope was also present on red cells 
from all normal donors. The other CDw75 mAb were unreactive with red cells from some normal 
donors. The CDw75 epitope detected with EBU.65 was present on most CD4+ T cells and on a 
minority of CD8+ cells. HH2 and EBU. I 41 stained only small numbers of T lymphocytes. OKB4 did 
not react with T cells. EBU.65 . CD4 T cells had low levels of expression of CD45R0, CD29. CD54 
and CD58, and had high levels of CD45RA antigen. Phytohaemagglutinin (PHA) activation of cells 
led to the loss of EBU.65 binding. These results suggest that the CDw75 epitope recognized by the 
EBU.65 mAb is a marker of naive T lymphocytes. On B CLL cells the epitopes detected with HH2. 
EBU.65 and EBU.141 were destroyed by treatment with neuraminidase. Treatment of B -CLL cells 
and red cells with neuraminidase increased the binding of OKB4. suggesting that this epitope is 
masked by sialic acid. The results suggest that CDw75 is a sialylated cell- surface antigen expressed in 
a number of tissue -specific isoforms. 
INTRODUCTION 
CDw75 was characterized at the 4th Leucocyte Typing Work- 
shop as an antigen predominantly expressed on B lymphocytes.' 
' Four monoclonal antibodies (mAb) comprising CDw75. and a 
further CDw75 -like mAb (EBU.65), had a characteristic stain- 
ing pattern in immunohistochemistry and reacted strongly with 
germinal centre B cells and with a subset of cells at the periphery 
of the germinal centre dark zone proximal to the follicular 
mantle.' The biochemical characteristics of CDw75 antigens. 
like their function. have yet to be described. However. the 
CDw75 gene had been cloned and shown to be identical in 
nucleotide sequence to a previously identified human /f- galacto- 
side x 2.6- sialyltransferase.'' The homologous gene in other 
Abbreviations: BL. Burkitt lymphoma: CLL. B -cell chronic lym- 
phoctic leukaemia: FITC. fluorescein isothiocyanate: mAb. mono- 
- clonal antibodies: PBL. peripheral blood lymphocytes: PHA. phyto- 
haemagglutinin: RBC. red blood cells. 
Correspondence: Dr K. Guy. MRC Human Genetics Unit, Western 
General Hospital. Crewe Road. Edinburgh EH4 2XU. U.K. 
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species encodes liver and kidney enzymes, expressed predomin- 
antly in the Golgi apparatus.` /ß- galactoside x 2.6-sialyltransfer- 
ase is one of a number of structurally unrelated enzymes which 
catalyse the addition of sialic acid to growing carbohydrate 
chains of glycoproteins. Carbohydrate structures on leucocyte 
differentiation antigens appear to be important in a number of 
aspects of lymphocyte physiology. For example. they serve as 
ligands for cell adhesion molecules.6 Tissue -specific and deve- 
lopmentally regulated expression of carbohydrate moieties in 
non- lymphoid tissues have also been described.' There are also 
differences in sialic acid composition among normal and 
neoplastic tissues.' 
Studies at the 4th International Leucocyte Typing Work- 
shop showed that CDw75 is a major component of the lymphoid 
cell surface" but did not fully resolve the tissue distribution of 
the antigen. In view of the possibility that the CDw75 gene 
encodes a functional x 2,6- sialyltransferase expressed as a 
lymphoid ecto- enzyme, the aim of the present study was to 
determine the characteristics of expression of CDw75 antigens 
in peripheral blood cells. 
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Table 1. mAb used and their sources 


























Scottish Ab Production Unit 
Serotech, Bicester, U.K. 
Dako, Glostrup, Denmark 
Dako 
4th Leucocyte Typing Workshop 
3rd Leucocyte Typing Workshop 
3rd Leucocyte Typing Workshop 
Coulter, Luton, U.K. 
Binding Site, Birmingham U.K. 




Becton -Dickinson, Mountain View, CA 
Dr van Heyningen 
American Tissue Culture Collection, 
Rockville, MD 
American Tissue Culture Collection 
MATERIALS AND METHODS 
tfonoclonal antibodies 
The EBU, HH2 and OKB4 reagents were generous gifts from 
the originators of the clones. Other mAb were obtained from a 
variety of sources (Table 1). Antibodies were titrated to 
determine optimal conditions for use in flow cytometry. 
Cell- surface antigen expression analysed by flow cytometry 
Only highly viable cell populations (routinely > 95 %) were 
examined. Indirect single- and 2- colour immunofluorescence 
tests were performed by standard techniques. Briefly, in single - 
colour tests, antibody binding was detected with F(ab')2 anti 
mouse Ig conjugated with FITC (Sigma, Poole, U.K.). In 2- 
, colour tests, IgG mAb were labelled with biotin- anti -mouse 
IgG and streptavidin -phycoerythrin (Amersham International, 
Amersham, U.K.); all CDw75 mAb are of IgM isotype and were 
'detected with FITC- anti -mouse IgM (Sigma). This reagent was 
absorbed with IgM- positive human Burkitt lymphoma cells to 
remove anti -human Ig reactivity, and minimal residual binding 
of the antibody to human cells was blocked in the test by the 
addition of 0.01% normal human serum. Cells were suspended 
and washed in phosphate- buffered saline (PBS) with 1 % bovine 
serum albumin (BSA; Sigma), pH 7.2. All fluorochrome- 
conjugated reagents were titrated to determine optimal condi- 
tions for use. IgG 1 and IgG2a anti -alphafetoprotein mAb and a 
CD14 IgM mAb were included in all tests as isotype- matched 
negative controls. Flow cytometric analysis was performed with 
a benchtop flow cytometer (FACScan, Becton -Dickinson, 
Mountain View, CA) equipped with an argon -ion laser emitting 
light at a fixed wavelength of 488 nm. Light scatter signals were 
collected in linear and fluorescence output in logarithmic 
modes. 
Cells and cell culture 
The Namalwa panel of variant sublines comprises DNA - 
fingerprint identical variants of the original Namalwa cell line. 
The characteristics of the lines have been described in detail;10 
they were cultured in RPMI -1640 medium containing 10% 
foetal calf serum (FCS) in an atmosphere of 5% CO2 in air. 
Blood samples from CLL patients and normal donors were 
centrifuged over cushions of Histopaque (Sigma) and leucocytes 
recovered from the interface. Normal peripheral blood cells 
(PBL) were obtained from laboratory staff and from leucocyte 
concentrates prepared from normal blood donors. Adherent 
cells were removed prior to immunofluorescence analysis by 
incubating cells in plastic tissue culture flasks for I hr at 37° in 
RPMI -1640 medium and 10% FCS. For activation studies, 
normal PBL were incubated at 37° with 100 µg /ml phytohaem- 
agglutinin (PHA; Wellcome, Beckenham, U.K.) in RPMI -1640 
and 10% FCS, and harvested at times shown. 
For neuraminidase treatment, CLL lymphocytes were 
washed twice in isotonic saline and 10' cells were incubated at 
37° for 30 min with type X (C. perfringens) neuraminidase 
(Sigma) at a final concentration of 0.05 U /ml. Viability of 
lymphocytes was unaffected by the neuraminidase treatment. 
The amount of neuraminidase used was determined by results of 
preliminary tests. 
Haemagglutination and RBC radiobinding assays 
For haemagglutination tests, red blood cells (RBC) were 
washed several times in isotonic saline and the huffy coat cells 
removed. 0.1 ml aliquots of mAb were added to 0.1 ml of 5% 
RBC suspensions in saline. After 1 hr at 20° the cells were 
centrifuged at 200 g for 2 min, very gently resuspended and 
examined for agglutination. Scores of 5 (complete agglutina- 
tion) to 1 (some small clumps of cells) were assigned. 
Radiobinding assays were carried out in U -well microtitre 
plates. 0.05 ml aliquots of 5% washed RBC and mAb were 
incubated for 1 hr at 20 °. Cells were washed twice in PBS -BSA 
1%, pH 7.2, and 0.05 ml of 125I- anti -mouse IgM (DuPont Ltd, 
Stevenage, U.K.) was added (-'80,000 c.p.m. /well added; 
specific activity of anti -IgM, - 50 MBq /ml). After a further 30 
min at 20 °, RBC were washed twice, transferred to fresh tubes 
and counted for bound anti -IgM. Kendall's test for rankable 
scores was used to analyse the results of radiobinding assays. 
RESULTS 
Expression of CDw75 on normal PBL 
Peripheral blood samples from laboratory staff and blood 
donors were tested by indirect immunofluorescence using a 
panel of CDw75 antibodies and other markers specific for T and 
B cells. OKB4, HH2 and EBU. 141 are mAb assigned to CDw75 
at the 4th Leucocyte Typing Workshop.' EBU.65 is a mAb 
which appears to be closely related in specificity to CDw75 
reagents.2.9" EBU.65 was in the same preliminary statistical 
cluster as the other mAb but was not included in CDw75. 
However, it seems very likely that EBU.65 also belongs in 
CDw75: in studies as part of the 4th Workshop,9" and in 
subsequent tests, with Namalwa variant sublines and cells from 
patients with B -cell malignancy (v.i. and also unpublished 
results), EBU.65 gave `CDw75 -like' staining patterns. More- 
over, EBU.141, HH2, OKB4 and EBU.65 all react with COS 
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Log fluorescence intensity 
Figure 1. Single- colour immunofluorescence: representative flow cyto- 
metry histograms from a series of tests using peripheral blood cells from 
12 normal donors. Fluorescence intensity is on a logarithmic and cells/ 
channel on a linear scale. Limits of negative controls indicated by the 
horizontal bar. Areas of HH2 and EBU.l41 histograms marked by 
asterisks indicate weakly staining cells. 
cells transfected with the CDw75 gene (I. Stamenkovic, personal 
communication).3 
The staining patterns of PBL from 12 normal individuals 
were quite similar, and typical flow cytometry histograms for 
cells from one individual are shown in Fig. I . Antigens detected 
by HH2 and EBU.141 were expressed at a high level on a minor 
population of cells and about a further 5 -10 °A of cells were 
weakly stained. EBU.141 (mean of 19 ±6% positive cells) 
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Figure 2. OKB4 tested against Namalwa variant sublines by single - 
colour immunofluorescence using. Representative results from one of 
six tests are shown. Other CDw75 mAb were also tested against 
Namalwa cells with similar results. 4F2 is a mAb to an activation 
antigen expressed at high levels on cell lines and was included as a 
positive control. Negative control (limits indicated by the horizontal 
bar) was the CDI4 mAb VIM 13 (IgM isotype- matched control). 
reacted with many more cells (51 ±7 %) than the other mAb. 
Like EBU.141 and HH2, EBU.65 reacted strongly with a minor 
population of cells and about a further 40% of cells were weakly 
stained. The total numbers of cells positive with one or other 
antibody varied to some extent from individual to individual, 
but the pattern of staining of cells shown in Fig. 1 was evident in 
all samples tested. In contrast to*the other CDw75 mAb, OKB4 
consistently failed to react with a significant number of cells 
(2± 1%) in almost all PBL studied. 
CDw75 is differentially expressed on Namalwa BL variant 
sublines 
In a concurrent series of tests using Namalwa Burkitt lym- 
phoma cell lines, OKB4 gave high levels of fluorescent staining 
(Fig. 2), and in titration tests antibody binding was readily 
detectable at a dilution of greater than 1 in 10,000. The failure of 
OKB4 to react with PBL was clearly not an effect due to, say, 
low titre of the mAb. 
Of the panel of Namalwa BL variant cells only two of the 
four sublines (PNT and IPN /45) had substantial levels of 
CDw75 expression detectable with OKB4. This differential 

















































Expression of CDw75 
EBU.65 
EBU.65 EBU.65 
Figure 3. PBL: 2- colour immunofluorescence using FITC- anti -mouse 
IgM for the detection of EBU.65 (horizontal scale) and biotin -anti- 
mouse IgG and streptavidin -phycoerythrin for other mAb (vertical 
scale). Fluorescence intensities are on log scales. Limits of isotype- 
matched negative controls indicated by the horizontal and vertical lines. 
Representative results are shown using cells from one donor in a series of 
tests with cells from nine different normals. 
tests performed over a period of about a year. The other CDw75 
mAb gave similiar staining patterns, although the reactions of 
EBU.65 were usually weaker on Namalwa cells than those of the 
other mAb. We have previously suggested that Namalwa 
variant sublines are analogues of B cells in different states of 
cellular maturity.10 CDw75 may be expressed at the mid stages 
of differentiation.' 
Binding of CDw75 mAb to subpopulations of PBL 
Normal PBL from nine donors were tested by 2- colour 
immunfluorescence, with CDw75 mAb and specific markers for 
B or T cells. Representative results using EBU.65 are shown in 
Fig. 3. The small population of strongly- stained cells with 
EBU.65, EBU.141 and HH2 were CD19+ B cells. All B cells 
were CDw75+. CDw75 was also expressed on T cells: the cells 
with a low level of EBU.65 expression were mostly CD4+ T cells 
and some CD8+ cells were also EBU.65+. There was consider- 
able variation in the numbers of EBU.65+ T cells among 
different donors: the numbers of EBU.65+ cells among CD2+ or 
CD3+ T cells ranged from 33% to 52 %. The range of expression 
of EBU.65+ cells among CD4+ T cells was 38 -75 %. Smaller 
proportions of CD8+ cells (range 8 -34 %) were EBU.65+. 
Usually CD8+, EBU.65+ T cells had high levels of CD8 
expression. Only small numbers of T cells (a mean of 7% CD2+ 
cells) were stained with EBU.141 or HH2. Most of these were 
CD4+ and only 2 -3% of CD8+ T cells were routinely EBU.141 + 
or HH2+ (data not shown). 
CDw75 and CD45R expression on lymphocytes 
The possibility that the expression of CDw75 antigens on 
subpopulations of T cells is a reflection of differences in the 

















Figure 4.Two- colour immunofluorescence: PBL 1-4 are lymphocytes 
from four different normal donors. Presentation of results as in Fig. 3. 
UCHLI is a CD45RO and F8 -I I -13 a CD45RA mAb. 
In the first instance the expression of leucocyte common (CD45) 
antigens and CDw75 antigens was compared (Fig. 4). CD45 
antigens were detected with UCHL I (CD45RO) and F8 -11 -13 
(CD45RA) mAb. The expression of CD45RA on T cells has 
been shown to define a population of virgin /immature or naive 
cells, while CD45RO+ cells comprise the memory T -cell popula- 
tion.''- 
There was considerable variation in the expression of CD45 
antigens on normal PBL from person to person. On cells from 
three of the four donors shown there was also very considerable 
heterogeneity in CD45RO and CD45RA expression among 
cells from the same individual. That is, there were populations of 
cells with apparently high levels of antigen expression and 
others with much lower levels of antigen using both UCHL 1 and 
F8 -11 -13 mAb. From the numbers of positive cells it was clear 
that some cells expressed both CD45RA and CD45RO. This 







Figure 5. Two- colour immunofluorescence with normal PBL. Represen- 
tative results from tests with several different normal donors are shown. 
Presentation of results as in Fig. 3. 
dual expression of CD45R epitopes has been seen in other 
studies and may accompany the passage of cells to and from 
memory T -cell compartments.12 
In all normal donors, most cells with a low level of CD45RO 
expression were EBU.65 positive (Fig. 4). Fewer cells in the 
CD45RO brightly staining fraction were EBU.65 positive. 
However, the numbers of cells in this brightly staining fraction 
and their binding of EBU.65 varied a lot from donor to donor. 
In three of the four normal donors shown, the majority of cells 
with a high level of CD45RA were EBU.65 +. In the other 
donor (PBL 3), where there were few CD45RAdim and few 
CD45RO6ngi" cells (Fig. 4e, f), about half of the CD45RA+ 
cells were EBU.65 +. B cells (strongly stained with EBU.65) were 
CD45RA +and CD45R0- in all donors. Because of the con- 
siderable variation in CD45 expression among normal donors, 
the heterogeneity among cells from a given donor, and the 











Figure 6. CD29 expression in normal PBL. Results from three different 
normal donors (a, b, c) are shown. The top histogram shows single - 
colour (donor a) and the rest 2- colour immunofluorescence. Presen- 
tation of results as in other figures. 
CD45RO expression, the meaning of these results is not 
straightforward. However, they suggest that -in most normal 
donors -the expression on T cells of the CDw75 epitope 
recognized by EBU.65 occurs predominantly on naive T 
lymphocytes. 
CDw75 and activation marker expression 
To examine expression of the EBU.65 epitope on T -cell 
subpopulations in more detail, cells from normal donors were 
tested with mAb to HLA -DR, CD25 (interleukin -2 receptor), 
CD29 (VLA integrin /3 -1 chain), CD54 (LFA -3), CD58 (ICAM- 
1) and CD44 (Pgp -1). Figure 5 shows representative results from 
a larger series. 
There was no consistent association between EBU.65 bind- 
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donors the majority of CD25+ cells were EBU.65- (Fig. 5a) but 
in others a significant proportion of CD25+ cells was also 
EBU.65+ (Fig. 5b). Similarly, there was no consistent associ- 
ation of HLA -DR on T cells (Fig. 5g) and EBU.65 antigen 
expression. However, in all donors tested, most CD54+ T cells 
were EBU.65 -. Most CD58+ T cells were also EBU.65 -. The 
numbers of CD58+ cells varied from donor to donor and in 
some a minor population of CD58+ cells was also EBU.65+ 
(Fig. 5f). There were no consistent differences in CD44 (Fig. 5h) 
expression among EBU.65+ and EBU.65- cells. 
Using 4B4, a CD29 mAb," there was consistent staining of 
two populations of cells with clear differences in antigen density 
(Fig. 6). The number of CD29+ cells (and the proportions of dim 
and bright cells) was very variable among different donors. In 
some donors, EBU.65 binding was confined to the dim CD29+ 
cells. In others some of the brightly stained cells were also 
1 EBU.65 +. Using a directly conjugated 4B4 preparation (FITC- 
4B4), high levels of CD29 expression on PBL were found on cells 
with high levels of CD45RO, CD18, CD54 and CD58 antigens. 
As well as their patterns of CD45 antigens, memory T cells are 
characterized by the expression of high levels of CD18, CD29, 
CD54 and CD58.'4 Together with the findings on CD45R 
expression, the results suggest that most EBU.65+ T cells belong 
to a naive T -cell compartment rather than to memory popula- 
tions. 
Changes in CDw75 expression after PHA activation of PBL 
Cells from two normal donors stimulated with PHA were tested 
over a period of a week (Table 2). There was an initial rise in the 




Donor I Donor 2 
Day 0 Day 2 Day 5 Day 7 Day 0 Day 2 Day 5 Day 7 
HH2 9 36 26 29 8 26 29 33 
EBU.65 54 72 13 22 43 51 14 20 
EBU.I41 23 31 10 16 12 18 9 9 
OKB4 2 5 2 6 2 5 4 3 
CD3 94 99 100 - 87 97 - 100 
CD25 25 97 100 96 18 96 99 99 
CD45RA 96 100 97 - 82 98 95 86 
CD45RO 56 91 99 - 67 90 100 100 
CD54 18 97 99 95 34 95 99 98 
CD58 29 38 94 91 - - 
CD71 I 74 93 79 6 74 l00 68 
HLA-DR 7 75 50 52 7 56 64 56 
Cells were tested by indirect immunofluorescence and results are 
expressed as percentage positive cells. Negative controls were routinely 
I' positive cells. Viability of the cells was routinely > 95` %x. Cells not 
tested indicated by -. Nos 1 and 2 are cells from two normal blood 
donors. Cells stimulated with 100 pg /ml PHA and harvested on the days 
shown. Day 0 = unstimulated cells. 
numbers of EBU.65+ cells on Day 2 and thereafter a consider- 
able decline in EBU.65+ cells. The number of HH2+ cells was 
increased after 2 days and constant over the remaining 5 days of 
study. There was a loss of EBU.141+ cells and OKB4 binding 
was unaffected. By Day 2 of culture there were sharp increases in 
expression of CD25, CD29, CD54, CD58, HLA -DR and CD71 
(transferrin receptor). Analysis of CD4+ T cells by 2- colour 
immunofluorescence showed that there was a loss of the EBU.65 
and a gain of HH2 epitope expression during the culture period 
(data not shown). 
CDw75 expression in B-cell CLL 
Peripheral blood cells from about 40 CLL patients were tested 
with CDw75 mAb and other mAb, including CD3, CDI9 and 
CD5. HH2, EBU.141 and EBU.65 gave high levels of staining 
on all B lymphocytes on cells from nearly all patients (Fig. 7). 
Cells were also tested after treatment with neuraminidase (v.i.). 
Some T cells in samples from CLL patients were weakly 
CDw75 +. In about 10% of samples from CLL patients there 
was a low level of OK B4 staining and in the remaining cases 
OKB4 binding was not detectable. In a very few samples there 
were also significant differences in the patterns of staining 
obtained with HH2 and EBU.141 (data not shown) -HH2 
sometimes stained only a minor proportion of EBU.141 + and 
EBU.65+ cells. These atypical results were confirmed by repeat 
testing of samples obtained from the same patient on several 
different occasions. Together with the results of PHA activation 
of cells, these findings suggest that HH2 and EBU.141 mAb 
recognize different CDw75 epitopes. Indeed, the CDw75 mAb 
tested in this study appear to be directed to four different 
epitopes. 
Sialic acid is a component of CDw75 epitopes 
Cells from patients with CLL were also tested after neuramini- 
dase treatment. A previous report showed that neuraminidase 
treatment destroyed the epitope recognized by the LN 1 CDw75 
mAb." In about 20 cases tested, the binding of HH2, EBU.141 
and EBU.65 was completely ablated by neuraminidase treat- 
ment of the cells (Fig. 7). In a further three cases there was a 
partial reduction in HH2, EBU.141 and EBU.65 binding. In 
contrast, on the same panel of cells the binding of OKB4 was 
increased substantially, in almost all cases, by neuraminidase 
treatment. The binding of anti -HLA -DR, CDI9 and CD2 mAb 
to CLL cells was unaffected by neuraminidase. These results 
suggest that the HH2, EBU.141 and EBU.65 epitopes comprise 
or depend structurally upon, sialic acid residues. The CDw75 
OKB4 epitope is shielded from antibody binding by sialic acid. 
CDw75 epitopes are expressed on RBC 
A total of 23 samples of red cells from normal donors and from 
CLL patients was tested initially by haemagglutination. OKB4 
produced complete or strong agglutination in all cases. Not all 
samples were so strongly reactive with the other mAb, and using 
EBU.65 there was no detectable haemagglutination with more 
than half of the RBC samples tested. Haemagglutination with 
OKB4 was readily detectable at dilutions of more than 1/25,000. 
Neuraminidase treatment of RBC increased the titre of OKB4 
and abolished agglutination produced by HH2, EBU.65 and 







Log fluorescence intensity 
Figure 7. CDw75 expression in CLL patients. Single -colour immuno- 
fluorescence: representative flow cytometry histograms using cells from 
one CLL patient (CLL no. 1) from a series of more than 40 different 
patients' samples are shown. Results presented as in Fig. 1. Cells shown 
as untreated samples and after incubation with neuraminidase. Anti - 
HLA-DR and CDI9 results are included as negative controls for 
neuraminidase treatment. CD2 was similarly unaffected by neuramini- 
dase treatment. Also shown are cells from a second CLL patient (CLL 
no. 2) tested with OKB4. 
EBU.141 (data not shown). In further tests using cells from a 
normal donor panel typed for common blood group antigens, 
both haemagglutination and a radiobinding assay were used. By 
radiobinding assay, OKB4 binding was readily detectable on all 
samples tested (Table 3). EBU.65 binding was weak or neglig- 
ible on more than half of the same samples. There was also only 
a low level of EBU.141 and HH2 binding on RBC from several 
donors. With one exception (OKB4 versus EBU.65) there were 
Table 3. Reactions of CDw75 mAb with typed red cell panel 
from normal donors 
Donor 
no. c.p.m.125 -I -AMIgM bound 
OKB4 EBU.65 EBU.141 HH2 
1 5539 (5) 262 (1) 2309 (3) 6321 (4) 
2 9000 (5) 1162 (1) 5272 (4) 9116 (4) 
3 4414 (4) 306 (1) 2782 (4) 4123 (3) 
4 8383 (5) 2704 (4) 8739 (5) 11417 (4) 
5 4961 (4) 191 (0) 559 (I) 1751 (2) 
6 7512 (4) 37 (0) 1336 (2) 4142 (3) 
7 4309 (4) 244 (1) 2027 (2) 3825 (3) 
8 4158 (5) 153 (0) 505 (1) 1875 (I) 
9 6833 (5) 925 (2) 4430 (4) 7930 (4) 
10 7499 (5) 892 (4) 3436 (4) 7597 (4) 
Binding detected with '25l -anti -mouse IgM (duplicate 
wells). Results expressed as mean c.p.m. bound after subtrac- 
tion of binding of'251 -AMIg to cells measured in the presence 
of an irrelevant IgM mAb (background binding values 130- 
476 c.p.m.). Numbers in parentheses are the results of 
haemagglutination tests: (5)= complete agglutination and 
(0) =no detectable agglutination. 
highly significant positive correlations in the binding of the 
different mAb to RBC. 
Leucocytes from the panel of RBC donors tested were not 
available but on other normals and on cells from CLL patients 
there were high levels of expression of EBU.65, EBU.141 and 
HH2 antigens on lymphocytes from donors whose RBC were 
weak or negative for these antigens. It is a striking finding that 
the expression of the different CDw75 mAb to RBC is the 
reverse of their appearance on normal lymphocytes: that is, 
apparently high levels of OKB4 and low levels of EBU.65 
binding are found on RBC, while the opposite is true for PBL. 
The panel of normal RBC donors used had been typed for ABO, 
Rhesus, M, N, S, s, P1, Le', Leb, Lt', Lub, K, k, Fy', Fyb, Jk', 
Jkb, Xg' and Cob antigens. The specificity of CDw75 mAb did 
not correspond to any of the polymorphic blood group antigens. 
DISCUSSION 
B- galactoside a 2,6- sialyltransferase is an enzyme previously 
characterized in the rat as a component of the Golgi apparatus 
in liver cells.5.6 To our knowledge, in non -human species it has 
not been recognized as a molecule expressed in lymphoid tissues. 
Studies for the 4th International Workshop on Human Leuco- 
cyte Differentiation Antigens established the antigen recognized 
by CDw75 mAb as a major component of the lymphoid cell 
surface.16 Subsequently, using the HH2 mAb, the CDw75 gene 
was cloned after cDNA transfection in COS cells,3 and shown to 
be homologous in nucleotide sequence to the rat a 2,6- 
sialyltransferase gene. In human lymphoid cells the function of 
the CDw75 antigen is not known; if the molecule has sialyltrans- 
ferase activity it might be expected to have a significant impact 
on the glycosylation patterns of celi surface molecules. In this 
way CDw75 could be influential in determining the course of 




























































Expression of CDw75 213 
a 2,6- sialyltransferase should be expressed as an ecto- enzyme. It 
has been suggested that the enzymatic activity of some glycosyl- 
transferases could be redundant and they might have other 
functions -for example, in cell adherence -but as yet this is 
unresolved. The function of a 2,6- sialyltransferase has been 
explored in a developmental system: in Xenopus embryos 
injected with mRNA encoding a 2,6 sialyltransferase, polysialy- 
lation of the neural cell adhesion molecule (N -CAM) is 
prevented and abnormalities of neural development result." 
The principal finding of the present study is that a number of 
different isoforms of CDw75 exist and these are detectable by 
differences in antibody binding. Several isoforms occur simulta- 
neously in B cells, whereas subpopulations of T cells have a more 
restricted scheme of expression of the different CDw75 epitopes. 
B cells also have very much higher levels of CDw75 expression 
l than T cells. Sialic acid is a component of the epitopes 
recognized by CDw75 mAb since binding to red cells and 
leucocytes of three of the four mAb used can be abolished by 
treating cells with neuraminidase. The epitope recognized by the 
remaining mAb (OKB4) appears to be masked by sialic acid and 
is revealed on neuraminidase- treated cells. The different iso- 
forms of CDw75 might be created by additional glycosylation of 
a core carbohydrate sequence." The masking of epitopes by 
sialic acid is a feature of other antigens. For example, epitopes of 
the Xg blood group- related MIC2 gene product are shielded 
from antibody binding on red cells by sialic acid.19 Treatment of 
acute myeloid leukaemia cells with neuraminidase reveals the 
carbohydrate CD15 antigen, 3-fucosyl-N-acetyllactosamine.2° 
Epitope shielding could be a common phenomenon which might 
restrict cellular interactions involving sialic acid -containing 
carbohydrate moieties on glycoproteins. For CDw75, the 
presence of sialic acid as a component of a molecule which is a 
sialyltransferase is intriguing and raises the question of whether 
or not CDw75 is a target for additional lymphoid sialyltransfer- 
ases. 
So far there is little information on the biochemical charac- 
teristics of antigens recognized by CDw75 mAb, despite the fact 
that some of the mAb have been available for several 
years.1521 23 In contrast, in the rat, a 2,6- sialyltransferase has 
been purified to homogeneity.24 In a series of biochemical 
studies, using a wide variety of detergents, we have had great 
difficulty in retaining antigenicity of CDw75 after solubilization 
' of cells (J. M. Andrew, unpublished results). Biochemical 
studies as part of the 4th Leucocyte Typing Workshop also 
failed to determine the characteristics of antigens recognized by 
CDw75 mAb. This is a considerable block to defining the precise 
tissue distribution of CDw75. Antibodies directed to carbo- 
hydrate epitopes on glycoproteins are obviously unreliable for 
tracking the expression of the corresponding polypeptide, 
because of possible differences in the glycosylation of the 
molecule in different tissues. This is a particular difficulty in 
following the tissue distribution of human lymphoid a 2,6 
sialyltransferase with the available CDw75 mAb. Although only 
limited data are available, the tissue distribution of CDw75 has 
been examined by Northern blotting' and levels of mRNA did 
appear to correlate with the expected levels of CDw75 cell - 
surface antigen expressed on peripheral blood B and T cells. It is 
possible that differential glycosylation alone accounts for the 
apparent variations in structure of CDw75 on lymphocytes and 
red cells. However, there is a potential for significant hetero- 
geneity in polypeptide structure: in the rat, the a 2,6- sialyltrans- 
ferase gene specifies divergent polypeptides in liver and kidney.25 
This is achieved by alternative splicing mechanisms to generate 
more than one kidney enzyme and by differences in transcriptio- 
nal initiation sites to generate different kidney and liver 
polypeptides. 
Prior to their assignment to a specific cluster, CDw75 mAb 
were tested against leucocytes in a number of studies and OKB4 
was shown to react with the majority of normal peripheral blood 
B cells.23 However, in the present study we have been unable to 
demonstrate this level of reactivity. The reasons for this 
discrepancy are not clear since the OKB4 mAb we have used is 
of high titre and reacts with high fluorescence intensity on BL 
cell lines and, even when used at very high dilutions, it 
completely agglutinates red cells. In studies for the 4th Leuco- 
cyte Typing Workshop the consensus was that OKB4 reacted 
with about 30% of peripheral blood B cells.16 These differences 
in results might in part be explained by the finding in the present 
study that the OKB4 epitope on B cells is masked by sialic acid 
residues. 
The relationship of epitopes on leucocyte CD antigens to 
blood group antigens on red cells is an area for further study. 
For example, the 3- fucosyl -N- acetyllactosamine epitope [also 
known as X- hapten and stage- specific embryonic antigen 
(SSEA -1)] recognized by the CD15 mAb is formed in myeloid 
cells by the action of a chromosome 11- encoded a 3- fucosyl- 
transferase.26 The Lewis blood group fucosyltransferase (an 
a(1,3 /1,4)fucosyltransferase), which maps to chromosome 19, is 
also capable of synthesizing the SSEA -1 epitope.27 Some blood 
group antigens (Ina and Inb antigens) are present on leucocyte 
and erythrocyte CD44 molecules.28 The differential staining of 
leucocytes and red cells from some normal subjects by CDw75 
mAb is rather like the reactions of mAb against some epitopes of 
the CD44 glycoprotein: the Inb blood group antigen on CD44 
molecules is absent (or reduced in expression) from red cells in 
some individuals whose leucocytes are positive. While lack of 
expression of the EBU.65 epitope on red cells appears to be a 
relatively common polymorphism, in the case of CD44 it is the 
rare dominant form of Lutheran blood group- negative donors 
who are lacking in red cell Inb antigens. Inb expression on red 
cells is specifically influenced by the action of a dominant 
inhibitor gene called Jn(Lu) which affects red cell expression of a 
number of high frequency blood group antigens.29 
The tissue specificity of CDw75 mAb is likely to be 
determined by the specific pattern of glycosylation of the 
molecule in different tissues. Therefore, it may be necessary to 
prepare mAb against polypeptide determinants to fully appre- 
ciate the distribution of a 2,6- sialyltransferase in human cells. 
The differences in the tissue distribution of CDw75 epitopes 
reported herein is an indication of the likely importance of 
carbohydrate moieties to the micro -heterogeneity of leucocyte 
differentiation antigens. This may extend to modifications of the 
functional properties of these molecules. A detailed analysis of 
the structural relationships among products of the a 2,6- 
sialyltransferase gene expressed in different tissues should help 
in understanding the function of the CDw75 molecule in 
lymphocytes. 
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634 B -cell antigens 
B009 (6C12), B028 (J3 -6), B049 (1D8), B058 (BL- 
OFX/B8), and B064 (B5) were limited to the FAB -M4 
or -M5, and positive tests with B015 (CMRF -41), B027 
(J3 -89), and B055 (HB -4) were observed only with 
FAB -M1, -M2, or -M3 subtypes. mAb B011 (EBU- 
1166) is of special interest in that it reacted with seven 
of 11 AML including FAB -M1, -M3, -M4, and -M5 
types but not with blasts of B- and T- lineage ALL. 
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B19.7 Potential cluster analysis with variant sublines of Namalwa 
J. A. ROSS and J. ANDREW 
Table 1 Phenotype of Namalwa variant sublines 
using a panel of mAb 
Antibody 
designation 
Percentage positive cells* 
G4 NK CSN PNT KN2 
4F2' 94 97 96 98 98 
HLA II' 23 76 69 99 98 
HLA-DR 13 64 65 98 98 
HLA-DP 1 10 17 81 89 
HLA-DQ 3 15 26 94 85 
CD7 82 69 39 5 1 
CD9 86 94 97 90 94 
CD l0 5 35 83 96 59 
CDlla 7 20 6 7 11 
CD11b 2 10 10 4 2 
CDl1c 4 14 11 8 2 
CD17 18 10 39 3 4 
CD18 3 25 8 5 4 
CD19 18 59 74 78 16 
CD20 8 16 6 22 1 
CD21 4 9 26 10 2 
CD22 33 30 65 70 5 
CD23 13 36 30 20 4 
CD24 18 73 92 93 88 
CD25 20 26 9 8 84 
CD37 32 55 54 91 58 
continued 
Table 1 (continued) 
Antibody 
designation 
Percentage positive cells* 
G4 NK CSN PNT KN2 
CD38 95 91 92 98 98 
CD40 90 82 95 69 45 
IgM - 6 23 93 66 
CD43 91 59 74 95 96 
CD45 89 95 96 99 98 
CD45RO 94 92 81 20 34 
CD54 93 97 94 98 98 
CD71 67 75 76 84 89 
Indirect immunofluorescence using rabbit anti -mouse -FITC F(ab')Z. 
Results are expressed as percentage positive cells after subtraction 
of background negative control values. Fluorescence signals were 
collected in logarithmic mode on a FACScan flow cytometer. 
'4F2 recognizes an activation antigen on human cells. 
'DA6.231 recognizes a framework structure on MHC class II 
molecules. 
The Workshop B -cell Blind Panel was tested against 
a series of variant sublines of the Burkitt lymphoma 
cells Namalwa. The Namalwa variant lines derive from 
the same tumour biopsy and are DNA fingerprint 
identical. They have marked differences in Ig heavy - 
chain and light -chain structure and expression, and 
have a number of different mutations in the flanking 
B 
Fig. 1 Portion of a cell from the Burkitt's lymphoma line 
Namalwa (IPN /45) with mitochondria and rough endo- 
plasmic reticulum in the cytoplasm. A large number of 
viral particles are seen in the extracellular milieu. Type 
D retroviruses are seen at various stages of budding from 
the cell surface membrane to produce virions. 
sequences of the c -myc locus [ 1 ] . They display non - 
coordinate expression of a number of cell surface 
structures. The six sublines in the complete panel are, 
in increasing order of maturity, G4 -NK- CSN /70-+ 
IPN /45-- PPNT-+KN2.G4 and NK display some lineage 
B -cell antigens 635 
Fig. 2 Western blot of B029 (By2). The structure 
recognized by B029 appears to be differentially expressed 
in the Namalwas being greatest on CSN /70 and PNT. 
Weak bands are seen with NK and bands are almost 
absent from the KN2 lane. The bands appear to be 64, 
47, and a weak band at 18 kDa in all lines. Molecular 
weight markers are shown. 
infidelity (for example, CD7 expression), CSN /70 has 
no surface immunoglobulin (Ig), PNT has surface Ig, 
and KN2 secretes Ig. The different sublimes are 
phenotypically approximate to B cells arrested at 
Table 2 Reactivity of potential clusters with a cell panel including the Namalwa variant sublimes 
Workshop mAb Percentage positive cells* 
Code Clone name NK CSN IPN PNT KN2 PBLI PBL2 B-CLL Reactivityt 
B006 DFB1 34 85 99 99 99 63 74 86 CD45RA 
B044 Ki-B5 32 81 99 99 81 36 76 98 CD45RA 
B008 B5 53 94 92 98 59 7 6 86 Unclustered 
B064 B5 37 95 93 96 59 4 87 Unclustered 
B012 EBU-65 - 67 39 5 33 60 97 Unclustered 
B027 J3-89 3 5 60 26 6 29 57 98 Unclustered 
B019 M9 99 99 99 99 99 96 94 38 Unclustered 
B071 4TM-1 99 99 99 99 99 96 95 10 ?PC #4 
B031 VMP55 34 75 94 99 97 1 26 36 Unclustered 
B032 GHI/75 32 69 92 99 96 17 25 58 Unclustered 
B065 HB15a 20 20 4 PC#3 
B066 HB15b 16 23 4 PC#3 
B067 I D6 99 99 99 99 99 97 99 31 PC#4 
B068 5A6 99 99 99 99 99 97 95 35 PC#4 
8069 JS64 99 99 99 99 99 98 97 54 PC#4 
B070 4TM-1 99 99 99 99 99 97 96 67 PC#4 
*Indirect immunofluorescence using rabbit anti -mouse fluorescein isothiocyanate (FITC)- conjugated F(ab')2. Results are expressed as 
percentage of positive cells without subtraction of background negative control values (- 3%). fluorescence signals were collected in logarithmic 
mode on a FACScan flow cytometer. PBL, peripheral blood cells; B -CLL, B-cell chronic lymphocytic leukaemia. -, Negative controls. 
PC, Preliminary cluster to be assigned at Workshop. 
